28289-54-5 | 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine

Availability
Typically In Stock

Description

• Catalog Number: AF30393
• Chemical Name: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
• CAS Number: 28289-54-5
• Molecular Formula: C12H15N
• Molecular Weight: 173.2542
• MDL Number: MFCD00006120
• SMILES: CN1CCC(=CC1)c1ccccc1
• NSC Number: 139654

Computed Properties

• Complexity: 189
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 13
• Hydrogen Bond Acceptor Count: 1
• Rotatable Bond Count: 1
• XLogP3: 2.7

Literature

• LncRNA SNHG1 promotes α-synuclein aggregation and toxicity by targeting miR-15b-5p to activate SIAH1 in human neuroblastoma SH-SY5Y cells.

  Neurotoxicology 20180901

• Paraquat and MPTP induce alteration in the expression profile of long noncoding RNAs in the substantia nigra of mice: Role of the transcription factor Nrf2.

  Toxicology letters 20180701

• Protective effects of pituitary adenylate cyclase activating polypeptide against neurotoxic agents.

  Neurotoxicology 20180501

• Single low doses of MPTP decrease tyrosine hydroxylase expression in the absence of overt neuron loss.

  Neurotoxicology 20170501

• Amentoflavone protects dopaminergic neurons in MPTP-induced Parkinson's disease model mice through PI3K/Akt and ERK signaling pathways.

  Toxicology and applied pharmacology 20170315

• Nicotine suppresses the neurotoxicity by MPP(+)/MPTP through activating α7nAChR/PI3K/Trx-1 and suppressing ER stress.

  Neurotoxicology 20170301

• FosB and ΔFosB expression in brain regions containing differentially susceptible dopamine neurons following acute neurotoxicant exposure.

  Brain research 20161015

• Vesicular Monoamine Transporter 2 (VMAT2) Level Regulates MPTP Vulnerability and Clearance of Excess Dopamine in Mouse Striatal Terminals.

  Toxicological sciences : an official journal of the Society of Toxicology 20160901

• MPTP neurotoxicity is highly concordant between the sexes among BXD recombinant inbred mouse strains.

  Neurotoxicology 20160701

• Distinct Nrf2 Signaling Mechanisms of Fumaric Acid Esters and Their Role in Neuroprotection against 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Induced Experimental Parkinson's-Like Disease.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20160608

• Molecular Mechanism of Regulation of MTA1 Expression by Granulocyte Colony-stimulating Factor.

  The Journal of biological chemistry 20160603

• Neuroprotective and anti-inflammatory properties of a novel non-thiazolidinedione PPARγ agonist in vitro and in MPTP-treated mice.

  Neuroscience 20150827

• MPTP's pathway of toxicity indicates central role of transcription factor SP1.

  Archives of toxicology 20150501

• Novel para-phenyl substituted diindolylmethanes protect against MPTP neurotoxicity and suppress glial activation in a mouse model of Parkinson's disease.

  Toxicological sciences : an official journal of the Society of Toxicology 20150201

• Decreased expression of organic cation transporters, Oct1 and Oct2, in brain microvessels and its implication to MPTP-induced dopaminergic toxicity in aged mice.

  Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 20150101

• The role of parkin in the differential susceptibility of tuberoinfundibular and nigrostriatal dopamine neurons to acute toxicant exposure.

  Neurotoxicology 20150101

• Neuroprotective effects of ginkgetin against neuroinjury in Parkinson's disease model induced by MPTP via chelating iron.

  Free radical research 20150101

• Guanosine exerts neuroprotective effects by reversing mitochondrial dysfunction in a cellular model of Parkinson's disease.

  International journal of molecular medicine 20141101

• CNB-001, a novel pyrazole derivative mitigates motor impairments associated with neurodegeneration via suppression of neuroinflammatory and apoptotic response in experimental Parkinson's disease mice.

  Chemico-biological interactions 20140905

• Ceftriaxone mediated rescue of nigral oxidative damage and motor deficits in MPTP model of Parkinson's disease in rats.

  Neurotoxicology 20140901

• Neuroprotective effect of the chemical chaperone, trehalose in a chronic MPTP-induced Parkinson's disease mouse model.

  Neurotoxicology 20140901

• Gene expression regulation of Bcl2, Bax and cytochrome-C by geraniol on chronic MPTP/probenecid induced C57BL/6 mice model of Parkinson's disease.

  Chemico-biological interactions 20140625

• Neuroprotective effect of silymarin in a MPTP mouse model of Parkinson's disease.

  Toxicology 20140507

• The role of thioredoxin-1 in suppression of endoplasmic reticulum stress in Parkinson disease.

  Free radical biology & medicine 20140201

• BAG5 protects against mitochondrial oxidative damage through regulating PINK1 degradation.

  PloS one 20140101

• The c-Abl inhibitor, nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson's disease.

  Scientific reports 20140101

• Salvianolic acid B attenuates toxin-induced neuronal damage via Nrf2-dependent glial cells-mediated protective activity in Parkinson's disease models.

  PloS one 20140101

• Nicotine-encapsulated poly(lactic-co-glycolic) acid nanoparticles improve neuroprotective efficacy against MPTP-induced parkinsonism.

  Free radical biology & medicine 20131201

• Mangiferin attenuates MPTP induced dopaminergic neurodegeneration and improves motor impairment, redox balance and Bcl-2/Bax expression in experimental Parkinson's disease mice.

  Chemico-biological interactions 20131125

• Neuroprotection by tetrahydroxystilbene glucoside in the MPTP mouse model of Parkinson's disease.

  Toxicology letters 20131024

• Telmisartan attenuates MPTP induced dopaminergic degeneration and motor dysfunction through regulation of α-synuclein and neurotrophic factors (BDNF and GDNF) expression in C57BL/6J mice.

  Neuropharmacology 20131001

• Minocycline, levodopa and MnTMPyP induced changes in the mitochondrial proteome profile of MPTP and maneb and paraquat mice models of Parkinson's disease.

  Biochimica et biophysica acta 20130801

• The peptidyl-prolyl isomerase Pin1 up-regulation and proapoptotic function in dopaminergic neurons: relevance to the pathogenesis of Parkinson disease.

  The Journal of biological chemistry 20130726

• Sustained resistance to acute MPTP toxicity by hypothalamic dopamine neurons following chronic neurotoxicant exposure is associated with sustained up-regulation of parkin protein.

  Neurotoxicology 20130701

• Astaxanthin suppresses MPP(+)-induced oxidative damage in PC12 cells through a Sp1/NR1 signaling pathway.

  Marine drugs 20130401

• The anti-cancer agent SU4312 unexpectedly protects against MPP(+) -induced neurotoxicity via selective and direct inhibition of neuronal NOS.

  British journal of pharmacology 20130301

• Suppression of neuroinflammation by astrocytic dopamine D2 receptors via αB-crystallin.

  Nature 20130207

• Acetylcholinesterase deficiency decreases apoptosis in dopaminergic neurons in the neurotoxin model of Parkinson's disease.

  The international journal of biochemistry & cell biology 20130201

• Targeting Nrf2-mediated gene transcription by extremely potent synthetic triterpenoids attenuate dopaminergic neurotoxicity in the MPTP mouse model of Parkinson's disease.

  Antioxidants & redox signaling 20130110

• Mitochondrial inhibitor models of Huntington's disease and Parkinson's disease induce zinc accumulation and are attenuated by inhibition of zinc neurotoxicity in vitro or in vivo.

  Neuro-degenerative diseases 20130101

• Biochemical evaluation of the neurotoxicity of MPTP and MPP⁺ in embryonic and newborn mice.

  The Journal of toxicological sciences 20130101

• The effect of guggulipid and nimesulide on MPTP-induced mediators of neuroinflammation in rat astrocytoma cells, C6.

  Chemico-biological interactions 20121205

• Neuroprotective effects of agmatine in mice infused with a single intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

  Behavioural brain research 20121201

• 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neuroblastic apoptosis in the subventricular zone is caused by 1-methy-4-phenylpiridinium (MPP(+)) converted from MPTP through MAO-B.

  Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie 20121101

• Effect of oestrogen receptors on brain NMDA receptors of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice.

  Journal of neuroendocrinology 20121101

• Transient receptor potential vanilloid subtype 1 contributes to mesencephalic dopaminergic neuronal survival by inhibiting microglia-originated oxidative stress.

  Brain research bulletin 20121101

• Neuro-protective effects of bee venom by suppression of neuroinflammatory responses in a mouse model of Parkinson's disease: role of regulatory T cells.

  Brain, behavior, and immunity 20121101

• Loss of parvalbumin-positive neurons from the globus pallidus in animal models of Parkinson disease.

  Journal of neuropathology and experimental neurology 20121101

• The soluble isoform of CX3CL1 is necessary for neuroprotection in a mouse model of Parkinson's disease.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20121017

• Activation of transcription factor MEF2D by bis(3)-cognitin protects dopaminergic neurons and ameliorates Parkinsonian motor defects.

  The Journal of biological chemistry 20121005

• Licochalcone E activates Nrf2/antioxidant response element signaling pathway in both neuronal and microglial cells: therapeutic relevance to neurodegenerative disease.

  The Journal of nutritional biochemistry 20121001

• The effects of rehabilitative training on the behaviors of Parkinson's disease mouse and underlying mechanism.

  The International journal of neuroscience 20121001

• The nigrostriatal system in the presymptomatic and symptomatic stages in the MPTP monkey model: a PET, histological and biochemical study.

  Neurobiology of disease 20121001

• L-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson's disease.

  Neuropharmacology 20121001

• Ogg1 null mice exhibit age-associated loss of the nigrostriatal pathway and increased sensitivity to MPTP.

  Neurochemistry international 20121001

• Tauroursodeoxycholic acid prevents MPTP-induced dopaminergic cell death in a mouse model of Parkinson's disease.

  Molecular neurobiology 20121001

• Ranbp2 haploinsufficiency mediates distinct cellular and biochemical phenotypes in brain and retinal dopaminergic and glia cells elicited by the Parkinsonian neurotoxin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

  Cellular and molecular life sciences : CMLS 20121001

• Low nigrostriatal reserve for motor parkinsonism in nonhuman primates.

  Experimental neurology 20121001

• Non-human primate FOG develops with advanced parkinsonism induced by MPTP Treatment.

  Experimental neurology 20121001

• Sirtuin 2 (SIRT2) enhances 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced nigrostriatal damage via deacetylating forkhead box O3a (Foxo3a) and activating Bim protein.

  The Journal of biological chemistry 20120921

• Rosiglitazone, a PPAR-γ agonist, protects against striatal dopaminergic neurodegeneration induced by 6-OHDA lesions in the substantia nigra of rats.

  Toxicology letters 20120918

• The neuroprotection of hydrogen sulfide against MPTP-induced dopaminergic neuron degeneration involves uncoupling protein 2 rather than ATP-sensitive potassium channels.

  Antioxidants & redox signaling 20120915

• A critique of available scales and presentation of the Non-Human Primate Dyskinesia Rating Scale.

  Movement disorders : official journal of the Movement Disorder Society 20120915

• Molecular mechanism underlying the cerebral effect of Gly-Pro-Glu tripeptide bound to L-dopa in a Parkinson's animal model.

  Amino acids 20120901

• Metabotropic glutamate receptors in neurodegeneration/neuroprotection: still a hot topic?

  Neurochemistry international 20120901

• Cooperative action of JNK and AKT/mTOR in 1-methyl-4-phenylpyridinium-induced autophagy of neuronal PC12 cells.

  Journal of neuroscience research 20120901

• Neuroprotective effect of curcuminoids against inflammation-mediated dopaminergic neurodegeneration in the MPTP model of Parkinson's disease.

  Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology 20120901

• Comparison of the D2 receptor regulation and neurotoxicant susceptibility of nigrostriatal dopamine neurons in wild-type and CB1/CB2 receptor knockout mice.

  Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology 20120901

• Alterations in bioenergetic function induced by Parkinson's disease mimetic compounds: lack of correlation with superoxide generation.

  Journal of neurochemistry 20120901

• Aging of the dopaminergic system and motor behavior in mice intoxicated with the parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

  Journal of neurochemistry 20120901

• LLDT-67 attenuates MPTP-induced neurotoxicity in mice by up-regulating NGF expression.

  Acta pharmacologica Sinica 20120901

• Theaflavin ameliorates behavioral deficits, biochemical indices and monoamine transporters expression against subacute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mouse model of Parkinson's disease.

  Neuroscience 20120830

• Disruption of programmed masticatory movements in unilateral MPTP-treated monkeys as a model of jaw movement abnormality in Parkinson's disease.

  Journal of neural transmission (Vienna, Austria : 1996) 20120801

• Alterations of gene expression of sodium channels in dorsal root ganglion neurons of estrogen receptor knockout (ERKO) mice induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

  Endocrine 20120801

• L-745,870 reduces L-DOPA-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.

  The Journal of pharmacology and experimental therapeutics 20120801

• MPTP modulates hippocampal synaptic transmission and activity-dependent synaptic plasticity via dopamine receptors.

  Journal of neurochemistry 20120801

• Neural targets for relieving parkinsonian rigidity and bradykinesia with pallidal deep brain stimulation.

  Journal of neurophysiology 20120715

• Long-lasting transcriptional refractoriness triggered by a single exposure to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine.

  Neuroscience 20120712

• Meloxicam ameliorates motor dysfunction and dopaminergic neurodegeneration by maintaining Akt-signaling in a mouse Parkinson's disease model.

  Neuroscience letters 20120711

• Docosahexaenoic acid provides protective mechanism in bilaterally MPTP-lesioned rat model of Parkinson's disease.

  Folia histochemica et cytobiologica 20120704

• Blockade of metabotropic glutamate receptors inhibits cognition and neurodegeneration in an MPTP-induced Parkinson's disease rat model.

  Pharmacology, biochemistry, and behavior 20120701

• Dopamine pathway loss in nucleus accumbens and ventral tegmental area predicts apathetic behavior in MPTP-lesioned monkeys.

  Experimental neurology 20120701

• Loss of spinal motor neurons and alteration of alpha-synuclein immunostaining in MPTP induced Parkinsonism in mice.

  Journal of chemical neuroanatomy 20120701

• Neurotoxin-based models of Parkinson's disease.

  Neuroscience 20120601

• Blood-borne macrophage-neural cell interactions hitchhike on endosome networks for cell-based nanozyme brain delivery.

  Nanomedicine (London, England) 20120601

• Recovery of hypothalamic tuberoinfundibular dopamine neurons from acute toxicant exposure is dependent upon protein synthesis and associated with an increase in parkin and ubiquitin carboxy-terminal hydrolase-L1 expression.

  Neurotoxicology 20120601

• Electrophysiological characterization of the polyspecific organic cation transporter plasma membrane monoamine transporter.

  Drug metabolism and disposition: the biological fate of chemicals 20120601

• Effect of pesticides on the aggregation of mutant huntingtin protein.

  Molecular neurobiology 20120601

• Pharmacological manipulation of peroxisome proliferator-activated receptor γ (PPARγ) reveals a role for anti-oxidant protection in a model of Parkinson's disease.

  Experimental neurology 20120601

• Pegylated granulocyte colony-stimulating factor conveys long-term neuroprotection and improves functional outcome in a model of Parkinson's disease.

  Brain : a journal of neurology 20120601

• PEP-1-heat shock protein 27 protects from neuronal damage in cells and in a Parkinson's disease mouse model.

  The FEBS journal 20120601

• MPTP-induced model of Parkinson's disease in heat shock protein 70.1 knockout mice.

  Molecular medicine reports 20120601

• Animal models of L-DOPA-induced dyskinesia: an update on the current options.

  Neuroscience 20120601

• Glutathione S-transferase pi mediates MPTP-induced c-Jun N-terminal kinase activation in the nigrostriatal pathway.

  Molecular neurobiology 20120601

• Transduced Tat-DJ-1 protein protects against oxidative stress-induced SH-SY5Y cell death and Parkinson disease in a mouse model.

  Molecules and cells 20120531

• Protective effect of extract of Acanthopanax senticosus Harms on dopaminergic neurons in Parkinson's disease mice.

  Phytomedicine : international journal of phytotherapy and phytopharmacology 20120515

• Lithium and oxidative stress lessons from the MPTP model of Parkinson's disease.

  Neuroscience letters 20120510

• Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on retinal dopaminergic system in mice.

  Neuroscience letters 20120502

• Mitochondrial permeability transition pore component cyclophilin D distinguishes nigrostriatal dopaminergic death paradigms in the MPTP mouse model of Parkinson's disease.

  Antioxidants & redox signaling 20120501

• Gastrointestinal dysfunction in a Parkinson's disease rat model and the changes of dopaminergic, nitric oxidergic, and cholinergic neurotransmitters in myenteric plexus.

  Journal of molecular neuroscience : MN 20120501

• Overexpression of TFAM, NRF-1 and myr-AKT protects the MPP(+)-induced mitochondrial dysfunctions in neuronal cells.

  Biochimica et biophysica acta 20120501

• Sensorimotor assessment of the unilateral 6-hydroxydopamine mouse model of Parkinson's disease.

  Behavioural brain research 20120501

• Neddylation positively regulates the ubiquitin E3 ligase activity of parkin.

  Journal of neuroscience research 20120501

• α7 nicotinic acetylcholine receptor mediated neuroprotection in Parkinson's disease.

  Current drug targets 20120501

• Cinnabarinic acid, an endogenous metabolite of the kynurenine pathway, activates type 4 metabotropic glutamate receptors.

  Molecular pharmacology 20120501

• Investigate the chronic neurotoxic effects of diquat.

  Neurochemical research 20120501

• Susceptibility to a parkinsonian toxin varies during primate development.

  Experimental neurology 20120501

• Correlation between decreased motor activity and dopaminergic degeneration in the ventrolateral putamen in monkeys receiving repeated MPTP administrations: a positron emission tomography study.

  Neuroscience research 20120501

• Differential susceptibility to the PPAR-γ agonist pioglitazone in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 6-hydroxydopamine rodent models of Parkinson's disease.

  Pharmacological research 20120501

• Increased α-synuclein phosphorylation and nitration in the aging primate substantia nigra.

  Cell death & disease 20120501

• Sustained expression of PGC-1α in the rat nigrostriatal system selectively impairs dopaminergic function.

  Human molecular genetics 20120415

• Parkinson's disease: don't mess with calcium.

  The Journal of clinical investigation 20120402

• Neurotoxin-induced ER stress in mouse dopaminergic neurons involves downregulation of TRPC1 and inhibition of AKT/mTOR signaling.

  The Journal of clinical investigation 20120402

• Molecular imaging of cell death in an experimental model of Parkinson's disease with a novel apoptosis-targeting peptide.

  Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging 20120401

• A novel compound PTIQ protects the nigral dopaminergic neurones in an animal model of Parkinson's disease induced by MPTP.

  British journal of pharmacology 20120401

• Transgenic expression and activation of PGC-1α protect dopaminergic neurons in the MPTP mouse model of Parkinson's disease.

  Cellular and molecular life sciences : CMLS 20120401

• Occurrence and distribution of salsolinol-like compound, 1-acetyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline (ADTIQ) in parkinsonian brains.

  Journal of neural transmission (Vienna, Austria : 1996) 20120401

• Abnormal metabolic brain networks in a nonhuman primate model of parkinsonism.

  Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 20120401

• Redox modification of Akt mediated by the dopaminergic neurotoxin MPTP, in mouse midbrain, leads to down-regulation of pAkt.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20120401

• Effects of MK-801 on recognition and neurodegeneration in an MPTP-induced Parkinson's rat model.

  Behavioural brain research 20120401

• Animal models of Parkinson's disease.

  The FEBS journal 20120401

• Lithium and valproate prevent olfactory discrimination and short-term memory impairments in the intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) rat model of Parkinson's disease.

  Behavioural brain research 20120401

• Signaling pathways mediating the neuroprotective effects of sex steroids and SERMs in Parkinson's disease.

  Frontiers in neuroendocrinology 20120401

• Murine motor and behavior functional evaluations for acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) intoxication.

  Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology 20120301

• Modeling mitochondrial dysfunctions in the brain: from mice to men.

  Journal of inherited metabolic disease 20120301

• Lanosterol induces mitochondrial uncoupling and protects dopaminergic neurons from cell death in a model for Parkinson's disease.

  Cell death and differentiation 20120301

• Increase in endoplasmic reticulum-associated tissue transglutaminase and enzymatic activation in a cellular model of Parkinson's disease.

  Neurobiology of disease 20120301

• Efficient gene therapy for Parkinson's disease using astrocytes as hosts for localized neurotrophic factor delivery.

  Molecular therapy : the journal of the American Society of Gene Therapy 20120301

• Altered dopamine metabolism and increased vulnerability to MPTP in mice with partial deficiency of mitochondrial complex I in dopamine neurons.

  Human molecular genetics 20120301

• Partial dopamine depletion in MPTP-treated mice differentially altered motor skill learning and action control.

  Behavioural brain research 20120301

• Harpagoside attenuates MPTP/MPP⁺ induced dopaminergic neurodegeneration and movement disorder via elevating glial cell line-derived neurotrophic factor.

  Journal of neurochemistry 20120301

• Social enrichment attenuates nigrostriatal lesioning and reverses motor impairment in a progressive 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.

  Neurobiology of disease 20120301

• Meta-analysis of genetic and environmental Parkinson's disease models reveals a common role of mitochondrial protection pathways.

  Neurobiology of disease 20120301

• Ablation of serum response factor in dopaminergic neurons exacerbates susceptibility towards MPTP-induced oxidative stress.

  The European journal of neuroscience 20120301

• Prevention of β-amyloid degeneration of microglia by erythropoietin depends on Wnt1, the PI 3-K/mTOR pathway, Bad, and Bcl-xL.

  Aging 20120301

• Modeling Parkinson's disease in primates: The MPTP model.

  Cold Spring Harbor perspectives in medicine 20120301

• [Protective effect of nicotinamide in a mouse Parkinson's disease model].

  Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences 20120301

• Lipopolysaccharide-induced nigral inflammation leads to increased IL-1β tissue content and expression of astrocytic glial cell line-derived neurotrophic factor.

  Neuroscience letters 20120227

• Selective neuroprotective effects of the S18Y polymorphic variant of UCH-L1 in the dopaminergic system.

  Human molecular genetics 20120215

• Dangguijakyak-san protects dopamine neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity under postmenopausal conditions.

  Journal of ethnopharmacology 20120215

• Plasticity of subventricular zone neuroprogenitors in MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) mouse model of Parkinson's disease involves cross talk between inflammatory and Wnt/β-catenin signaling pathways: functional consequences for neuroprotection and repair.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20120208

• Oral administration of coenzyme Q₁₀ reduces MPTP-induced loss of dopaminergic nerve terminals in the striatum in mice.

  Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 20120201

• Direct reprogramming of human fibroblasts into dopaminergic neuron-like cells.

  Cell research 20120201

• Reduced calcium/calmodulin-dependent protein kinase II activity in the hippocampus is associated with impaired cognitive function in MPTP-treated mice.

  Journal of neurochemistry 20120201

• The mitochondrial chaperone protein TRAP1 mitigates α-Synuclein toxicity.

  PLoS genetics 20120201

• Ghrelin protects spinal cord motoneurons against chronic glutamate excitotoxicity by inhibiting microglial activation.

  The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology 20120201

• Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export.

  Nature medicine 20120129

• Theaflavin, a black tea polyphenol, protects nigral dopaminergic neurons against chronic MPTP/probenecid induced Parkinson's disease.

  Brain research 20120118

• Bee venom protects SH-SY5Y human neuroblastoma cells from 1-methyl-4-phenylpyridinium-induced apoptotic cell death.

  Brain research 20120106

• 5-HT2A receptor levels increase in MPTP-lesioned macaques treated chronically with L-DOPA.

  Neurobiology of aging 20120101

• Regulation of cortical and striatal 5-HT1A receptors in the MPTP-lesioned macaque.

  Neurobiology of aging 20120101

• Clavulanic acid does not affect convulsions in acute seizure tests in mice.

  Journal of neural transmission (Vienna, Austria : 1996) 20120101

• Docosahexaenoic acid promotes dopaminergic differentiation in induced pluripotent stem cells and inhibits teratoma formation in rats with Parkinson-like pathology.

  Cell transplantation 20120101

• Oestrogen receptors and signalling pathways: implications for neuroprotective effects of sex steroids in Parkinson's disease.

  Journal of neuroendocrinology 20120101

• Traditional chinese medicine for senile dementia.

  Evidence-based complementary and alternative medicine : eCAM 20120101

• Effect of globus pallidus internus stimulation on neuronal activity in the pedunculopontine tegmental nucleus in the primate model of Parkinson's disease.

  Experimental neurology 20120101

• Phytochemical characteristics, free radical scavenging activities, and neuroprotection of five medicinal plant extracts.

  Evidence-based complementary and alternative medicine : eCAM 20120101

• High-fat diet exacerbates MPTP-induced dopaminergic degeneration in mice.

  Neurobiology of disease 20120101

• Oxidative stress, mitochondrial dysfunction, and aging.

  Journal of signal transduction 20120101

• Asiaticoside: attenuation of neurotoxicity induced by MPTP in a rat model of Parkinsonism via maintaining redox balance and up-regulating the ratio of Bcl-2/Bax.

  Pharmacology, biochemistry, and behavior 20120101

• External pallidal stimulation improves parkinsonian motor signs and modulates neuronal activity throughout the basal ganglia thalamic network.

  Experimental neurology 20120101

• Intranasal administration of neurotoxicants in animals: support for the olfactory vector hypothesis of Parkinson's disease.

  Neurotoxicity research 20120101

• Imbalanced Dopaminergic Transmission Mediated by Serotonergic Neurons in L-DOPA-Induced Dyskinesia.

  Parkinson's disease 20120101

• Adaptive alternative splicing correlates with less environmental risk of parkinsonism.

  Neuro-degenerative diseases 20120101

• 4-iodophenyl isothiocyanate: a neuroprotective compound.

  Restorative neurology and neuroscience 20120101

• The MPTP neurotoxic lesion model of Parkinson's disease activates the apolipoprotein E cascade in the mouse brain.

  Experimental neurology 20120101

• Clinical application of stem cell therapy in Parkinson's disease.

  BMC medicine 20120101

• Alpha oscillations in the pedunculopontine nucleus correlate with gait performance in parkinsonism.

  Brain : a journal of neurology 20120101

• CART peptide is a potential endogenous antioxidant and preferentially localized in mitochondria.

  PloS one 20120101

• Connecting the dots between PubMed abstracts.

  PloS one 20120101

• NADPH oxidase and reactive oxygen species contribute to alcohol-induced microglial activation and neurodegeneration.

  Journal of neuroinflammation 20120101

• Apoptosis signal-regulating kinase 1 mediates MPTP toxicity and regulates glial activation.

  PloS one 20120101

• The neuroprotective disease-modifying potential of psychotropics in Parkinson's disease.

  Parkinson's disease 20120101

• Baicalein antagonizes rotenone-induced apoptosis in dopaminergic SH-SY5Y cells related to Parkinsonism.

  Chinese medicine 20120101

• Genetic dissection of strain dependent paraquat-induced neurodegeneration in the substantia nigra pars compacta.

  PloS one 20120101

• Elevated pontine and putamenal GABA levels in mild-moderate Parkinson disease detected by 7 tesla proton MRS.

  PloS one 20120101

• Anti-inflammation effects of hydrogen saline in LPS activated macrophages and carrageenan induced paw oedema.

  Journal of inflammation (London, England) 20120101

• An alteration in the lateral geniculate nucleus of experimental glaucoma monkeys: in vivo positron emission tomography imaging of glial activation.

  PloS one 20120101

• Lactulose: an effective preventive and therapeutic option for ischemic stroke by production of hydrogen.

  Medical gas research 20120101

• Evaluation of blood-brain barrier transport and CNS drug metabolism in diseased and control brain after intravenous L-DOPA in a unilateral rat model of Parkinson's disease.

  Fluids and barriers of the CNS 20120101

• Antiparkinsonian mechanism of electroconvulsive therapy in MPTP-lesioned non-human primates.

  Neuro-degenerative diseases 20120101

• Involvement of PPAR-γ in the neuroprotective and anti-inflammatory effects of angiotensin type 1 receptor inhibition: effects of the receptor antagonist telmisartan and receptor deletion in a mouse MPTP model of Parkinson's disease.

  Journal of neuroinflammation 20120101

• No differential regulation of dopamine transporter (DAT) and vesicular monoamine transporter 2 (VMAT2) binding in a primate model of Parkinson disease.

  PloS one 20120101

• Minocycline markedly reduces acute visceral nociception via inhibiting neuronal ERK phosphorylation.

  Molecular pain 20120101

• A 6-hydroxydopamine in vivo model of Parkinson's disease.

  Methods in molecular biology (Clifton, N.J.) 20120101

• Aspects of innate immunity and Parkinson's disease.

  Frontiers in pharmacology 20120101

• Effects of L-carnitine against oxidative stress in human hepatocytes: involvement of peroxisome proliferator-activated receptor alpha.

  Journal of biomedical science 20120101

• Natural plant products and extracts that reduce immunoexcitotoxicity-associated neurodegeneration and promote repair within the central nervous system.

  Surgical neurology international 20120101

• N-acetylcysteine protects against apoptosis through modulation of group I metabotropic glutamate receptor activity.

  PloS one 20120101

• Effect of Quercetin in the 1-Methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-Induced Mouse Model of Parkinson's Disease.

  Evidence-based complementary and alternative medicine : eCAM 20120101

• Methylphenidate exposure induces dopamine neuron loss and activation of microglia in the basal ganglia of mice.

  PloS one 20120101

• Neuroprotective Effects of San-Huang-Xie-Xin-Tang in the MPP(+)/MPTP Models of Parkinson's Disease In Vitro and In Vivo.

  Evidence-based complementary and alternative medicine : eCAM 20120101

• Riluzole neuroprotection in a Parkinson's disease model involves suppression of reactive astrocytosis but not GLT-1 regulation.

  BMC neuroscience 20120101

• Neuroprotective effects of 17β-estradiol rely on estrogen receptor membrane initiated signals.

  Frontiers in physiology 20120101

• Genetic Screening of the Mitochondrial Rho GTPases MIRO1 and MIRO2 in Parkinson's Disease.

  The open neurology journal 20120101

• Diverse Roles of JNK and MKK Pathways in the Brain.

  Journal of signal transduction 20120101

• The ketogenic diet as a treatment paradigm for diverse neurological disorders.

  Frontiers in pharmacology 20120101

• MicroRNAs in Neurotoxicity.

  Journal of toxicology 20120101

• Classic and new animal models of Parkinson's disease.

  Journal of biomedicine & biotechnology 20120101

• Nicotinamide, NAD(P)(H), and Methyl-Group Homeostasis Evolved and Became a Determinant of Ageing Diseases: Hypotheses and Lessons from Pellagra.

  Current gerontology and geriatrics research 20120101

• Nonuniform cardiac denervation observed by 11C-meta-hydroxyephedrine PET in 6-OHDA-treated monkeys.

  PloS one 20120101

• Oxidative stress and microglial cells in Parkinson's disease.

  Mediators of inflammation 20120101

• Mesenchymal stem cells augment neurogenesis in the subventricular zone and enhance differentiation of neural precursor cells into dopaminergic neurons in the substantia nigra of a parkinsonian model.

  Cell transplantation 20120101

• Hormone replacement therapy and risk for neurodegenerative diseases.

  International journal of Alzheimer's disease 20120101

• Genetic rat models of Parkinson's disease.

  Parkinson's disease 20120101

• Neuroinflammation in Parkinson's Disease and Related Disorders: A Lesson from Genetically Manipulated Mouse Models of α-Synucleinopathies.

  Parkinson's disease 20120101

• Role of alpha-synuclein protein levels in mitochondrial morphology and cell survival in cell lines.

  PloS one 20120101

• Concordant signaling pathways produced by pesticide exposure in mice correspond to pathways identified in human Parkinson's disease.

  PloS one 20120101

• Reactive oxygen species and inhibitors of inflammatory enzymes, NADPH oxidase, and iNOS in experimental models of Parkinson's disease.

  Mediators of inflammation 20120101

• Heterogeneous responses to antioxidants in noradrenergic neurons of the Locus coeruleus indicate differing susceptibility to free radical content.

  Oxidative medicine and cellular longevity 20120101

• Dementia in Parkinson's Disease Correlates with α-Synuclein Pathology but Not with Cortical Astrogliosis.

  Parkinson's disease 20120101

• Preclinical models to investigate retinal ischemia: advances and drawbacks.

  Frontiers in neurology 20120101

• Mitochondria: redox metabolism and dysfunction.

  Biochemistry research international 20120101

• Urate and its transgenic depletion modulate neuronal vulnerability in a cellular model of Parkinson's disease.

  PloS one 20120101

• Role of vitamin d in Parkinson's disease.

  ISRN neurology 20120101

• Gene therapy for Parkinson's disease.

  Parkinson's disease 20120101

• Genetics and epigenetics of Parkinson's disease.

  TheScientificWorldJournal 20120101

• α7 nicotinic acetylcholine receptor-mediated neuroprotection against dopaminergic neuron loss in an MPTP mouse model via inhibition of astrocyte activation.

  Journal of neuroinflammation 20120101

• The Path to microRNA Therapeutics in Psychiatric and Neurodegenerative Disorders.

  Frontiers in genetics 20120101

• Current understanding of the glial response to disorders of the aging CNS.

  Frontiers in pharmacology 20120101

• Magnolol Protects against MPTP/MPP(+)-Induced Toxicity via Inhibition of Oxidative Stress in In Vivo and In Vitro Models of Parkinson's Disease.

  Parkinson's disease 20120101

• Imaging of microglia in patients with neurodegenerative disorders.

  Frontiers in pharmacology 20120101

• Modulation of Neuronal Survival Factor MEF2 by Kinases in Parkinson's Disease.

  Frontiers in physiology 20120101

• Centella asiatica (L.) Urban: From Traditional Medicine to Modern Medicine with Neuroprotective Potential.

  Evidence-based complementary and alternative medicine : eCAM 20120101

• Schisandrin B as a hormetic agent for preventing age-related neurodegenerative diseases.

  Oxidative medicine and cellular longevity 20120101

• Patterns of Cell Activity in the Subthalamic Region Associated with the Neuroprotective Action of Near-Infrared Light Treatment in MPTP-Treated Mice.

  Parkinson's disease 20120101

• High frequency deep brain stimulation attenuates subthalamic and cortical rhythms in Parkinson's disease.

  Frontiers in human neuroscience 20120101

• Mitochondrial Stress Signalling: HTRA2 and Parkinson's Disease.

  International journal of cell biology 20120101

• Mechanism of oxidative stress in neurodegeneration.

  Oxidative medicine and cellular longevity 20120101

• The antioxidant mechanisms underlying the aged garlic extract- and S-allylcysteine-induced protection.

  Oxidative medicine and cellular longevity 20120101

• Matrix metalloproteinases and minocycline: therapeutic avenues for fragile X syndrome.

  Neural plasticity 20120101

• Survival of Dopaminergic Amacrine Cells after Near-Infrared Light Treatment in MPTP-Treated Mice.

  ISRN neurology 20120101

• Endocannabinoid modulation of dopaminergic motor circuits.

  Frontiers in pharmacology 20120101

• Antioxidant protects against increases in low molecular weight hyaluronan and inflammation in asphyxiated newborn pigs resuscitated with 100% oxygen.

  PloS one 20120101

• Intensive rehabilitation treatment in parkinsonian patients with dyskinesias: a preliminary study with 6-month followup.

  Parkinson's disease 20120101

• Sodium phenylbutyrate controls neuroinflammatory and antioxidant activities and protects dopaminergic neurons in mouse models of Parkinson's disease.

  PloS one 20120101

• Non-stationary discharge patterns in motor cortex under subthalamic nucleus deep brain stimulation.

  Frontiers in integrative neuroscience 20120101

• 25-Hydroxyvitamin D depletion does not exacerbate MPTP-induced dopamine neuron damage in mice.

  PloS one 20120101

• Overexpression of parkin ameliorates dopaminergic neurodegeneration induced by 1- methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice.

  PloS one 20120101

• Behavioral improvement in MPTP-treated nonhuman primates in the HALLWAY task after transfer of TH cDNA to host astrocytes.

  Acta neurobiologiae experimentalis 20120101

• Dopaminergic neurons from midbrain-specified human embryonic stem cell-derived neural stem cells engrafted in a monkey model of Parkinson's disease.

  PloS one 20120101

• Acacetin protects dopaminergic cells against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neuroinflammation in vitro and in vivo.

  Biological & pharmaceutical bulletin 20120101

• Exercise does not protect against MPTP-induced neurotoxicity in BDNF haploinsufficient mice.

  PloS one 20120101

• Distinct effects of rotenone, 1-methyl-4-phenylpyridinium and 6-hydroxydopamine on cellular bioenergetics and cell death.

  PloS one 20120101

• The monoamine re-uptake inhibitor UWA-101 improves motor fluctuations in the MPTP-lesioned common marmoset.

  PloS one 20120101

• Unexpected neuronal protection of SU5416 against 1-Methyl-4-phenylpyridinium ion-induced toxicity via inhibiting neuronal nitric oxide synthase.

  PloS one 20120101

• 17α-Ethynyl-androst-5-ene-3β,7β,17β-triol (HE3286) Is Neuroprotective and Reduces Motor Impairment and Neuroinflammation in a Murine MPTP Model of Parkinson's Disease.

  Parkinson's disease 20120101

• PET analysis of dopaminergic neurodegeneration in relation to immobility in the MPTP-treated common marmoset, a model for Parkinson's disease.

  PloS one 20120101

• Anti-inflammatory and neuroprotective effects of an orally active apocynin derivative in pre-clinical models of Parkinson's disease.

  Journal of neuroinflammation 20120101

• Time-dependent slowly-reversible inhibition of monoamine oxidase A by N-substituted 1,2,3,6-tetrahydropyridines.

  Bioorganic & medicinal chemistry 20111215

• Cannabinoid receptor type 1 protects nigrostriatal dopaminergic neurons against MPTP neurotoxicity by inhibiting microglial activation.

  Journal of immunology (Baltimore, Md. : 1950) 20111215

• Sex- and brain region-specific role of cytochrome c oxidase in 1-methyl-4-phenylpyridinium-mediated astrocyte vulnerability.

  Journal of neuroscience research 20111201

• Antidepressant-like properties of sarizotan in experimental Parkinsonism.

  Psychopharmacology 20111201

• Novel variant Pro143Ala in HTRA2 contributes to Parkinson's disease by inducing hyperphosphorylation of HTRA2 protein in mitochondria.

  Human genetics 20111201

• SEA0400, a specific Na+/Ca2+ exchange inhibitor, prevents dopaminergic neurotoxicity in an MPTP mouse model of Parkinson's disease.

  Neuropharmacology 20111201

• Stimulatory effect of α-synuclein on the tau-phosphorylation by GSK-3β.

  The FEBS journal 20111201

• Environmental- and injury-related epidemic-assistance investigations, 1946-2005.

  American journal of epidemiology 20111201

• Positive autoregulation of GDNF levels in the ventral tegmental area mediates long-lasting inhibition of excessive alcohol consumption.

  Translational psychiatry 20111201

• Prospect of cell therapy for Parkinson's disease.

  Anatomy & cell biology 20111201

• The use of Stronger Neo-Minophagen C, a glycyrrhizin-containing preparation, in robust neuroprotection in the postischemic brain.

  Anatomy & cell biology 20111201

• Isotopic reinforcement of essential polyunsaturated fatty acids diminishes nigrostriatal degeneration in a mouse model of Parkinson's disease.

  Toxicology letters 20111130

• Preventive and therapeutic effects of caffeic acid against inflammatory injury in striatum of MPTP-treated mice.

  European journal of pharmacology 20111130

• Chronic progesterone treatment of male rats with unilateral 6-hydroxydopamine lesion of the dorsal striatum exacerbates [corrected] parkinsonian symptoms.

  Neuroscience 20111124

• Impact of exercise on mitochondrial transcription factor expression and damage in the striatum of a chronic mouse model of Parkinson's disease.

  Neuroscience letters 20111121

• Dopamine-depletion and increased α-synuclein load induce degeneration of cortical cholinergic fibers in mice.

  Journal of the neurological sciences 20111115

• Chronic systemic treatment with a high-dose proteasome inhibitor in mice produces akinesia unrelated to nigrostriatal degeneration.

  Neurobiology of aging 20111101

• Contamination of mesenchymal stem-cells with fibroblasts accelerates neurodegeneration in an experimental model of Parkinson's disease.

  Stem cell reviews 20111101

• Pallidothalamic-projecting neurons in Macaca fascicularis co-express GABAergic and glutamatergic markers as seen in control, MPTP-treated and dyskinetic monkeys.

  Brain structure & function 20111101

• Association analysis of PARP1 polymorphisms with Parkinson's disease.

  Parkinsonism & related disorders 20111101

• Postnatal development of tyrosine hydroxylase mRNA-expressing neurons in mouse neostriatum.

  The European journal of neuroscience 20111101

• Subthalamo-pallidal interactions underlying parkinsonian neuronal oscillations in the primate basal ganglia.

  The European journal of neuroscience 20111101

• Natural toxins implicated in the development of Parkinson's disease.

  Therapeutic advances in neurological disorders 20111101

• Protective effects of valproic acid on the nigrostriatal dopamine system in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.

  Neuroscience 20111027

• L-Dihydroxyphenylalanine modulates the steady-state expression of mouse striatal tyrosine hydroxylase, aromatic L-amino acid decarboxylase, dopamine and its metabolites in an MPTP mouse model of Parkinson's disease.

  Life sciences 20111024

• Closed-loop deep brain stimulation is superior in ameliorating parkinsonism.

  Neuron 20111020

• Heat shock protein 70 kDa over-expression and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced nigrostriatal degeneration in mice.

  Neuroscience 20111013

• S-Allylcysteine, a garlic compound, protects against oxidative stress in 1-methyl-4-phenylpyridinium-induced parkinsonism in mice.

  The Journal of nutritional biochemistry 20111001

• The effect of docosahexaenoic Acid on visual evoked potentials in a mouse model of Parkinson's disease: the role of cyclooxygenase-2 and nuclear factor kappa-B.

  Neurotoxicity research 20111001

• JNK isoforms differentially regulate neurite growth and regeneration in dopaminergic neurons in vitro.

  Journal of molecular neuroscience : MN 20111001

• Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease.

  British journal of pharmacology 20111001

• The TrkB-positive dopaminergic neurons are less sensitive to MPTP insult in the substantia nigra of adult C57/BL mice.

  Neurochemical research 20111001

• Neuroprotection effects of retained acupuncture in neurotoxin-induced Parkinson's disease mice.

  Brain, behavior, and immunity 20111001

• The influence and the mechanism of docosahexaenoic acid on a mouse model of Parkinson's disease.

  Neurochemistry international 20111001

• Regulation of myocyte enhancer factor-2 transcription factors by neurotoxins.

  Neurotoxicology 20111001

• Melatonin protects against neurobehavioral and mitochondrial deficits in a chronic mouse model of Parkinson's disease.

  Pharmacology, biochemistry, and behavior 20111001

• Profiling changes in gait dynamics resulting from progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced nigrostriatal lesioning.

  Journal of neuroscience research 20111001

• Phosphatidylinositol 3-kinase/Akt signaling pathway mediates acupuncture-induced dopaminergic neuron protection and motor function improvement in a mouse model of Parkinson's disease.

  The International journal of neuroscience 20111001

• Regulation of bat echolocation pulse acoustics by striatal dopamine.

  The Journal of experimental biology 20111001

• Antiparkinsonian properties of a nerve growth factor dipeptide mimetic GK-2 in in vivo experiments.

  Bulletin of experimental biology and medicine 20111001

• Midbrain dopamine neurons associated with reward processing innervate the neurogenic subventricular zone.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20110914

• Engrailed protects mouse midbrain dopaminergic neurons against mitochondrial complex I insults.

  Nature neuroscience 20110904

• Mice lacking major brain gangliosides develop parkinsonism.

  Neurochemical research 20110901

• Cell-mediated transfer of catalase nanoparticles from macrophages to brain endothelial, glial and neuronal cells.

  Nanomedicine (London, England) 20110901

• Estrogen receptors and gonadal steroids in vulnerability and protection of dopamine neurons in a mouse model of Parkinson's disease.

  Neuropharmacology 20110901

• Pten ablation in adult dopaminergic neurons is neuroprotective in Parkinson's disease models.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20110901

• Aged monkeys as a partial model for Parkinson's disease.

  Pharmacology, biochemistry, and behavior 20110901

• Neural circuit architecture defects in a Drosophila model of Fragile X syndrome are alleviated by minocycline treatment and genetic removal of matrix metalloproteinase.

  Disease models & mechanisms 20110901

• An angiogenic inhibitor, cyclic RGDfV, attenuates MPTP-induced dopamine neuron toxicity.

  Experimental neurology 20110901

• Differential DAergic Control of D1 and D2 Receptor Agonist Over Locomotor Activity and GABA Level in the Striatum.

  Experimental neurobiology 20110901

• Involvement of the Fc gamma receptor in a chronic N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of dopaminergic loss.

  The Journal of biological chemistry 20110819

• Probing the steric space at the floor of the D1 dopamine receptor orthosteric binding domain: 7α-, 7β-, 8α-, and 8β-methyl substituted dihydrexidine analogues.

  Journal of medicinal chemistry 20110811

• The effect of nNOS inhibitors on toxin-induced cell death in dopaminergic cell lines depends on the extent of enzyme expression.

  Brain research 20110802

• Constitutive Ret signaling is protective for dopaminergic cell bodies but not for axonal terminals.

  Neurobiology of aging 20110801

• Both stereoselective (R)- and (S)-1-Methyl-1,2,3,4-tetrahydroisoquinoline enantiomers protect striatal terminals against rotenone-induced suppression of dopamine release.

  Neurotoxicity research 20110801

• The critical role of the MyD88-dependent pathway in non-CNS MPTP-mediated toxicity.

  Brain, behavior, and immunity 20110801

• The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's disease.

  Neurobiology of disease 20110801

• Assessment of fetal brain uptake of paraquat in utero using in vivo PET/CT imaging.

  Toxicological sciences : an official journal of the Society of Toxicology 20110801

• Inhibition of the bioactivation of the neurotoxin MPTP by antioxidants, redox agents and monoamine oxidase inhibitors.

  Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 20110801

• Parkinson's disease mouse models in translational research.

  Mammalian genome : official journal of the International Mammalian Genome Society 20110801

• Diesel exhaust activates and primes microglia: air pollution, neuroinflammation, and regulation of dopaminergic neurotoxicity.

  Environmental health perspectives 20110801

• MPTP-meditated hippocampal dopamine deprivation modulates synaptic transmission and activity-dependent synaptic plasticity.

  Toxicology and applied pharmacology 20110801

• MPP(+)-induced toxicity in the presence of dopamine is mediated by COX-2 through oxidative stress.

  Naunyn-Schmiedeberg's archives of pharmacology 20110801

• Endogenous morphine-like compound immunoreactivity increases in parkinsonism.

  Brain : a journal of neurology 20110801

• Parkin-mediated protection of dopaminergic neurons in a chronic MPTP-minipump mouse model of Parkinson disease.

  Journal of neuropathology and experimental neurology 20110801

• REM sleep behavior disorder in the marmoset MPTP model of early Parkinson disease.

  Sleep 20110801

• Transcriptional modulation by VIP: a rational target against inflammatory disease.

  Clinical epigenetics 20110801

• Chromone, a privileged scaffold for the development of monoamine oxidase inhibitors.

  Journal of medicinal chemistry 20110728

• Bioactive neo-clerodane diterpenoids from the whole plants of Ajuga ciliata Bunge.

  Journal of natural products 20110722

• Inhaled hydrogen sulfide prevents neurodegeneration and movement disorder in a mouse model of Parkinson's disease.

  Antioxidants & redox signaling 20110715

• Changes of gene expression profiles in the cervical spinal cord by acupuncture in an MPTP-intoxicated mouse model: microarray analysis.

  Gene 20110715

• Ethyl pyruvate rescues nigrostriatal dopaminergic neurons by regulating glial activation in a mouse model of Parkinson's disease.

  Journal of immunology (Baltimore, Md. : 1950) 20110715

• Identification of N-propylnoraporphin-11-yl 5-(1,2-dithiolan-3-yl)pentanoate as a new anti-Parkinson's agent possessing a dopamine D2 and serotonin 5-HT1A dual-agonist profile.

  Journal of medicinal chemistry 20110714

• Metabotropic glutamate receptor type 5 in levodopa-induced motor complications.

  Neurobiology of aging 20110701

• Chronic dietary supplementation with turmeric protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-mediated neurotoxicity in vivo: implications for Parkinson's disease.

  The British journal of nutrition 20110701

• Upregulation of microglial C1q expression has no effects on nigrostriatal dopaminergic injury in the MPTP mouse model of Parkinson disease.

  Journal of neuroimmunology 20110701

• Metabotropic glutamate receptor 5 antagonist protects dopaminergic and noradrenergic neurons from degeneration in MPTP-treated monkeys.

  Brain : a journal of neurology 20110701

• Parkin' control: regulation of PGC-1α through PARIS in Parkinson's disease.

  Disease models & mechanisms 20110701

• Recent progress toward hydrogen medicine: potential of molecular hydrogen for preventive and therapeutic applications.

  Current pharmaceutical design 20110701

• Features of microglia and neuroinflammation relevant to environmental exposure and neurotoxicity.

  International journal of environmental research and public health 20110701

• Pharmacological targeting of the transcription factor Nrf2 at the basal ganglia provides disease modifying therapy for experimental parkinsonism.

  Antioxidants & redox signaling 20110615

• Highly potent activity of (1R,2R,6S)-3-methyl-6-(prop-1-en-2-yl)cyclohex-3-ene-1,2-diol in animal models of Parkinson's disease.

  Journal of medicinal chemistry 20110609

• Role of the dopamine transporter in mediating the neuroleptic-induced reduction of tyrosine hydroxylase-immunoreactive midbrain neurons.

  Brain research 20110607

• Imidazolium salt (DBZIM) reduces gliosis in mice treated with neurotoxicant 2'-CH(3) -MPTP.

  CNS neuroscience & therapeutics 20110601

• DJ-1 cleavage by matrix metalloproteinase 3 mediates oxidative stress-induced dopaminergic cell death.

  Antioxidants & redox signaling 20110601

• Primary motor cortex of the parkinsonian monkey: differential effects on the spontaneous activity of pyramidal tract-type neurons.

  Cerebral cortex (New York, N.Y. : 1991) 20110601

• Neuroinflammation and α-synuclein dysfunction potentiate each other, driving chronic progression of neurodegeneration in a mouse model of Parkinson's disease.

  Environmental health perspectives 20110601

• Novel role of aquaporin-4 in CD4+ CD25+ T regulatory cell development and severity of Parkinson's disease.

  Aging cell 20110601

• Effects of D-cycloserine on MPTP-induced behavioral and neurological changes: potential for treatment of Parkinson's disease dementia.

  Behavioural brain research 20110601

• Rotenone, paraquat, and Parkinson's disease.

  Environmental health perspectives 20110601

• The selective mu-opioid receptor antagonist ADL5510 reduces levodopa-induced dyskinesia without affecting antiparkinsonian action in MPTP-lesioned macaque model of Parkinson's disease.

  Movement disorders : official journal of the Movement Disorder Society 20110601

• Harnessing neuroplasticity for clinical applications.

  Brain : a journal of neurology 20110601

• Cold water stress attenuates dopaminergic neurotoxicity induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice.

  Acta biochimica et biophysica Sinica 20110601

• Long-term potentiation and long-term depression: a clinical perspective.

  Clinics (Sao Paulo, Brazil) 20110601

• Epigallocatechin-3-gallate Regulates Inducible Nitric Oxide Synthase Expression in Human Umbilical Vein Endothelial Cells.

  Laboratory animal research 20110601

• The Interface between Cytoskeletal Aberrations and Mitochondrial Dysfunction in Alzheimer's Disease and Related Disorders.

  Experimental neurobiology 20110601

• Medical management of Parkinson's disease: focus on neuroprotection.

  Current neuropharmacology 20110601

• Kainic Acid-induced neurotoxicity: targeting glial responses and glia-derived cytokines.

  Current neuropharmacology 20110601

• Protective effects of synthetic kynurenines on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice.

  Brain research bulletin 20110530

• Effect of intermittent washout periods on progressive lesioning of the nigrostriatal pathway with 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

  Neuroscience 20110519

• Modeling of presymptomatic and symptomatic stages of parkinsonism in mice.

  Neuroscience 20110505

• Dynamic alterations of gene expression of nicotinic acetylcholine receptor α7, α4 and β2 subunits in an acute MPTP-lesioned mouse model.

  Neuroscience letters 20110502

• Coffee, ADORA2A, and CYP1A2: the caffeine connection in Parkinson's disease.

  European journal of neurology 20110501

• Fluoxetine prevents MPTP-induced loss of dopaminergic neurons by inhibiting microglial activation.

  Neuropharmacology 20110501

• The acute antiparkinsonian and antidyskinetic effect of AFQ056, a novel metabotropic glutamate receptor type 5 antagonist, in L-Dopa-treated parkinsonian monkeys.

  Parkinsonism & related disorders 20110501

• Modulation of α-synuclein aggregation by dopamine in the presence of MPTP and its metabolite.

  The FEBS journal 20110501

• The herbal preparation Padma® 28 protects against neurotoxicity in PC12 cells.

  Phytotherapy research : PTR 20110501

• Neuroprotective effects of creatine.

  Amino acids 20110501

• Brain 5-HT(2A) receptors in MPTP monkeys and levodopa-induced dyskinesias.

  The European journal of neuroscience 20110501

• Knockdown of cytosolic NADP(+) -dependent isocitrate dehydrogenase enhances MPP(+) -induced oxidative injury in PC12 cells.

  BMB reports 20110501

• A tale on animal models of Parkinson's disease.

  Movement disorders : official journal of the Movement Disorder Society 20110501

• Phenylbutyrate up-regulates the DJ-1 protein and protects neurons in cell culture and in animal models of Parkinson disease.

  The Journal of biological chemistry 20110429

• BL-1023 improves behavior and neuronal survival in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-intoxicated mice.

  Neuroscience 20110428

• Dopaminergic and behavioral correlates of progressive lesioning of the nigrostriatal pathway with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

  Neuroscience 20110428

• Possible role of propofol's cyclooxygenase-inhibiting property in alleviating dopaminergic neuronal loss in the substantia nigra in an MPTP-induced murine model of Parkinson's disease.

  Brain research 20110428

• Effects of treadmill exercise on behavioral recovery and neural changes in the substantia nigra and striatum of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse.

  Brain research 20110422

• Zonisamide-induced long-lasting recovery of dopaminergic neurons from MPTP-toxicity.

  Brain research 20110412

• Endometrial stem cell transplantation restores dopamine production in a Parkinson's disease model.

  Journal of cellular and molecular medicine 20110401

• Metabolic manipulators: a well founded strategy to combat mitochondrial dysfunction.

  Journal of inherited metabolic disease 20110401

• Dissociation of motor symptoms during deep brain stimulation of the subthalamic nucleus in the region of the internal capsule.

  Experimental neurology 20110401

• Neuroprotective changes of striatal degeneration-related gene expression by acupuncture in an MPTP mouse model of Parkinsonism: microarray analysis.

  Cellular and molecular neurobiology 20110401

• Mutant α-synuclein and aging reduce neurogenesis in the acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.

  Aging cell 20110401

• Mitochondrial quality control and Parkinson's disease: a pathway unfolds.

  Molecular neurobiology 20110401

• Baicalein protects the brain against neuron impairments induced by MPTP in C57BL/6 mice.

  Pharmacology, biochemistry, and behavior 20110401

• Bee venom reduces neuroinflammation in the MPTP-induced model of Parkinson's disease.

  The International journal of neuroscience 20110401

• Differential structural plasticity of corticostriatal and thalamostriatal axo-spinous synapses in MPTP-treated Parkinsonian monkeys.

  The Journal of comparative neurology 20110401

• Alterations in the mitochondrial proteome of neuroblastoma cells in response to complex 1 inhibition.

  Journal of proteome research 20110401

• The role of extracellular adenosine in chemical neurotransmission in the hippocampus and Basal Ganglia: pharmacological and clinical aspects.

  Current topics in medicinal chemistry 20110401

• IFN-γ signaling, with the synergistic contribution of TNF-α, mediates cell specific microglial and astroglial activation in experimental models of Parkinson's disease.

  Cell death & disease 20110401

• Polygalae radix inhibits toxin-induced neuronal death in the Parkinson's disease models.

  Journal of ethnopharmacology 20110324

• The endoplasmic reticulum stress sensor, ATF6α, protects against neurotoxin-induced dopaminergic neuronal death.

  The Journal of biological chemistry 20110311

• New evidences for fractalkine/CX3CL1 involved in substantia nigral microglial activation and behavioral changes in a rat model of Parkinson's disease.

  Neurobiology of aging 20110301

• Neuroprotective and anti-inflammatory effects of the adenosine A(2A) receptor antagonist ST1535 in a MPTP mouse model of Parkinson's disease.

  Synapse (New York, N.Y.) 20110301

• Running wheel activity restores MPTP-induced functional deficits.

  Journal of neural transmission (Vienna, Austria : 1996) 20110301

• Estradiol modulation of cortical, striatal and raphe nucleus 5-HT1A and 5-HT2A receptors of female hemiparkinsonian monkeys after long-term ovariectomy.

  Neuropharmacology 20110301

• Different sub-cellular localization of alpha-synuclein in the C57BL\6J mouse's central nervous system by two novel monoclonal antibodies.

  Journal of chemical neuroanatomy 20110301

• Chronic deprivation of TrkB signaling leads to selective late-onset nigrostriatal dopaminergic degeneration.

  Experimental neurology 20110301

• Low-dose 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine causes inflammatory activation of astrocytes in nuclear factor-κB reporter mice prior to loss of dopaminergic neurons.

  Journal of neuroscience research 20110301

• Gain of survival signaling by down-regulation of three key miRNAs in brain of calorie-restricted mice.

  Aging 20110301

• Experimental modeling of preclinical and clinical stages of Parkinson's disease.

  Bulletin of experimental biology and medicine 20110301

• In vitro study of neuroprotective properties of GK-2, a new original nerve growth factor mimetic.

  Bulletin of experimental biology and medicine 20110301

• Enhanced GDNF expression in dopaminergic cells of monkeys grafted with carotid body cell aggregates.

  Brain research 20110223

• Parkinsonian neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and alpha-synuclein mutations promote Tau protein phosphorylation at Ser262 and destabilize microtubule cytoskeleton in vitro.

  The Journal of biological chemistry 20110218

• α-Synuclein negatively regulates protein kinase Cδ expression to suppress apoptosis in dopaminergic neurons by reducing p300 histone acetyltransferase activity.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20110209

• Minor retinal degeneration in Parkinson's disease.

  Medical hypotheses 20110201

• Fatty acid amide hydrolase (FAAH) inhibition reduces L-3,4-dihydroxyphenylalanine-induced hyperactivity in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned non-human primate model of Parkinson's disease.

  The Journal of pharmacology and experimental therapeutics 20110201

• Reactive astrocytes and Wnt/β-catenin signaling link nigrostriatal injury to repair in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.

  Neurobiology of disease 20110201

• A neuroprotective role for angiogenin in models of Parkinson's disease.

  Journal of neurochemistry 20110201

• Transgenic conversion of omega-6 into omega-3 fatty acids in a mouse model of Parkinson's disease.

  Journal of lipid research 20110201

• Protective effect of panaxatriol saponins extracted from Panax notoginseng against MPTP-induced neurotoxicity in vivo.

  Journal of ethnopharmacology 20110127

• Enriched environment promotes similar neuronal and behavioral recovery in a young and aged mouse model of Parkinson's disease.

  Neuroscience 20110113

• Nucleolar disruption in dopaminergic neurons leads to oxidative damage and parkinsonism through repression of mammalian target of rapamycin signaling.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20110112

• Granulocyte-colony stimulating factor (G-CSF) enhances recovery in mouse model of Parkinson's disease.

  Neuroscience letters 20110107

• Implication of the c-Jun-NH2-terminal kinase pathway in the neuroprotective effect of puerarin against 1-methyl-4-phenylpyridinium (MPP+)-induced apoptosis in PC-12 cells.

  Neuroscience letters 20110103

• San-Huang-Xie-Xin-Tang Protects against Activated Microglia- and 6-OHDA-Induced Toxicity in Neuronal SH-SY5Y Cells.

  Evidence-based complementary and alternative medicine : eCAM 20110101

• Ganoderma lucidum Protects Dopaminergic Neuron Degeneration through Inhibition of Microglial Activation.

  Evidence-based complementary and alternative medicine : eCAM 20110101

• The Role of Th17 in Neuroimmune Disorders: A Target for CAM Therapy. Part III.

  Evidence-based complementary and alternative medicine : eCAM 20110101

• Acute but not chronic administration of pioglitazone promoted behavioral and neurochemical protective effects in the MPTP model of Parkinson's disease.

  Behavioural brain research 20110101

• Recombinant human mitochondrial transcription factor A stimulates mitochondrial biogenesis and ATP synthesis, improves motor function after MPTP, reduces oxidative stress and increases survival after endotoxin.

  Mitochondrion 20110101

• Environmental exposure, obesity, and Parkinson's disease: lessons from fat and old worms.

  Environmental health perspectives 20110101

• MPTP-induced neuroinflammation increases the expression of pro-inflammatory cytokines and their receptors in mouse brain.

  Neuroimmunomodulation 20110101

• Antiparkinsonian effects of aqueous methanolic extract of Hyoscyamus niger seeds result from its monoamine oxidase inhibitory and hydroxyl radical scavenging potency.

  Neurochemical research 20110101

• Assessment of metabolic changes in the striatum of a MPTP-intoxicated canine model: in vivo ¹H-MRS study of an animal model for Parkinson's disease.

  Magnetic resonance imaging 20110101

• Astaxanthin protects against MPTP/MPP+-induced mitochondrial dysfunction and ROS production in vivo and in vitro.

  Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 20110101

• Dyskinesias do not develop after chronic intermittent levodopa therapy in clinically hemiparkinsonian rhesus monkeys.

  Parkinsonism & related disorders 20110101

• Kainic acid-induced neurodegenerative model: potentials and limitations.

  Journal of biomedicine & biotechnology 20110101

• Protective Role of rAAV-NDI1, Serotype 5, in an Acute MPTP Mouse Parkinson's Model.

  Parkinson's disease 20110101

• Manganese inhalation as a Parkinson disease model.

  Parkinson's disease 20110101

• Limitations of animal models of Parkinson's disease.

  Parkinson's disease 20110101

• Microglial MAC1 receptor and PI3K are essential in mediating β-amyloid peptide-induced microglial activation and subsequent neurotoxicity.

  Journal of neuroinflammation 20110101

• Inflammatory mechanisms of neurodegeneration in toxin-based models of Parkinson's disease.

  Parkinson's disease 20110101

• Toxin-induced and genetic animal models of Parkinson's disease.

  Parkinson's disease 20110101

• Mitochondrial dysfunction in Parkinson's disease: pathogenesis and neuroprotection.

  Parkinson's disease 20110101

• Enhanced glutamate, IP3 and cAMP activity in the cerebral cortex of unilateral 6-hydroxydopamine induced Parkinson's rats: effect of 5-HT, GABA and bone marrow cell supplementation.

  Journal of biomedical science 20110101

• Increased mitochondrial calcium sensitivity and abnormal expression of innate immunity genes precede dopaminergic defects in Pink1-deficient mice.

  PloS one 20110101

• Use of non-steroidal anti-inflammatory drugs and risk of Parkinson's disease: nested case-control study.

  BMJ (Clinical research ed.) 20110101

• CX3CL1 reduces neurotoxicity and microglial activation in a rat model of Parkinson's disease.

  Journal of neuroinflammation 20110101

• Dispersed activity during passive movement in the globus pallidus of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated primate.

  PloS one 20110101

• BCG vaccine-induced neuroprotection in a mouse model of Parkinson's disease.

  PloS one 20110101

• Resistance to MPTP-neurotoxicity in α-synuclein knockout mice is complemented by human α-synuclein and associated with increased β-synuclein and Akt activation.

  PloS one 20110101

• Toxicity of neurons treated with herbicides and neuroprotection by mitochondria-targeted antioxidant SS31.

  International journal of environmental research and public health 20110101

• Mitochondrial Dysfunction: The Road to Alpha-Synuclein Oligomerization in PD.

  Parkinson's disease 20110101

• The endotoxin-induced neuroinflammation model of Parkinson's disease.

  Parkinson's disease 20110101

• The biochemical and cellular basis for nutraceutical strategies to attenuate neurodegeneration in Parkinson's disease.

  International journal of molecular sciences 20110101

• Evolution of extra-nigral damage predicts behavioural deficits in a rat proteasome inhibitor model of Parkinson's disease.

  PloS one 20110101

• The intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a new rodent model to test palliative and neuroprotective agents for Parkinson's disease.

  Current pharmaceutical design 20110101

• Phosphodiesterase 7 inhibition preserves dopaminergic neurons in cellular and rodent models of Parkinson disease.

  PloS one 20110101

• The Nrf2/ARE Pathway: A Promising Target to Counteract Mitochondrial Dysfunction in Parkinson's Disease.

  Parkinson's disease 20110101

• Hsp70 and its molecular role in nervous system diseases.

  Biochemistry research international 20110101

• Manganese-Induced Parkinsonism due to Ephedrone Abuse.

  Parkinson's disease 20110101

• Mitochondrial fusion/fission, transport and autophagy in Parkinson's disease: when mitochondria get nasty.

  Parkinson's disease 20110101

• Modeling antibiotic and cytotoxic effects of the dimeric isoquinoline IQ-143 on metabolism and its regulation in Staphylococcus aureus, Staphylococcus epidermidis and human cells.

  Genome biology 20110101

• Efficacy, safety, and patient preference of monoamine oxidase B inhibitors in the treatment of Parkinson's disease.

  Patient preference and adherence 20110101

• Dopamine signaling in dorsal versus ventral striatum: the dynamic role of cholinergic interneurons.

  Frontiers in systems neuroscience 20110101

• BmDJ-1 is a key regulator of oxidative modification in the development of the silkworm, Bombyx mori.

  PloS one 20110101

• Mitochondrial dysfunction in Parkinson's disease.

  Parkinson's disease 20110101

• [A comparative study of hemantane and amantadine effects on dopamine transporter expression in brain of normal and MPTP-treated C57BL/6 mice].

  Eksperimental'naia i klinicheskaia farmakologiia 20110101

• Drosophila models of Parkinson's disease: discovering relevant pathways and novel therapeutic strategies.

  Parkinson's disease 20110101

• Lack of neuroprotection in the absence of P2X7 receptors in toxin-induced animal models of Parkinson's disease.

  Molecular neurodegeneration 20110101

• Dynamic stereotypic responses of Basal Ganglia neurons to subthalamic nucleus high-frequency stimulation in the parkinsonian primate.

  Frontiers in systems neuroscience 20110101

• Minocycline fails to modulate cerebrospinal fluid HIV infection or immune activation in chronic untreated HIV-1 infection: results of a pilot study.

  AIDS research and therapy 20110101

• Balancing the brain: resting state networks and deep brain stimulation.

  Frontiers in integrative neuroscience 20110101

• Oxidation of the cysteine-rich regions of parkin perturbs its E3 ligase activity and contributes to protein aggregation.

  Molecular neurodegeneration 20110101

• Association of PGC-1alpha polymorphisms with age of onset and risk of Parkinson's disease.

  BMC medical genetics 20110101

• Lipopolysaccharide animal models for Parkinson's disease.

  Parkinson's disease 20110101

• Peripheral inflammation increases the damage in animal models of nigrostriatal dopaminergic neurodegeneration: possible implication in Parkinson's disease incidence.

  Parkinson's disease 20110101

• Optimizing a rodent model of Parkinson's disease for exploring the effects and mechanisms of deep brain stimulation.

  Parkinson's disease 20110101

• Do somatic mitochondrial DNA mutations contribute to Parkinson's disease?

  Parkinson's disease 20110101

• Do PPAR-Gamma Agonists Have a Future in Parkinson's Disease Therapy?

  Parkinson's disease 20110101

• Dopaminergic Balance between Reward Maximization and Policy Complexity.

  Frontiers in systems neuroscience 20110101

• Transcriptional Factor NF-κB as a Target for Therapy in Parkinson's Disease.

  Parkinson's disease 20110101

• Available and emerging treatments for Parkinson's disease: a review.

  Drug design, development and therapy 20110101

• Dexamethasone inhibits the Nox-dependent ROS production via suppression of MKP-1-dependent MAPK pathways in activated microglia.

  BMC neuroscience 20110101

• The antioxidative effect of electro-acupuncture in a mouse model of Parkinson's disease.

  PloS one 20110101

• Transplantation of neuronal-primed human bone marrow mesenchymal stem cells in hemiparkinsonian rodents.

  PloS one 20110101

• GSK-3 in Neurodegenerative Diseases.

  International journal of Alzheimer's disease 20110101

• Melatonin in mitochondrial dysfunction and related disorders.

  International journal of Alzheimer's disease 20110101

• Noradrenaline and Parkinson's disease.

  Frontiers in systems neuroscience 20110101

• Chronic apocynin treatment attenuates beta amyloid plaque size and microglial number in hAPP(751)(SL) mice.

  PloS one 20110101

• Assessing causal relationships in genomics: From Bradford-Hill criteria to complex gene-environment interactions and directed acyclic graphs.

  Emerging themes in epidemiology 20110101

• Neuroprotective effects of marine algae.

  Marine drugs 20110101

• Edaravone guards dopamine neurons in a rotenone model for Parkinson's disease.

  PloS one 20110101

• Therapeutic effects of hydrogen in animal models of Parkinson's disease.

  Parkinson's disease 20110101

• The involvement of neuroinflammation and kynurenine pathway in Parkinson's disease.

  Parkinson's disease 20110101

• The degenerating substantia nigra as a susceptible region for gene transfer-mediated inflammation.

  Parkinson's disease 20110101

• Loss of specificity in Basal Ganglia related movement disorders.

  Frontiers in systems neuroscience 20110101

• Protein kinase D1 (PKD1) activation mediates a compensatory protective response during early stages of oxidative stress-induced neuronal degeneration.

  Molecular neurodegeneration 20110101

• Nitric Oxide Synthase Inhibitor Improves De Novo and Long-Term l-DOPA-Induced Dyskinesia in Hemiparkinsonian Rats.

  Frontiers in systems neuroscience 20110101

• Distribution of tyrosine hydroxylase-expressing interneurons with respect to anatomical organization of the neostriatum.

  Frontiers in systems neuroscience 20110101

• The 5-HT(2A) Receptor Antagonist M100907 Produces Antiparkinsonian Effects and Decreases Striatal Glutamate.

  Frontiers in systems neuroscience 20110101

• Mitochondrial therapeutics in Alzheimer's disease and Parkinson's disease.

  Alzheimer's research & therapy 20110101

• Effect of endurance exercise training on the expression of GFAP, S100B, and NSE in the striatum of chronic/progressive mouse model of Parkinson's disease.

  NeuroRehabilitation 20110101

• Neuropharmacological approach against MPTP (1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine)-induced mouse model of Parkinson's disease.

  Acta neurobiologiae experimentalis 20110101

• Chaotic desynchronization as the therapeutic mechanism of deep brain stimulation.

  Frontiers in systems neuroscience 20110101

• α-Synuclein Alters Toll-Like Receptor Expression.

  Frontiers in neuroscience 20110101

• Neighboring Pallidal Neurons Do Not Exhibit more Synchronous Oscillations than Remote Ones in the MPTP Primate Model of Parkinson's Disease.

  Frontiers in systems neuroscience 20110101

• A Wnt1 regulated Frizzled-1/β-Catenin signaling pathway as a candidate regulatory circuit controlling mesencephalic dopaminergic neuron-astrocyte crosstalk: Therapeutical relevance for neuron survival and neuroprotection.

  Molecular neurodegeneration 20110101

• Bridging molecular genetics and biomarkers in lewy body and related disorders.

  International journal of Alzheimer's disease 20110101

• MPTP Neurotoxicity and Testosterone Induce Dendritic Remodeling of Striatal Medium Spiny Neurons in the C57Bl/6 Mouse.

  Parkinson's disease 20110101

• Pharmacological and physiological characterization of the tremulous jaw movement model of parkinsonian tremor: potential insights into the pathophysiology of tremor.

  Frontiers in systems neuroscience 20110101

• Estrogens regulate neuroinflammatory genes via estrogen receptors α and β in the frontal cortex of middle-aged female rats.

  Journal of neuroinflammation 20110101

• 24-Epibrassinolide, a Phytosterol from the Brassinosteroid Family, Protects Dopaminergic Cells against MPP-Induced Oxidative Stress and Apoptosis.

  Journal of toxicology 20110101

• Protective Action of Neurotrophic Factors and Estrogen against Oxidative Stress-Mediated Neurodegeneration.

  Journal of toxicology 20110101

• Upregulation of cathepsin D in the caudate nucleus of primates with experimental parkinsonism.

  Molecular neurodegeneration 20110101

• Enhanced catecholamine transporter binding in the locus coeruleus of patients with early Parkinson disease.

  BMC neurology 20110101

• Oxidative toxicity in neurodegenerative diseases: role of mitochondrial dysfunction and therapeutic strategies.

  Journal of toxicology 20110101

• 14-3-3theta protects against neurotoxicity in a cellular Parkinson's disease model through inhibition of the apoptotic factor Bax.

  PloS one 20110101

• Neuroprotective effect of kaempferol against a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse model of Parkinson's disease.

  Biological & pharmaceutical bulletin 20110101

• Past, present, and future of the pathophysiological model of the Basal Ganglia.

  Frontiers in neuroanatomy 20110101

• [Influence of hemantane and doxycycline on MPTP-evoked behavior violations in C57BL/6 mice].

  Eksperimental'naia i klinicheskaia farmakologiia 20110101

• The PPAR-γ agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys.

  Journal of neuroinflammation 20110101

• Renin angiotensin system and gender differences in dopaminergic degeneration.

  Molecular neurodegeneration 20110101

• Localization and Function of GABA Transporters GAT-1 and GAT-3 in the Basal Ganglia.

  Frontiers in systems neuroscience 20110101

• Degenerate wave and capacitive coupling increase human MSC invasion and proliferation while reducing cytotoxicity in an in vitro wound healing model.

  PloS one 20110101

• Immunoexcitotoxicity as a central mechanism in chronic traumatic encephalopathy-A unifying hypothesis.

  Surgical neurology international 20110101

• Early presymptomatic and long-term changes of rest activity cycles and cognitive behavior in a MPTP-monkey model of Parkinson's disease.

  PloS one 20110101

• Bladder, bowel, and sexual dysfunction in Parkinson's disease.

  Parkinson's disease 20110101

• Peripheral neuropathy in the Twitcher mouse involves the activation of axonal caspase 3.

  ASN neuro 20110101

• D-β-hydroxybutyrate is protective in mouse models of Huntington's disease.

  PloS one 20110101

• The locus coeruleus is directly implicated in L-DOPA-induced dyskinesia in parkinsonian rats: an electrophysiological and behavioural study.

  PloS one 20110101

• Controversies in neurology: why monoamine oxidase B inhibitors could be a good choice for the initial treatment of Parkinson's disease.

  BMC neurology 20110101

• Regulation by glycogen synthase kinase-3 of inflammation and T cells in CNS diseases.

  Frontiers in molecular neuroscience 20110101

• Multi-neuronal recordings in the Basal Ganglia in normal and dystonic rats.

  Frontiers in systems neuroscience 20110101

• New aspects of mitochondrial Uncoupling Proteins (UCPs) and their roles in tumorigenesis.

  International journal of molecular sciences 20110101

• Type A monoamine oxidase regulates life and death of neurons in neurodegeneration and neuroprotection.

  International review of neurobiology 20110101

• Generation of reactive oxygen species in 1-methyl-4-phenylpyridinium (MPP+) treated dopaminergic neurons occurs as an NADPH oxidase-dependent two-wave cascade.

  Journal of neuroinflammation 20110101

• The role of manganese superoxide dismutase in inflammation defense.

  Enzyme research 20110101

• The role of the MYD88-dependent pathway in MPTP-induced brain dopaminergic degeneration.

  Journal of neuroinflammation 20110101

• Protective effect of tetrahydroxystilbene glucoside on 6-OHDA-induced apoptosis in PC12 cells through the ROS-NO pathway.

  PloS one 20110101

• Low concentrations of methamphetamine can protect dopaminergic cells against a larger oxidative stress injury: mechanistic study.

  PloS one 20110101

• The role of inhibition in generating and controlling Parkinson's disease oscillations in the Basal Ganglia.

  Frontiers in systems neuroscience 20110101

• L-DOPA-Induced Dyskinesia and Abnormal Signaling in Striatal Medium Spiny Neurons: Focus on Dopamine D1 Receptor-Mediated Transmission.

  Frontiers in behavioral neuroscience 20110101

• Early exposure to paraquat sensitizes dopaminergic neurons to subsequent silencing of PINK1 gene expression in mice.

  International journal of biological sciences 20110101

• Dissociation of progressive dopaminergic neuronal death and behavioral impairments by Bax deletion in a mouse model of Parkinson's diseases.

  PloS one 20110101

• Stuck at the bench: Potential natural neuroprotective compounds for concussion.

  Surgical neurology international 20110101

• Beyond cAMP: The Regulation of Akt and GSK3 by Dopamine Receptors.

  Frontiers in molecular neuroscience 20110101

• Roles of oxidative stress, apoptosis, PGC-1α and mitochondrial biogenesis in cerebral ischemia.

  International journal of molecular sciences 20110101

• Differential expression of Wnts after spinal cord contusion injury in adult rats.

  PloS one 20110101

• Mortality from Parkinson's disease and other causes among a workforce manufacturing paraquat: a retrospective cohort study.

  BMJ open 20110101

• Moving forward: advances in the treatment of movement disorders with deep brain stimulation.

  Frontiers in integrative neuroscience 20110101

• Neuromelanin is an immune stimulator for dendritic cells in vitro.

  BMC neuroscience 20110101

• A TNF receptor 2 selective agonist rescues human neurons from oxidative stress-induced cell death.

  PloS one 20110101

• Differential regional expression patterns of α-synuclein, TNF-α, and IL-1β; and variable status of dopaminergic neurotoxicity in mouse brain after Paraquat treatment.

  Journal of neuroinflammation 20110101

• Interaction between α-synuclein and other proteins in neurodegenerative disorders.

  TheScientificWorldJournal 20110101

• The promise of neuroprotective agents in Parkinson's disease.

  Frontiers in neurology 20110101

• Acupuncture enhances the synaptic dopamine availability to improve motor function in a mouse model of Parkinson's disease.

  PloS one 20110101

• Oxidation of DJ-1 induced by 6-hydroxydopamine decreasing intracellular glutathione.

  PloS one 20110101

• History of innate immunity in neurodegenerative disorders.

  Frontiers in pharmacology 20110101

• Effects of drinking hydrogen-rich water on the quality of life of patients treated with radiotherapy for liver tumors.

  Medical gas research 20110101

• Improved brain MRI indices in the acute brain stem infarct sites treated with hydroxyl radical scavengers, Edaravone and hydrogen, as compared to Edaravone alone. A non-controlled study.

  Medical gas research 20110101

• The 2011 Medical Molecular Hydrogen Symposium: An inaugural symposium of the journal Medical Gas Research.

  Medical gas research 20110101

• Application of medical gases in the field of neurobiology.

  Medical gas research 20110101

• Molecular hydrogen protects chondrocytes from oxidative stress and indirectly alters gene expressions through reducing peroxynitrite derived from nitric oxide.

  Medical gas research 20110101

• Open-label trial and randomized, double-blind, placebo-controlled, crossover trial of hydrogen-enriched water for mitochondrial and inflammatory myopathies.

  Medical gas research 20110101

• Oxidative stress in neurodegenerative diseases: mechanisms and therapeutic perspectives.

  Oxidative medicine and cellular longevity 20110101

• Idebenone and resveratrol extend lifespan and improve motor function of HtrA2 knockout mice.

  PloS one 20110101

• Resveratrol protects rats from Aβ-induced neurotoxicity by the reduction of iNOS expression and lipid peroxidation.

  PloS one 20110101

• Apoptosis Induced by Manganese on Neuronal SK-N-MC Cell Line: Endoplasmic Reticulum (ER) Stress and Mitochondria Dysfunction.

  Environmental health and toxicology 20110101

• The translational value of the MPTP non-human primate model of Parkinsonism for deep brain stimulation research.

  Conference proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual Conference 20110101

• Inter-hemispheric asymmetry of nigrostriatal dopaminergic lesion: a possible compensatory mechanism in Parkinson's disease.

  Frontiers in systems neuroscience 20110101

• A role for locus coeruleus in Parkinson tremor.

  Frontiers in human neuroscience 20110101

• Correlation transfer from basal ganglia to thalamus in Parkinson's disease.

  Frontiers in computational neuroscience 20110101

• Inflammatory Animal Model for Parkinson's Disease: The Intranigral Injection of LPS Induced the Inflammatory Process along with the Selective Degeneration of Nigrostriatal Dopaminergic Neurons.

  ISRN neurology 20110101

• Serine 129 Phosphorylation of α-Synuclein Cross-Links with Tissue Transglutaminase to Form Lewy Body-Like Inclusion Bodies.

  ISRN neurology 20110101

• Peripheral vs. Central Sex Steroid Hormones in Experimental Parkinson's Disease.

  Frontiers in endocrinology 20110101

• Male/Female differences in neuroprotection and neuromodulation of brain dopamine.

  Frontiers in endocrinology 20110101

• Microdialysis study of striatal dopamine in MPTP-hemilesioned rats challenged with apomorphine and amphetamine.

  Behavioural brain research 20101220

• Exercise elevates dopamine D2 receptor in a mouse model of Parkinson's disease: in vivo imaging with [¹⁸F]fallypride.

  Movement disorders : official journal of the Movement Disorder Society 20101215

• Functional proteomic analysis for regulatory T cell surveillance of the HIV-1-infected macrophage.

  Journal of proteome research 20101203

• Exercise effects on motor and affective behavior and catecholamine neurochemistry in the MPTP-lesioned mouse.

  Behavioural brain research 20101201

• Protective effects of Chunghyuldan against ROS-mediated neuronal cell death in models of Parkinson's disease.

  Basic & clinical pharmacology & toxicology 20101201

• Morphological changes in serotoninergic neurites in the striatum and globus pallidus in levodopa primed MPTP treated common marmosets with dyskinesia.

  Neurobiology of disease 20101201

• Metabolic activity of the subthalamic nucleus in a primate model of L-dopa-unresponsive parkinsonism.

  Neurological research 20101201

• Neuroprotection by a mitochondria-targeted drug in a Parkinson's disease model.

  Free radical biology & medicine 20101201

• The partial dopamine agonist pardoprunox (SLV308) administered in combination with l-dopa improves efficacy and decreases dyskinesia in MPTP treated common marmosets.

  Experimental neurology 20101201

• Proanthocyanidin-rich fraction from Croton celtidifolius Baill confers neuroprotection in the intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine rat model of Parkinson's disease.

  Journal of neural transmission (Vienna, Austria : 1996) 20101201

• Otx2 controls neuron subtype identity in ventral tegmental area and antagonizes vulnerability to MPTP.

  Nature neuroscience 20101201

• Effects of rotenone and other mitochondrial complex I inhibitors on the brine shrimp Artemia.

  Acta biologica Hungarica 20101201

• Oxidative stress induced by the Fe/ascorbic acid system or model ischemia in vitro: effect of carvedilol and pyridoindole antioxidant SMe1EC2 in young and adult rat brain tissue.

  Interdisciplinary toxicology 20101201

• Mesenchymal stem cells for treatment of CNS injury.

  Current neuropharmacology 20101201

• The role of axonopathy in Parkinson's disease.

  Experimental neurobiology 20101201

• Gene disruption of caspase-3 prevents MPTP-induced Parkinson's disease in mice.

  Biochemical and biophysical research communications 20101112

• Redox regulation of mitochondrial fission, protein misfolding, synaptic damage, and neuronal cell death: potential implications for Alzheimer's and Parkinson's diseases.

  Apoptosis : an international journal on programmed cell death 20101101

• Activation of ataxia telangiectasia muted under experimental models and human Parkinson's disease.

  Cellular and molecular life sciences : CMLS 20101101

• Selenium partially reverses the depletion of striatal dopamine and its metabolites in MPTP-treated C57BL mice.

  Neurochemistry international 20101101

• The mechanism of action of MPTP-induced neuroinflammation and its modulation by melatonin in rat astrocytoma cells, C6.

  Free radical research 20101101

• Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia.

  Annals of neurology 20101101

• Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examples.

  Archives of toxicology 20101101

• [Effects of subchronic hemantane administration on dopamine and serotonin receptors in intact and MPP+-treated rat brain ex vivo].

  Eksperimental'naia i klinicheskaia farmakologiia 20101101

• Elevation of oxidized DJ-1 in the brain and erythrocytes of Parkinson disease model animals.

  Neuroscience letters 20101015

• Pardoprunox reverses motor deficits but induces only mild dyskinesia in MPTP-treated common marmosets.

  Movement disorders : official journal of the Movement Disorder Society 20101015

• Substance abuse and movement disorders.

  Movement disorders : official journal of the Movement Disorder Society 20101015

• MPTP-induced parkinsonism extends to a subclass of TH-positive neurons in the gut.

  Brain research 20101008

• Cortical regulation of striatal medium spiny neuron dendritic remodeling in parkinsonism: modulation of glutamate release reverses dopamine depletion-induced dendritic spine loss.

  Cerebral cortex (New York, N.Y. : 1991) 20101001

• Neuroprotective and anti-inflammatory activities of ketogenic diet on MPTP-induced neurotoxicity.

  Journal of molecular neuroscience : MN 20101001

• Intranigral LPS administration produces dopamine, glutathione but not behavioral impairment in comparison to MPTP and 6-OHDA neurotoxin models of Parkinson's disease.

  Neurochemical research 20101001

• Dopaminergic cell damage and vulnerability to MPTP in Pink1 knockdown zebrafish.

  Neurobiology of disease 20101001

• N(ɛ)-(carboxymethyl)lysine linkage to α-synuclein and involvement of advanced glycation end products in α-synuclein deposits in an MPTP-intoxicated mouse model.

  Biochimie 20101001

• Preladenant, a selective A(2A) receptor antagonist, is active in primate models of movement disorders.

  Experimental neurology 20101001

• Licofelone attenuates MPTP-induced neuronal toxicity: behavioral, biochemical and cellular evidence.

  Inflammopharmacology 20101001

• Oestrogen receptor beta ligand: a novel treatment to enhance endogenous functional remyelination.

  Brain : a journal of neurology 20101001

• Experimental model of combined pain and depression status in rats.

  Bulletin of experimental biology and medicine 20101001

• [Pathophysiology of Parkinson's disease: an update].

  Bulletin de l'Academie nationale de medecine 20101001

• The effects of docosahexaenoic acid on glial derived neurotrophic factor and neurturin in bilateral rat model of Parkinson's disease.

  Folia histochemica et cytobiologica 20100930

• Neuroprotective effects of an herbal medicine, Yi-Gan San on MPP+/MPTP-induced cytotoxicity in vitro and in vivo.

  Journal of ethnopharmacology 20100915

• Pathogenic lysosomal depletion in Parkinson's disease.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20100915

• Zonisamide reduces cell death in SH-SY5Y cells via an anti-apoptotic effect and by upregulating MnSOD.

  Neuroscience letters 20100906

• HIV-associated neurocognitive disorder: pathogenesis and therapeutic opportunities.

  Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology 20100901

• Gene-environment interactions in Parkinson's disease and other forms of parkinsonism.

  Neurotoxicology 20100901

• A direct projection from the subthalamic nucleus to the ventral thalamus in monkeys.

  Neurobiology of disease 20100901

• Modeling a sensitization stage and a precipitation stage for Parkinson's disease using prenatal and postnatal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration.

  Neuroscience 20100901

• Inhibition of inducible nitric oxide synthase expression and cell death by (-)-epigallocatechin-3-gallate, a green tea catechin, in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.

  Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 20100901

• Functional disconnection of the substantia nigra pars compacta from the pedunculopontine nucleus impairs learning of a conditioned avoidance task.

  Neurobiology of learning and memory 20100901

• The roles of the thioredoxin system and peroxiredoxins in 1-methyl-4-phenyl-pyridinium ion-induced cytotoxicity in rat pheochromocytoma cells.

  Toxicology in vitro : an international journal published in association with BIBRA 20100901

• Identification of novel monoamine oxidase B inhibitors by structure-based virtual screening.

  Bioorganic & medicinal chemistry letters 20100901

• Amelioration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced behavioural dysfunction and oxidative stress by Pycnogenol in mouse model of Parkinson's disease.

  Behavioural pharmacology 20100901

• The dopamine D3 receptor antagonist, S33138, counters cognitive impairment in a range of rodent and primate procedures.

  The international journal of neuropsychopharmacology 20100901

• Therapeutic potential of targeting group III metabotropic glutamate receptors in the treatment of Parkinson's disease.

  British journal of pharmacology 20100901

• Therapeutic effect of a novel anti-parkinsonian agent zonisamide against MPTP (1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine) neurotoxicity in mice.

  Metabolic brain disease 20100901

• PINK1 and Parkin to control mitochondria remodeling.

  Anatomy & cell biology 20100901

• Melatonin metabolism in the central nervous system.

  Current neuropharmacology 20100901

• The role of mitochondria in brain aging and the effects of melatonin.

  Current neuropharmacology 20100901

• Neurotoxins: free radical mechanisms and melatonin protection.

  Current neuropharmacology 20100901

• Neurotoxic effects of tetrahydroisoquinolines and underlying mechanisms.

  Experimental neurobiology 20100901

• Role of cortical and striatal 5-HT1A receptors in alleviating antipsychotic-induced extrapyramidal disorders.

  Progress in neuro-psychopharmacology & biological psychiatry 20100816

• Depressive-like behaviors alterations induced by intranigral MPTP, 6-OHDA, LPS and rotenone models of Parkinson's disease are predominantly associated with serotonin and dopamine.

  Progress in neuro-psychopharmacology & biological psychiatry 20100816

• Novel D3 dopamine receptor-preferring agonist D-264: Evidence of neuroprotective property in Parkinson's disease animal models induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and lactacystin.

  Journal of neuroscience research 20100815

• MPTP treatment increases expression of pre-pro-nociceptin/orphanin FQ mRNA in a subset of substantia nigra reticulata neurons.

  Neuroscience 20100811

• Mesencephalic and striatal protein profiles in mice over-expressing glucose-6-phosphate dehydrogenase in dopaminergic neurons.

  Journal of proteomics 20100805

• Decreased RGS9 protein level in the striatum of rodents undergoing MPTP or 6-OHDA neurotoxicity.

  Neuroscience letters 20100802

• An in vivo pharmacological evaluation of pardoprunox (SLV308)--a novel combined dopamine D(2)/D(3) receptor partial agonist and 5-HT(1A) receptor agonist with efficacy in experimental models of Parkinson's disease.

  European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 20100801

• Cellular localization of the organic cation transporters, OCT1 and OCT2, in brain microvessel endothelial cells and its implication for MPTP transport across the blood-brain barrier and MPTP-induced dopaminergic toxicity in rodents.

  Journal of neurochemistry 20100801

• alpha-Synuclein- and MPTP-generated rodent models of Parkinson's disease and the study of extracellular striatal dopamine dynamics: a microdialysis approach.

  CNS & neurological disorders drug targets 20100801

• Macrophage-mediated GDNF delivery protects against dopaminergic neurodegeneration: a therapeutic strategy for Parkinson's disease.

  Molecular therapy : the journal of the American Society of Gene Therapy 20100801

• Promise and pitfalls of animal models of schizophrenia.

  Current psychiatry reports 20100801

• The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia.

  Acta neuropathologica 20100801

• Morin exerts neuroprotective actions in Parkinson disease models in vitro and in vivo.

  Acta pharmacologica Sinica 20100801

• Apoptosis-inducing factor deficiency sensitizes dopaminergic neurons to parkinsonian neurotoxins.

  Annals of neurology 20100801

• Extracellular dopamine potentiates mn-induced oxidative stress, lifespan reduction, and dopaminergic neurodegeneration in a BLI-3-dependent manner in Caenorhabditis elegans.

  PLoS genetics 20100801

• Effect of histamine H2 receptor antagonism on levodopa-induced dyskinesia in the MPTP-macaque model of Parkinson's disease.

  Movement disorders : official journal of the Movement Disorder Society 20100730

• Neurotrophic and neurorescue effects of Echinacoside in the subacute MPTP mouse model of Parkinson's disease.

  Brain research 20100730

• Gene expression profiling in progressively MPTP-lesioned macaques reveals molecular pathways associated with sporadic Parkinson's disease.

  Brain research 20100730

• Microglial activation and age-related dopaminergic neurodegeneration in MPTP-treated SAMP8 mice.

  Brain research 20100723

• Meloxicam protects cell damage from 1-methyl-4-phenyl pyridinium toxicity via the phosphatidylinositol 3-kinase/Akt pathway in human dopaminergic neuroblastoma SH-SY5Y cells.

  Brain research 20100716

• Salicylic acid protects against chronic L-DOPA-induced 6-OHDA generation in experimental model of parkinsonism.

  Brain research 20100716

• Objective and quantitative evaluation of motor function in a monkey model of Parkinson's disease.

  Journal of neuroscience methods 20100715

• Paroxetine prevents loss of nigrostriatal dopaminergic neurons by inhibiting brain inflammation and oxidative stress in an experimental model of Parkinson's disease.

  Journal of immunology (Baltimore, Md. : 1950) 20100715

• Regeneration of the MPTP-lesioned dopaminergic system after convection-enhanced delivery of AAV2-GDNF.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20100714

• VTA neurons show a potentially protective transcriptional response to MPTP.

  Brain research 20100709

• Paraquat and Parkinson's disease.

  Cell death and differentiation 20100701

• Hexokinase II gene transfer protects against neurodegeneration in the rotenone and MPTP mouse models of Parkinson's disease.

  Journal of neuroscience research 20100701

• Mulberry fruit protects dopaminergic neurons in toxin-induced Parkinson's disease models.

  The British journal of nutrition 20100701

• Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson's disease.

  Journal of neurochemistry 20100701

• Estrogen reduces BDNF level, but maintains dopaminergic cell density in the striatum of MPTP mouse model.

  The International journal of neuroscience 20100701

• Metabolic changes detected in vivo by 1H MRS in the MPTP-intoxicated mouse.

  NMR in biomedicine 20100701

• Exercise protects against MPTP-induced neurotoxicity in mice.

  Brain research 20100623

• Time course of MPTP toxicity on translational control protein expression in mice brain.

  Toxicology letters 20100616

• A rotarod test for evaluation of motor skill learning.

  Journal of neuroscience methods 20100615

• The timing of administration, dose dependence and efficacy of dopa decarboxylase inhibitors on the reversal of motor disability produced by L-DOPA in the MPTP-treated common marmoset.

  European journal of pharmacology 20100610

• Serine 129 phosphorylation reduces the ability of alpha-synuclein to regulate tyrosine hydroxylase and protein phosphatase 2A in vitro and in vivo.

  The Journal of biological chemistry 20100604

• Effects of cysteamine on MPTP-induced dopaminergic neurodegeneration in mice.

  Brain research 20100604

• Changes of AMPA receptors in MPTP monkeys with levodopa-induced dyskinesias.

  Neuroscience 20100602

• Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys.

  Neuropharmacology 20100601

• Dual motor response to l-dopa and nociceptin/orphanin FQ receptor antagonists in 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) treated mice: Paradoxical inhibition is relieved by D(2)/D(3) receptor blockade.

  Experimental neurology 20100601

• Protective effects of heme oxygenase-1 against MPP(+)-induced cytotoxicity in PC-12 cells.

  Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 20100601

• Localization and function of GABA transporters in the globus pallidus of parkinsonian monkeys.

  Experimental neurology 20100601

• Genes regulated in MPTP-treated macaques and human Parkinson's disease suggest a common signature in prefrontal cortex.

  Neurobiology of disease 20100601

• Dopaminergic cells in the periaqueductal grey matter of MPTP-treated monkeys and mice; patterns of survival and effect of deep brain stimulation and lesion of the subthalamic nucleus.

  Parkinsonism & related disorders 20100601

• Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.

  The Journal of pharmacology and experimental therapeutics 20100601

• Sex differences in motor behavior in the MPTP mouse model of Parkinson's disease.

  Pharmacology, biochemistry, and behavior 20100601

• Post-MPTP treatment with granulocyte colony-stimulating factor improves nigrostriatal function in the mouse model of Parkinson's disease.

  Molecular neurobiology 20100601

• Therapeutic effect of a novel anti-parkinsonian agent zonisamide against MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity in mice.

  Metabolic brain disease 20100601

• Biochemical alterations of the striatum in an MPTP-treated mouse model of Parkinson's disease.

  Metabolic brain disease 20100601

• Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson's disease (PD SURG trial): a randomised, open-label trial.

  The Lancet. Neurology 20100601

• Interactions of 1-methyl-3-phenylpyrrolidine and 3-methyl-1-phenyl-3-azabicyclo[3.1.0]hexane with monoamine oxidase B.

  Bioorganic & medicinal chemistry 20100601

• Aged Tgfbeta2/Gdnf double-heterozygous mice show no morphological and functional alterations in the nigrostriatal system.

  Journal of neural transmission (Vienna, Austria : 1996) 20100601

• Effect of preferential cyclooxygenase-2 (COX-2) inhibitor against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced striatal lesions in rats: behavioral, biochemical and histological evidences.

  Indian journal of experimental biology 20100601

• Why do we need multifunctional neuroprotective and neurorestorative drugs for Parkinson's and Alzheimer's diseases as disease modifying agents.

  Experimental neurobiology 20100601

• Poly(ADP-ribose)polymerase inhibitor can attenuate the neuronal death after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice.

  Journal of neuroscience research 20100515

• Towards model-based control of Parkinson's disease.

  Philosophical transactions. Series A, Mathematical, physical, and engineering sciences 20100513

• Prosurvival effect of human wild-type alpha-synuclein on MPTP-induced toxicity to central but not peripheral catecholaminergic neurons isolated from transgenic mice.

  Neuroscience 20100505

• Neuroprotection by caffeine: time course and role of its metabolites in the MPTP model of Parkinson's disease.

  Neuroscience 20100505

• Chronic administration with rotenone does not enhance MPTP neurotoxicity in C57BL/6 mice.

  Journal of molecular neuroscience : MN 20100501

• Effect of L-Dopa on metabotropic glutamate receptor 5 in the brain of parkinsonian monkeys.

  Journal of neurochemistry 20100501

• Differing short-term neuroprotective effects of the fibrates fenofibrate and bezafibrate in MPTP and 6-OHDA experimental models of Parkinson's disease.

  Behavioural pharmacology 20100501

• Drinking hydrogen water ameliorated cognitive impairment in senescence-accelerated mice.

  Journal of clinical biochemistry and nutrition 20100501

• Insulin like growth factor-1 prevents 1-mentyl-4-phenylphyridinium-induced apoptosis in PC12 cells through activation of glycogen synthase kinase-3beta.

  Toxicology 20100430

• Nicotine- and caffeine-mediated changes in gene expression patterns of MPTP-lesioned mouse striatum: Implications in neuroprotection mechanism.

  Chemico-biological interactions 20100429

• Catalpol attenuates MPTP induced neuronal degeneration of nigral-striatal dopaminergic pathway in mice through elevating glial cell derived neurotrophic factor in striatum.

  Neuroscience 20100428

• Protocatechuic acid inhibits neurotoxicity induced by MPTP in vivo.

  Neuroscience letters 20100426

• Lentiviral overexpression of GRK6 alleviates L-dopa-induced dyskinesia in experimental Parkinson's disease.

  Science translational medicine 20100421

• Striatal Akt/GSK3 signaling pathway in the development of L-Dopa-induced dyskinesias in MPTP monkeys.

  Progress in neuro-psychopharmacology & biological psychiatry 20100416

• Ethyl pyruvate has a neuroprotective effect through activation of extracellular signal-regulated kinase in Parkinson's disease model.

  Biochemical and biophysical research communications 20100409

• Nest building performance following MPTP toxicity in mice.

  Behavioural brain research 20100402

• Nrf2 regulates microglial dynamics and neuroinflammation in experimental Parkinson's disease.

  Glia 20100401

• MPTP-induced dopaminergic degeneration and deficits in object recognition in rats are accompanied by neuroinflammation in the hippocampus.

  Pharmacology, biochemistry, and behavior 20100401

• Transient elevation of adult hippocampal neurogenesis after dopamine depletion.

  Experimental neurology 20100401

• Vulnerability of peripheral catecholaminergic neurons to MPTP is not regulated by alpha-synuclein.

  Neurobiology of disease 20100401

• Preventive role of PD-1 on MPTP-induced dopamine depletion in mice.

  Cell biochemistry and function 20100401

• Detection of MPTP-induced substantia nigra hyperechogenicity in Rhesus monkeys by transcranial ultrasound.

  Ultrasound in medicine & biology 20100401

• Cytochrome P450 2D6 enzyme neuroprotects against 1-methyl-4-phenylpyridinium toxicity in SH-SY5Y neuronal cells.

  The European journal of neuroscience 20100401

• Cellular repair in the parkinsonian nonhuman primate brain.

  Rejuvenation research 20100401

• Involvement of NMDA receptors in both MPTP-induced neuroinflammation and deficits in episodic-like memory in Wistar rats.

  Behavioural brain research 20100317

• A new ethyladenine antagonist of adenosine A(2A) receptors: behavioral and biochemical characterization as an antiparkinsonian drug.

  Neuropharmacology 20100301

• Regulatory T cells attenuate Th17 cell-mediated nigrostriatal dopaminergic neurodegeneration in a model of Parkinson's disease.

  Journal of immunology (Baltimore, Md. : 1950) 20100301

• Environmental toxins and Parkinson's disease: putative roles of impaired electron transport chain and oxidative stress.

  Toxicology and industrial health 20100301

• Ultrastructural localization and function of dopamine D1-like receptors in the substantia nigra pars reticulata and the internal segment of the globus pallidus of parkinsonian monkeys.

  The European journal of neuroscience 20100301

• [Experimental modeling of functional deficiency of the nigrostriatal dopaminergic system in mice].

  Rossiiskii fiziologicheskii zhurnal imeni I.M. Sechenova 20100301

• Cyclooxygenase and neuroinflammation in Parkinson's disease neurodegeneration.

  Current neuropharmacology 20100301

• Altered AMPA receptor expression with treadmill exercise in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse model of basal ganglia injury.

  Journal of neuroscience research 20100215

• A selective TrkB agonist with potent neurotrophic activities by 7,8-dihydroxyflavone.

  Proceedings of the National Academy of Sciences of the United States of America 20100209

• Neuroprotective effect of PACAP on translational control alteration and cognitive decline in MPTP parkinsonian mice.

  Neurotoxicity research 20100201

• Single intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice models early preclinical phase of Parkinson's disease.

  Neurotoxicity research 20100201

• Melatonin treatment potentiates neurodegeneration in a rat rotenone Parkinson's disease model.

  Journal of neuroscience research 20100201

• Synaptic recruitment of AMPA glutamate receptor subunits in levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate.

  Synapse (New York, N.Y.) 20100201

• Oxidants induce alternative splicing of alpha-synuclein: Implications for Parkinson's disease.

  Free radical biology & medicine 20100201

• The antiepileptic drug zonisamide inhibits MAO-B and attenuates MPTP toxicity in mice: clinical relevance.

  Experimental neurology 20100201

• Small peptide inhibitor of JNKs protects against MPTP-induced nigral dopaminergic injury via inhibiting the JNK-signaling pathway.

  Laboratory investigation; a journal of technical methods and pathology 20100201

• Molecular modeling study of 4-phenylpiperazine and 4-phenyl-1,2,3,6-tetrahydropyridine derivatives: a new step towards the design of high-affinity 5-HT1A ligands.

  Bioorganic & medicinal chemistry letters 20100201

• Gene expression profile of acupuncture treatment in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease model.

  Neurological research 20100201

• Neuroprotective effects of bee venom pharmaceutical acupuncture in acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse model of Parkinson's disease.

  Neurological research 20100201

• Neuroprotective effect of Centella asiatica extract (CAE) on experimentally induced parkinsonism in aged Sprague-Dawley rats.

  The Journal of toxicological sciences 20100201

• [Caffeine as a preventive drug for Parkinson's disease: epidemiologic evidence and experimental support].

  Revista de neurologia 20100201

• Curcumin prevents dopaminergic neuronal death through inhibition of the c-Jun N-terminal kinase pathway.

  Rejuvenation research 20100201

• Rapamycin protects against neuron death in in vitro and in vivo models of Parkinson's disease.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20100120

• BDNF levels are not related with levodopa-induced dyskinesias in MPTP monkeys.

  Movement disorders : official journal of the Movement Disorder Society 20100115

• Vertical grid test and modified horizontal grid test are sensitive methods for evaluating motor dysfunctions in the MPTP mouse model of Parkinson's disease.

  Brain research 20100108

• Increased expression of erythropoietin receptor in 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced Parkinsonian model.

  Physiological research 20100101

• Effect of non-dopaminergic drug treatment on Levodopa induced dyskinesias in MPTP monkeys: common implication of striatal neuropeptides.

  Neuropharmacology 20100101

• Effects of hydroxysafflor yellow A in the attenuation of MPTP neurotoxicity in mice.

  Neurochemical research 20100101

• Role of PPARs in Radiation-Induced Brain Injury.

  PPAR research 20100101

• The dopamine D(2) receptor partial agonist aplindore improves motor deficits in MPTP-treated common marmosets alone and combined with L-dopa.

  Journal of neural transmission (Vienna, Austria : 1996) 20100101

• Potentiation of methamphetamine neurotoxicity by intrastriatal lipopolysaccharide administration.

  Neurochemistry international 20100101

• Neuroprotection of midbrain dopaminergic cells in MPTP-treated mice after near-infrared light treatment.

  The Journal of comparative neurology 20100101

• Cerebral bioimaging of Cu, Fe, Zn, and Mn in the MPTP mouse model of Parkinson's disease using laser ablation inductively coupled plasma mass spectrometry (LA-ICP-MS).

  Journal of the American Society for Mass Spectrometry 20100101

• AMP-activated protein kinase is activated in Parkinson's disease models mediated by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

  Biochemical and biophysical research communications 20100101

• Treadmill gait analysis characterizes gait alterations in Parkinson's disease and amyotrophic lateral sclerosis mouse models.

  Journal of motor behavior 20100101

• L-DOPA-induced 6-hydroxydopamine production in the striata of rodents is sensitive to the degree of denervation.

  Neurochemistry international 20100101

• Embryonic stem cell-derived L1 overexpressing neural aggregates enhance recovery in Parkinsonian mice.

  Brain : a journal of neurology 20100101

• Indirubins deplete striatal monoamines in the Intact and MPTP-treated mouse brain and block kainate-induced striatal astrogliosis.

  Neurotoxicology and teratology 20100101

• Owner reports of attention, activity, and impulsivity in dogs: a replication study.

  Behavioral and brain functions : BBF 20100101

• Caffeine and a selective adenosine A2A receptor antagonist induce sensitization and cross-sensitization behavior associated with increased striatal dopamine in mice.

  Journal of biomedical science 20100101

• Interleukin 18 in the CNS.

  Journal of neuroinflammation 20100101

• Melatonin and structurally-related compounds protect synaptosomal membranes from free radical damage.

  International journal of molecular sciences 20100101

• Neuropsychiatric behaviors in the MPTP marmoset model of Parkinson's disease.

  The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 20100101

• Neuroprotective and neurotoxic phenotypes of activated microglia in neonatal mice with respective MPTP- and ethanol-induced brain injury.

  Neuro-degenerative diseases 20100101

• Selective molecular alterations in the autophagy pathway in patients with Lewy body disease and in models of alpha-synucleinopathy.

  PloS one 20100101

• Destruction of dopaminergic neurons in the midbrain by 6-hydroxydopamine decreases hippocampal cell proliferation in rats: reversal by fluoxetine.

  PloS one 20100101

• Cellular stress responses: cell survival and cell death.

  International journal of cell biology 20100101

• Low dosage of rasagiline and epigallocatechin gallate synergistically restored the nigrostriatal axis in MPTP-induced parkinsonism.

  Neuro-degenerative diseases 20100101

• Social odor recognition: a novel behavioral model for cognitive dysfunction in Parkinson's disease.

  Neuro-degenerative diseases 20100101

• Effects of Pharmacological Block of GABA(A) Receptors on Pallidal Neurons in Normal and Parkinsonian State.

  Frontiers in cellular neuroscience 20100101

• Does the difference between physically active and couch potato lie in the dopamine system?

  International journal of biological sciences 20100101

• Disruption of astrocyte STAT3 signaling decreases mitochondrial function and increases oxidative stress in vitro.

  PloS one 20100101

• Parkinson's disease: functional changes in frontal and parietal cortex using 18 F- fluoro-deoxy glucose positron emission tomography/computed tomography.

  Neurology India 20100101

• Microglia in the aging brain: relevance to neurodegeneration.

  Molecular neurodegeneration 20100101

• [Study of extracellular concentration of dopamine and its metabolites in mice striatum by a microdialysis technique at intraperitoneal administration of MPTP].

  Zhurnal vysshei nervnoi deiatelnosti imeni I P Pavlova 20100101

• 5-HT2A receptor antagonists improve motor impairments in the MPTP mouse model of Parkinson's disease.

  Neuropharmacology 20100101

• Risk of Parkinson's disease after tamoxifen treatment.

  BMC neurology 20100101

• Nitrated alpha-synuclein induces the loss of dopaminergic neurons in the substantia nigra of rats.

  PloS one 20100101

• Lysosomal function in macromolecular homeostasis and bioenergetics in Parkinson's disease.

  Molecular neurodegeneration 20100101

• Kainic acid-induced microglial activation is attenuated in aged interleukin-18 deficient mice.

  Journal of neuroinflammation 20100101

• Uncovering molecular biomarkers that correlate cognitive decline with the changes of hippocampus' gene expression profiles in Alzheimer's disease.

  PloS one 20100101

• Enhancement of L-3-hydroxybutyryl-CoA dehydrogenase activity and circulating ketone body levels by pantethine. Relevance to dopaminergic injury.

  BMC neuroscience 20100101

• Curcumin reduces alpha-synuclein induced cytotoxicity in Parkinson's disease cell model.

  BMC neuroscience 20100101

• Animal models of neurological disease.

  Advances in experimental medicine and biology 20100101

• Cassiae semen, a seed of Cassia obtusifolia, has neuroprotective effects in Parkinson's disease models.

  Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 20100101

• Effect of prolonged exposure to diesel engine exhaust on proinflammatory markers in different regions of the rat brain.

  Particle and fibre toxicology 20100101

• Proton magnetic resonance spectroscopy reveals neuroprotection by oral minocycline in a nonhuman primate model of accelerated NeuroAIDS.

  PloS one 20100101

• GT1b-induced neurotoxicity is mediated by the Akt/GSK-3/tau signaling pathway but not caspase-3 in mesencephalic dopaminergic neurons.

  BMC neuroscience 20100101

• Selective neuronal vulnerability to oxidative stress in the brain.

  Frontiers in aging neuroscience 20100101

• Endurance exercise training promotes angiogenesis in the brain of chronic/progressive mouse model of Parkinson's Disease.

  NeuroRehabilitation 20100101

• Cross-talk between mitochondria and proteasome in Parkinson's disease pathogenesis.

  Frontiers in aging neuroscience 20100101

• Reduction of L-type amino acid transporter 1 mRNA expression in brain capillaries in a mouse model of Parkinson's disease.

  Biological & pharmaceutical bulletin 20100101

• A53T-alpha-synuclein overexpression impairs dopamine signaling and striatal synaptic plasticity in old mice.

  PloS one 20100101

• [Modeling of preclinical and early clinical stages of Parkinson's disease].

  Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 20100101

• Cord blood stem cell-mediated induction of apoptosis in glioma downregulates X-linked inhibitor of apoptosis protein (XIAP).

  PloS one 20100101

• Different susceptibility to the Parkinson's toxin MPTP in mice lacking the redox master regulator Nrf2 or its target gene heme oxygenase-1.

  PloS one 20100101

• Computational physiology of the basal ganglia in Parkinson's disease.

  Progress in brain research 20100101

• Electrophysiological characteristics of globus pallidus neurons.

  PloS one 20100101

• [Oxidative processes and lipid metabolism in the experimental induced Parkinsonian syndrome].

  Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 20100101

• [Optimization of counting process of dopaminergic neurons in substantia nigra of parkinsonian mice].

  Tsitologiia 20100101

• Oral N-acetyl-cysteine attenuates loss of dopaminergic terminals in alpha-synuclein overexpressing mice.

  PloS one 20100101

• Distinct changes in cAMP and extracellular signal-regulated protein kinase signalling in L-DOPA-induced dyskinesia.

  PloS one 20100101

• Neuroprotective effect of gypenosides against oxidative injury in the substantia nigra of a mouse model of Parkinson's disease.

  The Journal of international medical research 20100101

• Role of nitric oxide and its metabolites as potential markers in lung cancer.

  Annals of thoracic medicine 20100101

• Mitochondrial preconditioning: a potential neuroprotective strategy.

  Frontiers in aging neuroscience 20100101

• Zonisamide attenuates MPTP neurotoxicity in marmosets.

  Journal of pharmacological sciences 20100101

• Neuroprotection and Functional Recovery Associated with Decreased Microglial Activation Following Selective Activation of mGluR2/3 Receptors in a Rodent Model of Parkinson's Disease.

  Parkinson's disease 20100101

• Oxidative stress in skin fibroblasts cultures from patients with Parkinson's disease.

  BMC neurology 20100101

• Neuroanatomical study of the A11 diencephalospinal pathway in the non-human primate.

  PloS one 20100101

• Subtle cardiovascular dysfunction in the unilateral 6-hydroxydopamine-lesioned rat.

  Parkinson's disease 20100101

• Fcγ receptors are required for NF-κB signaling, microglial activation and dopaminergic neurodegeneration in an AAV-synuclein mouse model of Parkinson's disease.

  Molecular neurodegeneration 20100101

• Glial innate immunity generated by non-aggregated alpha-synuclein in mouse: differences between wild-type and Parkinson's disease-linked mutants.

  PloS one 20100101

• Protein aggregation containing β-amyloid, α-synuclein and hyperphosphorylated τ in cultured cells of hippocampus, substantia nigra and locus coeruleus after rotenone exposure.

  BMC neuroscience 20100101

• Estrogens of multiple classes and their role in mental health disease mechanisms.

  International journal of women's health 20100101

• Nigrostriatal neuronal death following chronic dichlorvos exposure: crosstalk between mitochondrial impairments, α synuclein aggregation, oxidative damage and behavioral changes.

  Molecular brain 20100101

• Vulnerability of mesostriatal dopaminergic neurons in Parkinson's disease.

  Frontiers in neuroanatomy 20100101

• Combining nitric oxide release with anti-inflammatory activity preserves nigrostriatal dopaminergic innervation and prevents motor impairment in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.

  Journal of neuroinflammation 20100101

• Catechol-O-methyltransferase inhibitors in preclinical models as adjuncts of L-dopa treatment.

  International review of neurobiology 20100101

• In vivo imaging of retinal gliosis: a platform for diagnosis of PD and Screening of anti-PD compounds.

  Conference proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual Conference 20100101

• Modeling the motor striatum under Deep Brain Stimulation in normal and MPTP conditions.

  Conference proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual Conference 20100101

• Modeling the effects of Deep Brain Stimulation on sensorimotor cortex in normal and MPTP conditions.

  Conference proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual Conference 20100101

• Extrastriatal dopaminergic circuits of the Basal Ganglia.

  Frontiers in neuroanatomy 20100101

• The New Inhibitor of Monoamine Oxidase, M30, has a Neuroprotective Effect Against Dexamethasone-Induced Brain Cell Apoptosis.

  Frontiers in neuroscience 20100101

• Alterations in mGluR5 expression and signaling in Lewy body disease and in transgenic models of alpha-synucleinopathy--implications for excitotoxicity.

  PloS one 20100101

• Dopamine transporter binding is unaffected by L-DOPA administration in normal and MPTP-treated monkeys.

  PloS one 20100101

• Regional characterization of energy metabolism in the brain of normal and MPTP-intoxicated mice using new markers of glucose and phosphate transport.

  Journal of biomedical science 20100101

• ER stress response plays an important role in aggregation of α-synuclein.

  Molecular neurodegeneration 20100101

• Role of Basal Ganglia in sleep-wake regulation: neural circuitry and clinical significance.

  Frontiers in neuroanatomy 20100101

• Parkinson's disease: is it a toxic syndrome?

  Neurology research international 20100101

• Striatal spine plasticity in Parkinson's disease.

  Frontiers in neuroanatomy 20100101

• Tryptophan, Neurodegeneration and HIV-Associated Neurocognitive Disorder.

  International journal of tryptophan research : IJTR 20100101

• Mitochondrial therapy for Parkinson's disease: neuroprotective pharmaconutrition may be disease-modifying.

  Clinical pharmacology : advances and applications 20100101

• Unexpected lack of hypersensitivity in LRRK2 knock-out mice to MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine).

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20091216

• Elevated interleukin-1beta induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine aggravating dopaminergic neurodegeneration in old male mice.

  Brain research 20091211

• Protective effect of cyclooxygenase (COX)-inhibitors against drug-induced catatonia and MPTP-induced striatal lesions in rats.

  Pharmacology, biochemistry, and behavior 20091201

• CNS infiltration of peripheral immune cells: D-Day for neurodegenerative disease?

  Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology 20091201

• Safety evaluation of AAV2-GDNF gene transfer into the dopaminergic nigrostriatal pathway in aged and parkinsonian rhesus monkeys.

  Human gene therapy 20091201

• MPTP lesion causes neuroinflammation and deficits in object recognition in Wistar rats.

  Behavioral neuroscience 20091201

• Striatal spine plasticity in Parkinson's disease: pathological or not?

  Parkinsonism & related disorders 20091201

• Iron transport in Parkinson's disease.

  Parkinsonism & related disorders 20091201

• Triggering endogenous neuroprotective processes through exercise in models of dopamine deficiency.

  Parkinsonism & related disorders 20091201

• Do mtDNA Mutations Participate in the Pathogenesis of Sporadic Parkinson's Disease?

  Current genomics 20091201

• Requirement of a dopaminergic neuronal phenotype for toxicity of low concentrations of 1-methyl-4-phenylpyridinium to human cells.

  Toxicology and applied pharmacology 20091115

• Gender differences on MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity in C57BL/6 mice.

  Molecular and cellular endocrinology 20091113

• Modulation of brain-derived neurotrophic factor as a potential neuroprotective mechanism of action of omega-3 fatty acids in a parkinsonian animal model.

  Progress in neuro-psychopharmacology & biological psychiatry 20091113

• Ghrelin promotes and protects nigrostriatal dopamine function via a UCP2-dependent mitochondrial mechanism.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20091111

• Cruciferous nutraceutical 3H-1,2-dithiole-3-thione protects human primary astrocytes against neurocytotoxicity elicited by MPTP, MPP(+), 6-OHDA, HNE and acrolein.

  Neurochemical research 20091101

• Doxycycline is neuroprotective against nigral dopaminergic degeneration by a dual mechanism involving MMP-3.

  Neurotoxicity research 20091101

• MPTP-induced neuroblast apoptosis in the subventricular zone is not regulated by dopamine or other monoamine transporters.

  Neurotoxicology 20091101

• Neuroprotective effect of L-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson's disease: a direct comparison study.

  Journal of neurochemistry 20091101

• Melatonin inhibits 6-hydroxydopamine production in the brain to protect against experimental parkinsonism in rodents.

  Journal of pineal research 20091101

• Simvastatin inhibits the activation of p21ras and prevents the loss of dopaminergic neurons in a mouse model of Parkinson's disease.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20091028

• Inhibition of prolyl hydroxylase protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity: model for the potential involvement of the hypoxia-inducible factor pathway in Parkinson disease.

  The Journal of biological chemistry 20091016

• JNK inhibitor protects dopaminergic neurons by reducing COX-2 expression in the MPTP mouse model of subacute Parkinson's disease.

  Journal of the neurological sciences 20091015

• Dopamine gene therapy for Parkinson's disease in a nonhuman primate without associated dyskinesia.

  Science translational medicine 20091014

• Toxic influence of chronic oral administration of paraquat on nigrostriatal dopaminergic neurons in C57BL/6 mice.

  Chinese medical journal 20091005

• Sirtuin 1 overexpression mice show a reference memory deficit, but not neuroprotection.

  Biochemical and biophysical research communications 20091002

• Alterations of nocturnal activity in rats following subchronic oral administration of the neurotoxin 1-trichloromethyl-1,2,3,4-tetrahydro-beta-carboline.

  Journal of neural transmission (Vienna, Austria : 1996) 20091001

• Neuronal NOS and cyclooxygenase-2 contribute to DNA damage in a mouse model of Parkinson disease.

  Free radical biology & medicine 20091001

• Sleep disorders in Parkinson's disease: the contribution of the MPTP non-human primate model.

  Experimental neurology 20091001

• Nur77 mRNA levels and L-Dopa-induced dyskinesias in MPTP monkeys treated with docosahexaenoic acid.

  Neurobiology of disease 20091001

• Nitroindazole compounds inhibit the oxidative activation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxin to neurotoxic pyridinium cations by human monoamine oxidase (MAO).

  Free radical research 20091001

• Effects of a novel dopamine uptake inhibitor upon extracellular dopamine from superfused murine striatal tissue.

  European journal of pharmacology 20091001

• Effects of pergolide mesilate on metallothionein mRNAs expression in a mouse model for Parkinson disease.

  Biological & pharmaceutical bulletin 20091001

• [Neuroprotective effects and mechanisms of Chuanxiong Chatiao pulvis against MPTP-induced dopaminergic neurotoxicity in mice model of Parkinson's disease].

  Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica 20091001

• [Effection of Qing-Xuan tablets on behavior pattern and striatal TNF-alpha of Parkinson model mice].

  Zhong yao cai = Zhongyaocai = Journal of Chinese medicinal materials 20091001

• MPTP administration increases plasma levels of acute phase proteins in non-human primates (Macaca fascicularis).

  Neuroscience letters 20090929

• Withania somnifera root extract improves catecholamines and physiological abnormalities seen in a Parkinson's disease model mouse.

  Journal of ethnopharmacology 20090925

• Iron-catalyzed selective oxidation of N-methyl amines: highly efficient synthesis of methylene-bridged bis-1,3-dicarbonyl compounds.

  Organic letters 20090917

• Striatal overexpression of DeltaJunD resets L-DOPA-induced dyskinesia in a primate model of Parkinson disease.

  Biological psychiatry 20090915

• A novel anti-Parkinsonian agent, zonisamide, attenuates MPTP-induced neurotoxicity in mice.

  Journal of molecular neuroscience : MN 20090901

• Mitochondria targeted peptides protect against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity.

  Antioxidants & redox signaling 20090901

• Pallidal stimulation that improves parkinsonian motor symptoms also modulates neuronal firing patterns in primary motor cortex in the MPTP-treated monkey.

  Experimental neurology 20090901

• The blood-brain barrier is intact after levodopa-induced dyskinesias in parkinsonian primates--evidence from in vivo neuroimaging studies.

  Neurobiology of disease 20090901

• Impaired glutamate homeostasis and programmed cell death in a chronic MPTP mouse model of Parkinson's disease.

  Experimental neurology 20090901

• Fucoidan protects against dopaminergic neuron death in vivo and in vitro.

  European journal of pharmacology 20090901

• Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease.

  The Journal of endocrinology 20090901

• Quantification of Paraquat, MPTP, and MPP+ in brain tissue using microwave-assisted solvent extraction (MASE) and high-performance liquid chromatography-mass spectrometry.

  Analytical and bioanalytical chemistry 20090901

• Acute and chronic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administrations elicit similar microglial activation in the substantia nigra of monkeys.

  Journal of neuropathology and experimental neurology 20090901

• Brain targeting of nerve growth factor using poly(butyl cyanoacrylate) nanoparticles.

  Journal of drug targeting 20090901

• TRPC1 inhibits apoptotic cell degeneration induced by dopaminergic neurotoxin MPTP/MPP(+).

  Cell calcium 20090901

• The substantia nigra pars compacta of the Göttingen minipig: an anatomical and stereological study.

  Brain structure & function 20090901

• Basal ganglia neuroprotection with anticonvulsants after energy stress: a comparative study.

  Metabolic brain disease 20090901

• The neurotrophic and neuroprotective effects of psychotropic agents.

  Dialogues in clinical neuroscience 20090901

• Cytosolic labile zinc accumulation in degenerating dopaminergic neurons of mouse brain after MPTP treatment.

  Brain research 20090825

• Long term high frequency stimulation of STN increases dopamine in the corpus striatum of hemiparkinsonian rhesus monkey.

  Brain research 20090825

• New MRI, 18F-DOPA and 11C-(+)-alpha-dihydrotetrabenazine templates for Macaca fascicularis neuroimaging: advantages to improve PET quantification.

  NeuroImage 20090815

• Behavior, neurotransmitters and inflammation in three regimens of the MPTP mouse model of Parkinson's disease.

  Physiology & behavior 20090804

• Effect of caffeine on the expression of cytochrome P450 1A2, adenosine A2A receptor and dopamine transporter in control and 1-methyl 4-phenyl 1, 2, 3, 6-tetrahydropyridine treated mouse striatum.

  Brain research 20090804

• Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease.

  Neurobiology of disease 20090801

• Not lost in translation Sensing the loss and filling the gap during regeneration.

  Seminars in cell & developmental biology 20090801

• Redox activated MAP kinase death signaling cascade initiated by ASK1 is not activated in female mice following MPTP: novel mechanism of neuroprotection.

  Neurotoxicity research 20090801

• Evidence for a dopaminergic innervation of the pedunculopontine nucleus in monkeys, and its drastic reduction after MPTP intoxication.

  Journal of neurochemistry 20090801

• Effects of dopamine depletion on network entropy in the external globus pallidus.

  Journal of neurophysiology 20090801

• Multipoint analysis of reduced (125)I-meta-iodobenzylguanidine uptake and norepinephrine turnover in the hearts of mice with 1-methyl-4-phenyl-1,2,3,6-tetrahydroxypyridine-induced parkinsonism.

  Nuclear medicine and biology 20090801

• Neuroprotective effect of long-term NDI1 gene expression in a chronic mouse model of Parkinson disorder.

  Rejuvenation research 20090801

• No Lewy pathology in monkeys with over 10 years of severe MPTP Parkinsonism.

  Movement disorders : official journal of the Movement Disorder Society 20090730

• Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys.

  Parkinsonism & related disorders 20090701

• Systemic administration of proteasome inhibitor protects against MPTP neurotoxicity in mice.

  Cellular and molecular neurobiology 20090701

• Macroautophagy of the GPR37 orphan receptor and Parkinson disease-associated neurodegeneration.

  Autophagy 20090701

• Neuroprotective actions of sex steroids in Parkinson's disease.

  Frontiers in neuroendocrinology 20090701

• Cervical carotid and circle of willis arterial anatomy of macaque monkeys: a comparative anatomy study.

  Anatomical record (Hoboken, N.J. : 2007) 20090701

• Blockade of PrRP attenuates MPTP-induced toxicity in mice.

  Peptides 20090701

• Cortical serotonin and norepinephrine denervation in parkinsonism: preferential loss of the beaded serotonin innervation.

  The European journal of neuroscience 20090701

• Risk is in the air: an intranasal MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) rat model of Parkinson's disease.

  Annals of the New York Academy of Sciences 20090701

• Tyrosine hydroxylase-positive amacrine interneurons in the mouse retina are resistant against the application of various parkinsonian toxins.

  Brain research bulletin 20090630

• Activation of phosphatidylinositol-linked D1-like receptor modulates FGF-2 expression in astrocytes via IP3-dependent Ca2+ signaling.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20090617

• Short-term depression of synaptic transmission during stimulation in the globus pallidus of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20090617

• Two new test methods to quantify motor deficits in a marmoset model for Parkinson's disease.

  Behavioural brain research 20090608

• Implication of NMDA receptors in the antidyskinetic activity of cabergoline, CI-1041, and Ro 61-8048 in MPTP monkeys with levodopa-induced dyskinesias.

  Journal of molecular neuroscience : MN 20090601

• GSTpi expression in MPTP-induced dopaminergic neurodegeneration of C57BL/6 mouse midbrain and striatum.

  Journal of molecular neuroscience : MN 20090601

• Interactions between cortical rhythms and spiking activity of single basal ganglia neurons in the normal and parkinsonian state.

  Cerebral cortex (New York, N.Y. : 1991) 20090601

• Phenylpyrrole derivatives as neural and inducible nitric oxide synthase (nNOS and iNOS) inhibitors.

  European journal of medicinal chemistry 20090601

• Decreased inflammation and augmented expression of trophic factors correlate with MOG-induced neuroprotection of the injured nigrostriatal system in the murine MPTP model of Parkinson's disease.

  International immunopharmacology 20090601

• MPTP-induced model of Parkinson's disease in cytochrome P450 2E1 knockout mice.

  Neuropharmacology 20090601

• MPTP intoxication in mice: a useful model of Leigh syndrome to study mitochondrial diseases in childhood.

  Metabolic brain disease 20090601

• Blockade of the translocation and activation of c-Jun N-terminal kinase 3 (JNK3) attenuates dopaminergic neuronal damage in mouse model of Parkinson's disease.

  Neurochemistry international 20090601

• Copper reduces striatal protein nitration and tyrosine hydroxylase inactivation induced by MPP+ in rats.

  Neurochemistry international 20090601

• Activation of p38 MAPK in the substantia nigra leads to nuclear translocation of NF-kappaB in MPTP-treated mice: implication in Parkinson's disease.

  Journal of neurochemistry 20090601

• Differences between subacute and chronic MPTP mice models: investigation of dopaminergic neuronal degeneration and alpha-synuclein inclusions.

  Journal of neurochemistry 20090601

• Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's diseases.

  Journal of neurochemistry 20090601

• WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.

  The European journal of neuroscience 20090601

• Meta-analysis of 28,141 individuals identifies common variants within five new loci that influence uric acid concentrations.

  PLoS genetics 20090601

• The expression of CYP2D22, an ortholog of human CYP2D6, in mouse striatum and its modulation in 1-methyl 4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease phenotype and nicotine-mediated neuroprotection.

  Rejuvenation research 20090601

• Neurogenesis in Neurotoxin-induced Animal Models for Parkinson's Disease-A Review of the Current Status.

  Journal of toxicologic pathology 20090601

• Effect of estradiol on striatal dopamine activity of female hemiparkinsonian monkeys.

  Journal of neuroscience research 20090515

• Strain-specific sensitivity to MPTP of C57BL/6 and BALB/c mice is age dependent.

  Neuroreport 20090506

• Does melatonin help save dopaminergic cells in MPTP-treated mice?

  Parkinsonism & related disorders 20090501

• Nicotine is neuroprotective when administered before but not after nigrostriatal damage in rats and monkeys.

  Journal of neurochemistry 20090501

• Functional effects of AAV2-GDNF on the dopaminergic nigrostriatal pathway in parkinsonian rhesus monkeys.

  Human gene therapy 20090501

• Zocor Forte (simvastatin) has a neuroprotective effect against LPS striatal dopaminergic terminals injury, whereas against MPP+ does not.

  European journal of pharmacology 20090501

• In vitro dopaminergic neuroprotective and in vivo antiparkinsonian-like effects of Delta 3,2-hydroxybakuchiol isolated from Psoralea corylifolia (L.).

  Cellular and molecular life sciences : CMLS 20090501

• Neuroprotective effect of ghrelin in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease by blocking microglial activation.

  Neurotoxicity research 20090501

• Zonisamide increases dopamine turnover in the striatum of mice and common marmosets treated with MPTP.

  Journal of pharmacological sciences 20090501

• Mitochondria and energetic depression in cell pathophysiology.

  International journal of molecular sciences 20090501

• High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease.

  Neurology 20090421

• Antagonism of haloperidol-induced swim impairment in L-dopa and caffeine treated mice: a pre-clinical model to study Parkinson's disease.

  Journal of neuroscience methods 20090415

• Protective actions of the vesicular monoamine transporter 2 (VMAT2) in monoaminergic neurons.

  Molecular neurobiology 20090401

• Microglial activation is inhibited by corticosterone in dopaminergic neurodegeneration.

  Journal of neuroimmunology 20090331

• Age- and sex-differences in the nitric oxide synthase expression and dopamine concentration in the murine model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

  Brain research 20090319

• Systemic lipopolysaccharide plus MPTP as a model of dopamine loss and gait instability in C57Bl/6J mice.

  Behavioural brain research 20090317

• Quantitative evaluation of MPTP-treated nonhuman parkinsonian primates in the HALLWAY task.

  Journal of neuroscience methods 20090315

• Combined kinase inhibition modulates parkin inactivation.

  Human molecular genetics 20090301

• Identification of zebrafish A2 adenosine receptors and expression in developing embryos.

  Gene expression patterns : GEP 20090301

• PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease.

  The European journal of neuroscience 20090301

• Granulocyte-macrophage colony-stimulating factor promotes survival of dopaminergic neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced murine Parkinson's disease model.

  The European journal of neuroscience 20090301

• Bone marrow-derived mesenchymal stem cell therapy as a candidate disease-modifying strategy in Parkinson's disease and multiple system atrophy.

  Journal of clinical neurology (Seoul, Korea) 20090301

• Effect of a prolyl endopeptidase inhibitor benzyloxycarbonyl-alanyl-proline on the development of experimental depressive syndrome in rats.

  Bulletin of experimental biology and medicine 20090301

• Targeting the progression of Parkinson's disease.

  Current neuropharmacology 20090301

• Protective effect against Parkinson's disease-related insults through the activation of XBP1.

  Brain research 20090227

• Objective quantification of arm rigidity in MPTP-treated primates.

  Journal of neuroscience methods 20090215

• Beneficial effects of pioglitazone on cognitive impairment in MPTP model of Parkinson's disease.

  Behavioural brain research 20090211

• Dopamine innervation in the thalamus: monkey versus rat.

  Cerebral cortex (New York, N.Y. : 1991) 20090201

• The effects of piroxicam in the attenuation of MPP+/MPTP toxicity in vitro and in vivo.

  Neurochemical research 20090201

• 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure fails to produce delayed degeneration of substantia nigra neurons in monkeys.

  Journal of neuroscience research 20090201

• Dopaminergic denervation and spine loss in the striatum of MPTP-treated monkeys.

  Experimental neurology 20090201

• Role of nuclear transcription factor kappa B (NF-kappaB) for MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahyropyridine)-induced apoptosis in nigral neurons of mice.

  Experimental and molecular pathology 20090201

• MPTP and MPP+ target specific aminergic cell populations in larval zebrafish.

  Journal of neurochemistry 20090201

• Ghrelin antagonized 1-methyl-4-phenylpyridinium (MPP(+))-induced apoptosis in MES23.5 cells.

  Journal of molecular neuroscience : MN 20090201

• Neurochemical plasticity in the enteric nervous system of a primate animal model of experimental Parkinsonism.

  Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society 20090201

• The neurophysiology and effect of deep brain stimulation in a patient with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism.

  Journal of neurosurgery 20090201

• Quantitative approach for incorporating methylmercury risks and omega-3 fatty acid benefits in developing species-specific fish consumption advice.

  Environmental health perspectives 20090201

• Pyrethroid and organophosphate insecticide exposure in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease: an immunohistochemical analysis of tyrosine hydroxylase and glial fibrillary acidic protein in dorsolateral striatum.

  Toxicology and industrial health 20090201

• Assessment of symptomatic and neuroprotective efficacy of Mucuna pruriens seed extract in rodent model of Parkinson's disease.

  Neurotoxicity research 20090201

• [Effects of SV heat-resisting protein on the microglial cells in MPTP-treated mice].

  Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology 20090201

• [The effect of TSPG in vivo on transplantation of neural stem cells in treatment of Parkinson's disease mouse].

  Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology 20090201

• Potential mechanisms of neuroprotection induced by low dose total-body gamma-irradiation in C57 mice administered with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

  Neuroscience letters 20090130

• Acupuncture inhibits ferric iron deposition and ferritin-heavy chain reduction in an MPTP-induced parkinsonism model.

  Neuroscience letters 20090130

• Neuroprotective effects of (+/-)-catechin against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity in mice.

  Neuroscience letters 20090130

• Effects of endurance exercise on ventral tegmental area neurons in the chronic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and probenecid-treated mice.

  Neuroscience letters 20090130

• Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease.

  The Journal of clinical investigation 20090105

• Oxidative and inflammatory pathways in Parkinson's disease.

  Neurochemical research 20090101

• Modulation of neurotoxicant-induced increases in intracellular calcium by phytoestrogens differ for amyloid beta peptide (Abeta) and 1-methyl-4-phenyl-pyridine (MPP(+)).

  Journal of applied toxicology : JAT 20090101

• Suppression of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced nitric-oxide synthase 2 expression in astrocytes by a novel diindolylmethane analog protects striatal neurons against apoptosis.

  Molecular pharmacology 20090101

• Alpha1-adrenoceptors mediate dihydroxyphenylalanine-induced activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaques.

  The Journal of pharmacology and experimental therapeutics 20090101

• Enhanced susceptibility to MPTP neurotoxicity in magnesium-deficient C57BL/6N mice.

  Neuroscience research 20090101

• Rg1 reduces nigral iron levels of MPTP-treated C57BL6 mice by regulating certain iron transport proteins.

  Neurochemistry international 20090101

• Involvement of ubiquitin proteasome system in protective mechanisms of Puerarin to MPP(+)-elicited apoptosis.

  Neuroscience research 20090101

• Transplantation of embryonic stem cell-derived dopaminergic neurons in MPTP-treated monkeys.

  Methods in molecular biology (Clifton, N.J.) 20090101

• 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) does not elicit long-lasting increases in cyclooxygenase-2 expression in dopaminergic neurons of monkeys.

  Journal of neuropathology and experimental neurology 20090101

• Restorative effect of endurance exercise on behavioral deficits in the chronic mouse model of Parkinson's disease with severe neurodegeneration.

  BMC neuroscience 20090101

• Meeting report: consensus statement-Parkinson's disease and the environment: collaborative on health and the environment and Parkinson's Action Network (CHE PAN) conference 26-28 June 2007.

  Environmental health perspectives 20090101

• Evolution of neurotoxins: from research modalities to clinical realities.

  Current protocols in neuroscience 20090101

• [Effect of phosphorylated-ERK1/2 on inducible nitric oxide synthase expression in the substantia nigra of mice with MPTP-induced Parkinson disease].

  Nan fang yi ke da xue xue bao = Journal of Southern Medical University 20090101

• PINK1 defect causes mitochondrial dysfunction, proteasomal deficit and alpha-synuclein aggregation in cell culture models of Parkinson's disease.

  PloS one 20090101

• Increased DJ-1 expression under oxidative stress and in Alzheimer's disease brains.

  Molecular neurodegeneration 20090101

• Silencing of PINK1 expression affects mitochondrial DNA and oxidative phosphorylation in dopaminergic cells.

  PloS one 20090101

• Lipopolysaccharide-induced interleukin-6 production is controlled by glycogen synthase kinase-3 and STAT3 in the brain.

  Journal of neuroinflammation 20090101

• [No-dependent modulation of the sensitivity of the mitochondrial permeability transition pore opening under ischemia-reperfusion of the isolated heart].

  Rossiiskii fiziologicheskii zhurnal imeni I.M. Sechenova 20090101

• FE65 binds Teashirt, inhibiting expression of the primate-specific caspase-4.

  PloS one 20090101

• Axonal degeneration of nigra-striatum dopaminergic neurons induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice.

  The Journal of international medical research 20090101

• Striatal neuroinflammation promotes Parkinsonism in rats.

  PloS one 20090101

• Involvment of cytosolic and mitochondrial GSK-3beta in mitochondrial dysfunction and neuronal cell death of MPTP/MPP-treated neurons.

  PloS one 20090101

• Neuroprotective effects of the triterpenoid, CDDO methyl amide, a potent inducer of Nrf2-mediated transcription.

  PloS one 20090101

• Oxidative modifications, mitochondrial dysfunction, and impaired protein degradation in Parkinson's disease: how neurons are lost in the Bermuda triangle.

  Molecular neurodegeneration 20090101

• Cellular immune response to intrastriatally implanted allogeneic bone marrow stromal cells in a rat model of Parkinson's disease.

  Journal of neuroinflammation 20090101

• Primate adult brain cell autotransplantation, a pilot study in asymptomatic MPTP-treated monkeys.

  Cell transplantation 20090101

• Effects of prolylendopeptidase inhibitor benzyloxycarbonyl-methionyl-2(S)-cyanopyrrolidine on experimental depressive syndrome development in rats.

  Bulletin of experimental biology and medicine 20090101

• Postulated vasoactive neuropeptide immunopathology affecting the blood-brain/blood-spinal barrier in certain neuropsychiatric fatigue-related conditions: A role for phosphodiesterase inhibitors in treatment?

  Neuropsychiatric disease and treatment 20090101

• Evidence for oxidative stress in the developing cerebellum of the rat after chronic mild carbon monoxide exposure (0.0025% in air).

  BMC neuroscience 20090101

• Conditional transgenic mice expressing C-terminally truncated human alpha-synuclein (alphaSyn119) exhibit reduced striatal dopamine without loss of nigrostriatal pathway dopaminergic neurons.

  Molecular neurodegeneration 20090101

• Subchronic infusion of the product of inflammation prostaglandin J2 models sporadic Parkinson's disease in mice.

  Journal of neuroinflammation 20090101

• Paraquat induces oxidative stress, neuronal loss in substantia nigra region and parkinsonism in adult rats: neuroprotection and amelioration of symptoms by water-soluble formulation of coenzyme Q10.

  BMC neuroscience 20090101

• Differential response of C57BL/6J mouse and DBA/2J mouse to optic nerve crush.

  BMC neuroscience 20090101

• Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial.

  Nutrition & metabolism 20090101

• Activation of mGlu3 receptors stimulates the production of GDNF in striatal neurons.

  PloS one 20090101

• Neuroprotective effects of compounds with antioxidant and anti-inflammatory properties in a Drosophila model of Parkinson's disease.

  BMC neuroscience 20090101

• Role of two efflux proteins, ABCB1 and ABCG2 in blood-brain barrier transport of bromocriptine in a murine model of MPTP-induced dopaminergic degeneration.

  Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques 20090101

• Enrichment from birth accelerates the functional and cellular development of a motor control area in the mouse.

  PloS one 20090101

• Oxidative inactivation of mitochondrial aconitase results in iron and H2O2-mediated neurotoxicity in rat primary mesencephalic cultures.

  PloS one 20090101

• Hydrogen in drinking water reduces dopaminergic neuronal loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.

  PloS one 20090101

• [Dynamics of spectral parameters of the rat brain electrical activity in the model of depressive pain syndrome].

  Zhurnal vysshei nervnoi deiatelnosti imeni I P Pavlova 20090101

• NADPH oxidase mediates beta-amyloid peptide-induced activation of ERK in hippocampal organotypic cultures.

  Molecular brain 20090101

• Outer mitochondrial membrane localization of apoptosis-inducing factor: mechanistic implications for release.

  ASN neuro 20090101

• Does neuroinflammation fan the flame in neurodegenerative diseases?

  Molecular neurodegeneration 20090101

• The background of mitochondrial DNA haplogroup J increases the sensitivity of Leber's hereditary optic neuropathy cells to 2,5-hexanedione toxicity.

  PloS one 20090101

• Dissociable effects of dopamine on neuronal firing rate and synchrony in the dorsal striatum.

  Frontiers in integrative neuroscience 20090101

• Spatial distribution of Parkinson's disease mortality in Spain, 1989-1998, as a guide for focused aetiological research or health-care intervention.

  BMC public health 20090101

• Coenzyme Q10 effects in neurodegenerative disease.

  Neuropsychiatric disease and treatment 20090101

• Effects of chronic low dose rotenone treatment on human microglial cells.

  Molecular neurodegeneration 20090101

• Copper sulfate prevents tyrosine hydroxylase reduced activity and motor deficits in a Parkinson's disease model in mice.

  Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion 20090101

• The neurobiology of the substantia nigra pars compacta: from motor to sleep regulation.

  Journal of neural transmission. Supplementum 20090101

• Distinct effects of intranigral L-DOPA infusion in the MPTP rat model of Parkinson's disease.

  Journal of neural transmission. Supplementum 20090101

• Mitochondrial dysfunction in the striatum of aged chronic mouse model of Parkinson's disease.

  Frontiers in aging neuroscience 20090101

• Biotelemetric monitoring of brain neurochemistry in conscious rats using microsensors and biosensors.

  Sensors (Basel, Switzerland) 20090101

• Damage to the nigrostriatal system in the MPTP-treated SAMP8 mouse.

  Neuroscience letters 20081226

• Effects of estrogens on striatal damage after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity in male and female mice.

  Molecular and cellular endocrinology 20081216

• A novel adenosine A(1) and A(2A) receptor antagonist ASP5854 ameliorates motor impairment in MPTP-treated marmosets: comparison with existing anti-Parkinson's disease drugs.

  Behavioural brain research 20081212

• Effects of acute administration of the hydroalcoholic extract of mate tea leaves (Ilex paraguariensis) in animal models of learning and memory.

  Journal of ethnopharmacology 20081208

• Biperiden enhances L-DOPA methyl ester and dopamine D(l) receptor agonist SKF-82958 but antagonizes D(2)/D(3) receptor agonist rotigotine antihemiparkinsonian actions.

  European journal of pharmacology 20081203

• Adenosine A(2A) receptors in Parkinson's disease treatment.

  Purinergic signalling 20081201

• Induction of the drug metabolizing enzyme CYP2D in monkey brain by chronic nicotine treatment.

  Neuropharmacology 20081201

• Balance of increases and decreases in firing rate of the spontaneous activity of basal ganglia high-frequency discharge neurons.

  Journal of neurophysiology 20081201

• Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.

  Brain : a journal of neurology 20081201

• The effect of alpha-synuclein knockdown on MPP+ toxicity in models of human neurons.

  The European journal of neuroscience 20081201

• Modulation of alpha-synuclein expression in transgenic animals for modelling synucleinopathies--is the juice worth the squeeze?

  Neurotoxicity research 20081201

• Oxidative stress in Parkinson's disease: a mechanism of pathogenic and therapeutic significance.

  Annals of the New York Academy of Sciences 20081201

• Functional models of Parkinson's disease: a valuable tool in the development of novel therapies.

  Annals of neurology 20081201

• Differential effects of the dopamine neurotoxin MPTP in animals with a partial deletion of the GDNF receptor, GFR alpha1, gene.

  Brain research 20081119

• Selective activation of p38 mitogen-activated protein kinase in dopaminergic neurons of substantia nigra leads to nuclear translocation of p53 in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20081119

• The effects of MPTP on the activation of microglia/astrocytes and cytokine/chemokine levels in different mice strains.

  Journal of neuroimmunology 20081115

• Macrophage antigen complex-1 mediates reactive microgliosis and progressive dopaminergic neurodegeneration in the MPTP model of Parkinson's disease.

  Journal of immunology (Baltimore, Md. : 1950) 20081115

• Striatal 19S Rpt6 deficit is related to alpha-synuclein accumulation in MPTP-treated mice.

  Biochemical and biophysical research communications 20081114

• Proteasome inhibitor does not enhance MPTP neurotoxicity in mice.

  Cellular and molecular neurobiology 20081101

• Caenorhabditis elegans: an emerging model in biomedical and environmental toxicology.

  Toxicological sciences : an official journal of the Society of Toxicology 20081101

• Neural progenitor cells are protected against MPTP by MAO-B inhibitors.

  Neurotoxicology 20081101

• Molecular imaging reveals a correlation between 2'-CH3-MPTP-induced neonatal neurotoxicity and dopaminergic neurodegeneration in adult transgenic mice.

  International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience 20081101

• Memory, mood, dopamine, and serotonin in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse model of basal ganglia injury.

  Neurobiology of disease 20081101

• Modelling Parkinson-like neurodegeneration via osmotic minipump delivery of MPTP and probenecid.

  Journal of neurochemistry 20081101

• Quantifying the neural elements activated and inhibited by globus pallidus deep brain stimulation.

  Journal of neurophysiology 20081101

• Deep brain stimulation reduces neuronal entropy in the MPTP-primate model of Parkinson's disease.

  Journal of neurophysiology 20081101

• Proteomic analysis of the neuroprotective mechanisms of acupuncture treatment in a Parkinson's disease mouse model.

  Proteomics 20081101

• A role for oxidized DNA precursors in Huntington's disease-like striatal neurodegeneration.

  PLoS genetics 20081101

• Therapeutic modulation of apoptosis: targeting the BCL-2 family at the interface of the mitochondrial membrane.

  Yonsei medical journal 20081031

• Sensitive and selective liquid chromatography/tandem mass spectrometry methods for quantitative analysis of 1-methyl-4-phenyl pyridinium (MPP+) in mouse striatal tissue.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20081015

• Effects of levodopa on striatal monoamines in mice with levodopa-induced hyperactivity.

  Neuroscience letters 20081010

• Melatonin attenuates tyrosine hydroxylase loss and hypolocomotion in MPTP-lesioned rats.

  European journal of pharmacology 20081010

• A 5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model.

  Pharmacology, biochemistry, and behavior 20081001

• A neuroprotective agent, T-817MA (1-{3-[2-(1-benzothiophen-5-yl)ethoxy]propyl} azetidin-3-ol maleate), prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice.

  Neuropharmacology 20081001

• Deuterium isotope effects for the oxidation of 1-methyl-3-phenyl-3-pyrrolinyl analogues by monoamine oxidase B.

  Bioorganic & medicinal chemistry 20081001

• Parkinson disease: primacy of age as a risk factor for mitochondrial dysfunction.

  Metabolism: clinical and experimental 20081001

• Targeting reactive oxygen species, reactive nitrogen species and inflammation in MPTP neurotoxicity and Parkinson's disease.

  Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 20081001

• Lipid peroxidation, mitochondrial dysfunction and neurochemical and behavioural deficits in different neurotoxic models: protective role of S-allylcysteine.

  Free radical research 20081001

• Defining 'neuroinflammation'.

  Annals of the New York Academy of Sciences 20081001

• Extranigral neurodegeneration in Parkinson's disease.

  Annals of the New York Academy of Sciences 20081001

• Methamphetamine fails to alter the noradrenergic integrity of the heart.

  Annals of the New York Academy of Sciences 20081001

• MPTP- but not methamphetamine-induced parkinsonism extends to catecholamine neurons in the gut.

  Annals of the New York Academy of Sciences 20081001

• Behavioral recovery in MPTP-treated monkeys: neurochemical mechanisms studied by intrastriatal microdialysis.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20080917

• The tert-butoxyl radical mediated hydrogen atom transfer reactions of the Parkinsonian proneurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and selected tertiary amines.

  Bioorganic & medicinal chemistry 20080915

• Distinct mechanisms of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine resistance revealed by transcriptome mapping in mouse striatum.

  Neuroscience 20080909

• Dopamine transporter inhibitory and antiparkinsonian effect of common flowering quince extract.

  Pharmacology, biochemistry, and behavior 20080901

• Microsomal epoxide hydrolase deletion enhances tyrosine hydroxylase phosphorylation in mice after MPTP treatment.

  Journal of neuroscience research 20080901

• Endogenous dopamine suppresses initiation of swimming in prefeeding zebrafish larvae.

  Journal of neurophysiology 20080901

• Developmental heptachlor exposure increases susceptibility of dopamine neurons to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)in a gender-specific manner.

  Neurotoxicology 20080901

• Amiloride is neuroprotective in an MPTP model of Parkinson's disease.

  Neurobiology of disease 20080901

• Comparative pharmacological study of free radical scavenger, nitric oxide synthase inhibitor, nitric oxide synthase activator and cyclooxygenase inhibitor against MPTP neurotoxicity in mice.

  Metabolic brain disease 20080901

• Investigating the potential neuroprotective effects of statins on DNA damage in mouse striatum.

  Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 20080901

• Effects of sildenafil on nigrostriatal dopamine neurons in a murine model of Parkinson's disease.

  Journal of Alzheimer's disease : JAD 20080901

• Neuroprotective effect of benzylideneacetophenone derivative on the MPTP model of neurodegeneration in mice.

  Archives of pharmacal research 20080901

• Functional neuroanatomy of the noradrenergic locus coeruleus: its roles in the regulation of arousal and autonomic function part II: physiological and pharmacological manipulations and pathological alterations of locus coeruleus activity in humans.

  Current neuropharmacology 20080901

• Melatonin combats molecular terrorism at the mitochondrial level.

  Interdisciplinary toxicology 20080901

• Neuroprotective effects of resveratrol on MPTP-induced neuron loss mediated by free radical scavenging.

  Journal of agricultural and food chemistry 20080827

• Age and region-specific responses of microglia, but not astrocytes, suggest a role in selective vulnerability of dopamine neurons after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure in monkeys.

  Glia 20080815

• Neuroprotective effect of baicalein against MPTP neurotoxicity: behavioral, biochemical and immunohistochemical profile.

  Neuroscience letters 20080815

• Estrogen and SERM neuroprotection in animal models of Parkinson's disease.

  Molecular and cellular endocrinology 20080813

• Acrylamide: a dietary carcinogen formed in vivo?

  Journal of agricultural and food chemistry 20080813

• Hypersensitivity of aquaporin 4-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine and astrocytic modulation.

  Neurobiology of aging 20080801

• Taurine fails to protect against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced striatal dopamine depletion in mice.

  Amino acids 20080801

• Development of a stable, early stage unilateral model of Parkinson's disease in middle-aged rhesus monkeys.

  Experimental neurology 20080801

• Ghrelin antagonizes MPTP-induced neurotoxicity to the dopaminergic neurons in mouse substantia nigra.

  Experimental neurology 20080801

• Pathologic modifications of alpha-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated squirrel monkeys.

  Journal of neuropathology and experimental neurology 20080801

• Broad neuroprotective profile of nicotinamide in different mouse models of MPTP-induced parkinsonism.

  The European journal of neuroscience 20080801

• Significant effect of dimethylsulfoniopropionate on Parkinson's disease of senescence-accelerated mice induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

  Journal of nutritional science and vitaminology 20080801

• [Ginsenoside Rg1 modulates COX-2 expression in the substantia nigra of mice with MPTP-induced Parkinson disease through the P38 signaling pathway].

  Nan fang yi ke da xue xue bao = Journal of Southern Medical University 20080801

• Inversion of dopamine responses in striatal medium spiny neurons and involuntary movements.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20080723

• mGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeys.

  Neurobiology of aging 20080701

• Role of protein kinase Cdelta in paraquat-induced glial cell death.

  Journal of neuroscience research 20080701

• PYM50028, a novel, orally active, nonpeptide neurotrophic factor inducer, prevents and reverses neuronal damage induced by MPP+ in mesencephalic neurons and by MPTP in a mouse model of Parkinson's disease.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20080701

• Methamphetamine-induced neurotoxicity and microglial activation are not mediated by fractalkine receptor signaling.

  Journal of neurochemistry 20080701

• Striatal histone modifications in models of levodopa-induced dyskinesia.

  Journal of neurochemistry 20080701

• Neuroprotective activities of catalpol on MPP+/MPTP-induced neurotoxicity.

  Neurological research 20080701

• Resveratrol, a red wine polyphenol, protects dopaminergic neurons in MPTP-treated mice.

  Progress in neuro-psychopharmacology & biological psychiatry 20080701

• Central and systemic IL-1 exacerbates neurodegeneration and motor symptoms in a model of Parkinson's disease.

  Brain : a journal of neurology 20080701

• Electrochemical mass spectrometric studies on 1-cyclopropyl-4-phenyl-1,2,3,6-tetrahydropyridine.

  Rapid communications in mass spectrometry : RCM 20080701

• Parkinson's disease and the gut: a well known clinical association in need of an effective cure and explanation.

  Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society 20080701

• Relationship between the severity of hypokinesia induced by neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and neurochemical changes in brain structures of C57Bl/6 mice.

  Bulletin of experimental biology and medicine 20080701

• Protective effects of SUN N8075, a novel agent with antioxidant properties, in in vitro and in vivo models of Parkinson's disease.

  Brain research 20080612

• Globus pallidus plays a critical role in neurotrophic factor induced functional improvements in hemiparkinsonian monkeys.

  Biochemical and biophysical research communications 20080606

• Hemiparkinsonian rats rotate toward the side with the weaker dopaminergic neurotransmission.

  Behavioural brain research 20080603

• Role of lipoamide dehydrogenase and metallothionein on 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-induced neurotoxicity.

  Neurochemical research 20080601

• Role of reactive nitrogen and reactive oxygen species against MPTP neurotoxicity in mice.

  Journal of neural transmission (Vienna, Austria : 1996) 20080601

• Pre-synaptic dopaminergic compensation after moderate nigrostriatal damage in non-human primates.

  Journal of neurochemistry 20080601

• Role of tuberin in neuronal degeneration.

  Neurochemical research 20080601

• Role of reactive oxygen species in the neurotoxicity of environmental agents implicated in Parkinson's disease.

  Free radical biology & medicine 20080601

• Human neural stem cells migrate along the nigrostriatal pathway in a primate model of Parkinson's disease.

  Experimental neurology 20080601

• Failure of acute administration with proteasome inhibitor to provide a model of Parkinson's disease in mice.

  Metabolic brain disease 20080601

• Neuroprotective effects of PACAP27 in mice model of Parkinson's disease involved in the modulation of K(ATP) subunits and D2 receptors in the striatum.

  Neuropeptides 20080601

• Role of homocysteine in the treatment of Parkinson's disease.

  Expert review of neurotherapeutics 20080601

• Expression of Cbl-interacting protein of 85 kDa in MPTP mouse model of Parkinson's disease and 1-methyl-4-phenyl-pyridinium ion-treated dopaminergic SH-SY5Y cells.

  Acta biochimica et biophysica Sinica 20080601

• Calpain as a potential therapeutic target in Parkinson's disease.

  CNS & neurological disorders drug targets 20080601

• Fibroblast growth factor 2 enhances striatal and nigral neurogenesis in the acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.

  Neuroscience 20080515

• Alteration of dopaminergic markers in gastrointestinal tract of different rodent models of Parkinson's disease.

  Neuroscience 20080515

• Increased dopaminergic neuron sensitivity to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in transgenic mice expressing mutant A53T alpha-synuclein.

  Neurochemical research 20080501

• Comparison of the time courses of selective gene expression and dopaminergic depletion induced by MPP+ in MN9D cells.

  Neurochemistry international 20080501

• Activation of NF-kappaB p65/c-Rel dimer is associated with neuroprotection elicited by mGlu5 receptor agonists against MPP(+) toxicity in SK-N-SH cells.

  Journal of neural transmission (Vienna, Austria : 1996) 20080501

• In vitro and in vivo evidences that antioxidant action contributes to the neuroprotective effects of the neuronal nitric oxide synthase and monoamine oxidase-B inhibitor, 7-nitroindazole.

  Neurochemistry international 20080501

• Delayed treatment with arundic acid reduces the MPTP-induced neurotoxicity in mice.

  Cellular and molecular neurobiology 20080501

• Cotinine selectively activates a subpopulation of alpha3/alpha6beta2 nicotinic receptors in monkey striatum.

  The Journal of pharmacology and experimental therapeutics 20080501

• Attenuation of MPTP neurotoxicity by rolipram, a specific inhibitor of phosphodiesterase IV.

  Experimental neurology 20080501

• The PPARgamma agonist pioglitazone is effective in the MPTP mouse model of Parkinson's disease through inhibition of monoamine oxidase B.

  British journal of pharmacology 20080501

• Pallidal burst activity during therapeutic deep brain stimulation.

  Experimental neurology 20080501

• Nicotine and caffeine-mediated modulation in the expression of toxicant responsive genes and vesicular monoamine transporter-2 in 1-methyl 4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease phenotype in mouse.

  Brain research 20080501

• Neurotoxicity of MPTP to migrating neuroblasts: studies in acute and subacute mouse models of Parkinson's disease.

  Neurotoxicology 20080501

• Involvement of brain dopaminergic systems in the development of an MPTP-induced depressive state in rats.

  Neuroscience and behavioral physiology 20080501

• Quantitative gene expression profiling of mouse brain regions reveals differential transcripts conserved in human and affected in disease models.

  Physiological genomics 20080422

• Differential effects of overexpression of wild-type and mutant human alpha-synuclein on MPP+-induced neurotoxicity in PC12 cells.

  Neuroscience letters 20080418

• Transplantation of human amniotic cells exerts neuroprotection in MPTP-induced Parkinson disease mice.

  Brain research 20080418

• The novel cyclooxygenase-2 inhibitor GW637185X protects against l-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity.

  Neuroreport 20080416

• Lesion of the centromedian thalamic nucleus in MPTP-treated monkeys.

  Movement disorders : official journal of the Movement Disorder Society 20080415

• Beneficial effects of dietary omega-3 polyunsaturated fatty acid on toxin-induced neuronal degeneration in an animal model of Parkinson's disease.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20080401

• MPTP-treated mice: long-lasting loss of nigral TH-ir neurons but not paradoxical sleep alterations.

  Experimental brain research 20080401

• Effect of (R)-salsolinol and N-methyl-(R)-salsolinol on the balance impairment between dopamine and acetylcholine in rat brain: involvement in pathogenesis of Parkinson disease.

  Clinical chemistry 20080401

• The role of MPTP in Parkinson's disease: connecting brain and gut?

  Experimental neurology 20080401

• Stereochemical studies on the novel monoamine oxidase B substrates (1R,6S)- and (1S,6R)-3-methyl-6-phenyl-3-aza-bicyclo[4.1.0]heptane.

  Bioorganic & medicinal chemistry 20080401

• [Responsive changes to MPTP in rats with DAT inhibited by antisense oligonucleotides].

  Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics 20080401

• Inhibition of monoamine oxidase-B by the polyphenolic compound, curcumin and its metabolite tetrahydrocurcumin, in a model of Parkinson's disease induced by MPTP neurodegeneration in mice.

  Inflammopharmacology 20080401

• Inhibition of the outgrowth and elongation of neurites from pheochromocytoma cells by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and preventive effects of dimethylsulfoniopropionate in the presence of nerve growth factor.

  Journal of nutritional science and vitaminology 20080401

• [Isolation and identification of Suavissimoside R1 from roots of Rubus parvifollus used for protecting dopaminergic neurons against MPP+ toxicity].

  Zhong yao cai = Zhongyaocai = Journal of Chinese medicinal materials 20080401

• Neuropathological changes induced by neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in male Swiss albino mice.

  Toxicology and industrial health 20080401

• Glycyrrhizin Attenuates MPTP Neurotoxicity in Mouse and MPP-Induced Cell Death in PC12 Cells.

  The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology 20080401

• Role of glial cell derived neurotrophic factor in the protective effect of smilagenin on rat mesencephalic dopaminergic neurons damaged by MPP+.

  FEBS letters 20080319

• Glial reactions in Parkinson's disease.

  Movement disorders : official journal of the Movement Disorder Society 20080315

• Genetic findings in Parkinson's disease and translation into treatment: a leading role for mitochondria?

  Genes, brain, and behavior 20080301

• Therapeutic effects of coenzyme Q10 (CoQ10) and reduced CoQ10 in the MPTP model of Parkinsonism.

  Journal of neurochemistry 20080301

• Protective action of neuronal nitric oxide synthase inhibitor in the MPTP mouse model of Parkinson's disease.

  Metabolic brain disease 20080301

• Spinal cord degeneration in C57BL/6N mice following induction of experimental parkinsonism with MPTP.

  Journal of neurochemistry 20080301

• Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and alpha-synuclein-deleted mice.

  Experimental neurology 20080301

• Loss of aromatase cytochrome P450 function as a risk factor for Parkinson's disease?

  Brain research reviews 20080301

• Structure-activity relationships in the inhibition of monoamine oxidase B by 1-methyl-3-phenylpyrroles.

  Bioorganic & medicinal chemistry 20080301

• Thalamocortical relay fidelity varies across subthalamic nucleus deep brain stimulation protocols in a data-driven computational model.

  Journal of neurophysiology 20080301

• Therapeutic attenuation of mitochondrial dysfunction and oxidative stress in neurotoxin models of Parkinson's disease.

  Biochimica et biophysica acta 20080301

• Adenosine A2A receptor antagonists exert motor and neuroprotective effects by distinct cellular mechanisms.

  Annals of neurology 20080301

• Forebrain dopamine depletion impairs motor behavior in lamprey.

  The European journal of neuroscience 20080301

• Proteome analysis of ventral midbrain in MPTP-treated normal and L1cam transgenic mice.

  Proteomics 20080301

• Role of biotransformation studies in minimizing metabolism-related liabilities in drug discovery.

  The AAPS journal 20080301

• [Protective effects of Cistanche total glycosides on dopaminergic neuron in substantia nigra of model mice of Parkinson's disease].

  Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine 20080301

• Vesicular monoamine transporter substrate/inhibitor activity of MPTP/MPP+ derivatives: a structure-activity study.

  Journal of medicinal chemistry 20080227

• Systemic proteasomal inhibitor exposure enhances dopamine turnover and decreases dopamine levels but does not affect MPTP-induced striatal dopamine depletion in mice.

  Synapse (New York, N.Y.) 20080201

• Normalization of GABAA receptor specific binding in the substantia nigra reticulata and the prevention of L-dopa-induced dyskinesias in MPTP parkinsonian monkeys.

  Synapse (New York, N.Y.) 20080201

• Membrane-permeable Bcl-xL prevents MPTP-induced dopaminergic neuronal loss in the substantia nigra.

  Journal of neurochemistry 20080201

• Basal ganglia group II metabotropic glutamate receptors specific binding in non-human primate model of L-Dopa-induced dyskinesias.

  Neuropharmacology 20080201

• S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent. II. A neurochemical, electrophysiological and behavioral characterization in vivo.

  The Journal of pharmacology and experimental therapeutics 20080201

• Neuroprotective effects of genistein on dopaminergic neurons in the mice model of Parkinson's disease.

  Neuroscience research 20080201

• Trichloroethylene: Parkinsonism and complex 1 mitochondrial neurotoxicity.

  Annals of neurology 20080201

• Visualization of monoaminergic neurons and neurotoxicity of MPTP in live transgenic zebrafish.

  Developmental biology 20080201

• Mitochondrial dysfunction, oxidative stress, and apoptosis revealed by proteomic and transcriptomic analyses of the striata in two mouse models of Parkinson's disease.

  Journal of proteome research 20080201

• [Evaluation of motor disorders in animal models of Parkinson's disease].

  Revista de neurologia 20080201

• Antiparkinsonian effect of nerve growth factor adsorbed on polybutylcyanoacrylate nanoparticles coated with polysorbate-80.

  Bulletin of experimental biology and medicine 20080201

• Repeated intranigral MPTP administration: a new protocol of prolonged locomotor impairment mimicking Parkinson's disease.

  Journal of neuroscience methods 20080130

• Prolonged kynurenine 3-hydroxylase inhibition reduces development of levodopa-induced dyskinesias in parkinsonian monkeys.

  Behavioural brain research 20080125

• Exploring the neuroprotective effects of modafinil in a marmoset Parkinson model with immunohistochemistry, magnetic resonance imaging and spectroscopy.

  Brain research 20080116

• Low-pass filter properties of basal ganglia cortical muscle loops in the normal and MPTP primate model of parkinsonism.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20080116

• A cell-permeable peptide inhibitor TAT-JBD reduces the MPP+-induced caspase-9 activation but does not prevent the dopaminergic degeneration in substantia nigra of rats.

  Toxicology 20080114

• Unregulated cytosolic dopamine causes neurodegeneration associated with oxidative stress in mice.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20080109

• Estimation of D2-like receptor occupancy by dopamine in the putamen of hemiparkinsonian Monkeys.

  Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20080101

• MPTP-induced deficits in striatal synaptic plasticity are prevented by glial cell line-derived neurotrophic factor expressed via an adeno-associated viral vector.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20080101

• L-Dopa treatment abolishes the numerical increase in striatal dopaminergic neurons in parkinsonian monkeys.

  Journal of chemical neuroanatomy 20080101

• Neurobehavioral protection by single dose l-deprenyl against MPTP-induced parkinsonism in common marmosets.

  Psychopharmacology 20080101

• Influence of cell preparation and target location on the behavioral recovery after striatal transplantation of fetal dopaminergic neurons in a primate model of Parkinson's disease.

  Neurobiology of disease 20080101

• Bak Foong protects dopaminergic neurons against MPTP-induced neurotoxicity by its anti-apoptotic activity.

  Cell biology international 20080101

• Effects of low-frequency stimulation of the subthalamic nucleus on movement in Parkinson's disease.

  Experimental neurology 20080101

• Alteration in the differentiation-related molecular expression in the subventricular zone in a mouse model of Parkinson's disease.

  Neuroscience research 20080101

• Oxidative stress on EAAC1 is involved in MPTP-induced glutathione depletion and motor dysfunction.

  The European journal of neuroscience 20080101

• Nitrated alpha-synuclein immunity accelerates degeneration of nigral dopaminergic neurons.

  PloS one 20080101

• Protection by the NDI1 gene against neurodegeneration in a rotenone rat model of Parkinson's disease.

  PloS one 20080101

• Striatal proteomic analysis suggests that first L-dopa dose equates to chronic exposure.

  PloS one 20080101

• Proteome analysis of human substantia nigra in Parkinson's disease.

  Proteome science 20080101

• MAO-B elevation in mouse brain astrocytes results in Parkinson's pathology.

  PloS one 20080101

• Neuroinflammation mediated by IL-1beta increases susceptibility of dopamine neurons to degeneration in an animal model of Parkinson's disease.

  Journal of neuroinflammation 20080101

• Effects of aging on neuroprotective and neurotoxic properties of microglia in neurodegenerative diseases.

  Neuro-degenerative diseases 20080101

• Metabolic profiling reveals therapeutic effects of Herba Cistanches in an animal model of hydrocortisone-induced 'kidney-deficiency syndrome'.

  Chinese medicine 20080101

• Genetic variability of histamine receptors in patients with Parkinson's disease.

  BMC medical genetics 20080101

• [Use of 11C-(+)-alpha -dihydrotetrabenazine for the assessment of dopaminergic innervation in animal models of Parkinson's disease].

  Revista espanola de medicina nuclear 20080101

• Calpain-mediated MPP+ toxicity in mitochondrial DNA depleted cells.

  Neurotoxicity research 20080101

• Pesticide exposure and risk of Parkinson's disease: a family-based case-control study.

  BMC neurology 20080101

• Wheel running from a juvenile age delays onset of specific motor deficits but does not alter protein aggregate density in a mouse model of Huntington's disease.

  BMC neuroscience 20080101

• Peroxisome Proliferator-Activated Receptor-gamma in Amyotrophic Lateral Sclerosis and Huntington's Disease.

  PPAR research 20080101

• Squamosamide derivative FLZ protects dopaminergic neurons against inflammation-mediated neurodegeneration through the inhibition of NADPH oxidase activity.

  Journal of neuroinflammation 20080101

• Intraputamenal infusion of exogenous neurturin protein restores motor and dopaminergic function in the globus pallidus of MPTP-lesioned rhesus monkeys.

  Cell transplantation 20080101

• GDNF-secreting human neural progenitor cells increase tyrosine hydroxylase and VMAT2 expression in MPTP-treated cynomolgus monkeys.

  Cell transplantation 20080101

• Pharmacological MRI (phMRI) monitoring of treatment in hemiparkinsonian rhesus monkeys.

  Cell transplantation 20080101

• PINK1 is necessary for long term survival and mitochondrial function in human dopaminergic neurons.

  PloS one 20080101

• Role of CYP2E1 in the mouse model of MPTP toxicity.

  Parkinsonism & related disorders 20080101

• Modeling PD pathogenesis in mice: advantages of a chronic MPTP protocol.

  Parkinsonism & related disorders 20080101

• Transgenic rodent models of Parkinson's disease.

  Acta neurochirurgica. Supplement 20080101

• Adaptive immune neuroprotection in G93A-SOD1 amyotrophic lateral sclerosis mice.

  PloS one 20080101

• PPAR Regulation of Inflammatory Signaling in CNS Diseases.

  PPAR research 20080101

• Neuroprotective effects of edaravone-administration on 6-OHDA-treated dopaminergic neurons.

  BMC neuroscience 20080101

• Expression of TLR4 and CD14 in the central nervous system (CNS) in a MPTP mouse model of Parkinson's-like disease.

  Immunopharmacology and immunotoxicology 20080101

• Brain serotonin and dopamine modulators, perceptual responses and endurance performance during exercise in the heat following creatine supplementation.

  Journal of the International Society of Sports Nutrition 20080101

• TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease.

  Journal of neuroinflammation 20080101

• Potential developmental neurotoxicity of pesticides used in Europe.

  Environmental health : a global access science source 20080101

• NADPH oxidase as a therapeutic target in Alzheimer's disease.

  BMC neuroscience 20080101

• [Glutamate antibodies in the development of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinsonian syndrome in C57B1/6 mice].

  Patologicheskaia fiziologiia i eksperimental'naia terapiia 20080101

• Sesamin modulates tyrosine hydroxylase, superoxide dismutase, catalase, inducible NO synthase and interleukin-6 expression in dopaminergic cells under MPP+-induced oxidative stress.

  Oxidative medicine and cellular longevity 20080101

• Therapeutic Potential of PPARγ Activation in Stroke.

  PPAR research 20080101

• RGS9-2 negatively modulates L-3,4-dihydroxyphenylalanine-induced dyskinesia in experimental Parkinson's disease.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20071226

• [Changes of amino acids neurotransmitters in striatum of hemi-parkinsonian rhesus monkey after high frequency stimulation of subthalamic nucleus].

  Zhonghua wai ke za zhi [Chinese journal of surgery] 20071215

• Constitutive expression and functional characterization of mitochondrial glutaredoxin (Grx2) in mouse and human brain.

  Brain research 20071214

• Cannabinoid CB1 receptor stimulation affords neuroprotection in MPTP-induced neurotoxicity by attenuating S100B up-regulation in vitro.

  Journal of molecular medicine (Berlin, Germany) 20071201

• The number of dopaminergic cells is increased in the olfactory bulb of monkeys chronically exposed to MPTP.

  Synapse (New York, N.Y.) 20071201

• Pael receptor is involved in dopamine metabolism in the nigrostriatal system.

  Neuroscience research 20071201

• Bone-marrow-derived cell differentiation into microglia: a study in a progressive mouse model of Parkinson's disease.

  Neurobiology of disease 20071201

• The administration of entacapone prevents L-dopa-induced dyskinesia when added to dopamine agonist therapy in MPTP-treated primates.

  Experimental neurology 20071201

• Nicotine reduces levodopa-induced dyskinesias in lesioned monkeys.

  Annals of neurology 20071201

• Enhanced tyrosine hydroxylase expression in PC12 cells co-cultured with feline mesenchymal stem cells.

  Journal of veterinary science 20071201

• Anti-inflammatory and immune therapy for Alzheimer's disease: current status and future directions.

  Current neuropharmacology 20071201

• The neuropharmacology of (-)-stepholidine and its potential applications.

  Current neuropharmacology 20071201

• Proteome analysis of substantia nigra and striatal tissue in the mouse MPTP model of Parkinson's disease.

  Proteomics. Clinical applications 20071201

• MPTP administration in mice changes the ratio of splice isoforms of fosB and rgs9.

  Brain research 20071128

• Changes in the rates of the tricarboxylic acid (TCA) cycle and glutamine synthesis in the monkey brain with hemiparkinsonism induced by intracarotid infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): studies by non-invasive 13C-magnetic resonance spectroscopy.

  Brain research 20071121

• Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinson's disease.

  Journal of leukocyte biology 20071101

• Chronic inhalation of rotenone or paraquat does not induce Parkinson's disease symptoms in mice or rats.

  Experimental neurology 20071101

• Paraquat: the red herring of Parkinson's disease research.

  Toxicological sciences : an official journal of the Society of Toxicology 20071101

• [Protective effect of baicalin on mouse with Parkinson's disease induced by MPTP].

  Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine 20071101

• [The protective effect of nicotine on dopaminergic neuron of Parkinson's disease mice].

  Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology 20071101

• Complement 3-deficient mice are not protected against MPTP-induced dopaminergic neurotoxicity.

  Brain research 20071031

• Increased host neuronal survival and motor function in BMT Parkinsonian mice: involvement of immunosuppression.

  The Journal of comparative neurology 20071020

• Response to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) differs in mouse strains and reveals a divergence in JNK signaling and COX-2 induction prior to loss of neurons in the substantia nigra pars compacta.

  Brain research 20071017

• Quantitative [(123)I]FP-CIT pinhole SPECT imaging predicts striatal dopamine levels, but not number of nigral neurons in different mouse models of Parkinson's disease.

  NeuroImage 20071015

• Endurance exercise promotes cardiorespiratory rehabilitation without neurorestoration in the chronic mouse model of parkinsonism with severe neurodegeneration.

  Neuroscience 20071012

• Blockade of cannabinoid type 1 receptors augments the antiparkinsonian action of levodopa without affecting dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated rhesus monkeys.

  The Journal of pharmacology and experimental therapeutics 20071001

• Non-motor behavioural impairments in parkin-deficient mice.

  The European journal of neuroscience 20071001

• Prolonged toxicokinetics and toxicodynamics of paraquat in mouse brain.

  Environmental health perspectives 20071001

• Neuroprotective effect of dipeptide AVP(4-5)-NH2 is associated with nerve growth factor and heat shock protein HSP70.

  Bulletin of experimental biology and medicine 20071001

• Chronic exposure to low levels of aluminum alters cerebral cell signaling in response to acute MPTP administration.

  Toxicology and industrial health 20071001

• Inhibition of the leucine-rich repeat protein LINGO-1 enhances survival, structure, and function of dopaminergic neurons in Parkinson's disease models.

  Proceedings of the National Academy of Sciences of the United States of America 20070904

• Gene expression profiling of MPP+-treated MN9D cells: a mechanism of toxicity study.

  Neurotoxicology 20070901

• Toki-to protects dopaminergic neurons in the substantia nigra from neurotoxicity of MPTP in mice.

  Phytotherapy research : PTR 20070901

• Rapid down-regulation of Ret following exposure of dopaminergic neurons to neurotoxins.

  Journal of neurochemistry 20070901

• Neuroprotective effect of protein kinase C delta inhibitor rottlerin in cell culture and animal models of Parkinson's disease.

  The Journal of pharmacology and experimental therapeutics 20070901

• Loss of enteric dopaminergic neurons and associated changes in colon motility in an MPTP mouse model of Parkinson's disease.

  Experimental neurology 20070901

• Exacerbation of dopaminergic terminal damage in a mouse model of Parkinson's disease by the G-protein-coupled receptor protease-activated receptor 1.

  Molecular pharmacology 20070901

• Evaluation of neuroprotective and anti-fatigue effects of sildenafil.

  Life sciences 20070901

• Aminochrome as a preclinical experimental model to study degeneration of dopaminergic neurons in Parkinson's disease.

  Neurotoxicity research 20070901

• Brain-derived neurotrophic factor expression in the substantia nigra does not change after lesions of dopaminergic neurons.

  Neurotoxicity research 20070901

• Adenosine A(1) receptor: Functional receptor-receptor interactions in the brain.

  Purinergic signalling 20070901

• MPP(+)-induced cytotoxicity in neuroblastoma cells: Antagonism and reversal by guanosine.

  Purinergic signalling 20070901

• Homocysteine is toxic for dopaminergic neurons in primary mesencephalic culture.

  Neuroreport 20070827

• 17Beta-estradiol reduces nitrotyrosine immunoreactivity and increases SOD1 and SOD2 immunoreactivity in nigral neurons in male mice following MPTP insult.

  Brain research 20070820

• A beam-walking apparatus to assess behavioural impairments in MPTP-treated mice: pharmacological validation with R-(-)-deprenyl.

  Journal of neuroscience methods 20070815

• Spatial and functional relationship between poly(ADP-ribose) polymerase-1 and poly(ADP-ribose) glycohydrolase in the brain.

  Neuroscience 20070810

• The effects of serotoninergic, noradrenergic, cholinergic and dopaminergic drugs on vigilance states in MPTP-treated mice.

  Brain research 20070803

• Interaction between nicotine and MPTP/MPP+ in rat brain endothelial cells.

  Life sciences 20070802

• Effect of acute administration of hydroalcohol extract of Ilex paraguariensis St Hilaire (Aquifoliaceae) in animal models of Parkinson's disease.

  Phytotherapy research : PTR 20070801

• Impaired mutagenic activities of MPDP(+) (1-methyl-4-phenyl-2,3-dihydropyridinium) and MPP(+) (1-methyl-4-phenylpyridinium) due to their interactions with methylxanthines.

  Bioorganic & medicinal chemistry 20070801

• Increased vulnerability of nigrostriatal terminals in DJ-1-deficient mice is mediated by the dopamine transporter.

  Neurobiology of disease 20070801

• Survival of midbrain dopaminergic cells after lesion or deep brain stimulation of the subthalamic nucleus in MPTP-treated monkeys.

  Brain : a journal of neurology 20070801

• In vivo evidence of D3 dopamine receptor sensitization in parkinsonian primates and rodents with l-DOPA-induced dyskinesias.

  Neurobiology of disease 20070801

• Correlation between levels of pigment epithelium-derived factor and vascular endothelial growth factor in the striatum of patients with Parkinson's disease.

  Experimental neurology 20070801

• The use of knock-out mice unravels distinct roles for mGlu2 and mGlu3 metabotropic glutamate receptors in mechanisms of neurodegeneration/neuroprotection.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20070801

• Chinese herbs and herbal extracts for neuroprotection of dopaminergic neurons and potential therapeutic treatment of Parkinson's disease.

  CNS & neurological disorders drug targets 20070801

• [Effect of phosphorylated c-Jun expression on COX-2 expression in the substantia nigra of MPTP mouse model of subacute Parkinson disease].

  Nan fang yi ke da xue xue bao = Journal of Southern Medical University 20070801

• Microarray analysis of laser capture microdissected substantia nigra pars compacta after a single administration of MPTP in common marmosets.

  Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology 20070801

• Neurotoxicity studies with the monoamine oxidase B substrate 1-methyl-3-phenyl-3-pyrroline.

  Life sciences 20070719

• Comparative analysis of the effects of resveratrol in two apoptotic models: inhibition of complex I and potassium deprivation in cerebellar neurons.

  Neuroscience 20070713

• Unique responses to mitochondrial complex I inhibition in tuberoinfundibular dopamine neurons may impart resistance to toxic insult.

  Neuroscience 20070713

• Neurotoxicity in murine striatal dopaminergic pathways following long-term application of low doses of permethrin and MPTP.

  Toxicology letters 20070710

• SPECT imaging, immunohistochemical and behavioural correlations in the primate models of Parkinson's disease.

  Parkinsonism & related disorders 20070701

• Activation of apoptosis signal regulating kinase 1 (ASK1) and translocation of death-associated protein, Daxx, in substantia nigra pars compacta in a mouse model of Parkinson's disease: protection by alpha-lipoic acid.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20070701

• Apoptotic mode of cell death in substantia nigra following intranigral infusion of the parkinsonian neurotoxin, MPP+ in Sprague-Dawley rats: cellular, molecular and ultrastructural evidences.

  Neurochemical research 20070701

• Nigrostriatal damage preferentially decreases a subpopulation of alpha6beta2* nAChRs in mouse, monkey, and Parkinson's disease striatum.

  Molecular pharmacology 20070701

• Neuroprotective effects of pituitary adenylate cyclase-activating polypeptide (PACAP) in MPP+-induced alteration of translational control in Neuro-2a neuroblastoma cells.

  Journal of neuroscience research 20070701

• Lamotrigine is neuroprotective in the energy deficiency model of MPTP intoxicated mice.

  Pediatric research 20070701

• Striatal leucine-rich repeat kinase 2 mRNA is increased in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned common marmosets (Callithrix jacchus) with L-3, 4-dihydroxyphenylalanine methyl ester-induced dyskinesia.

  The European journal of neuroscience 20070701

• 'Rejuvenation' protects neurons in mouse models of Parkinson's disease.

  Nature 20070628

• Neuroprotective effects of echinacoside in the mouse MPTP model of Parkinson's disease.

  European journal of pharmacology 20070614

• Localization and expression of group I metabotropic glutamate receptors in the mouse striatum, globus pallidus, and subthalamic nucleus: regulatory effects of MPTP treatment and constitutive Homer deletion.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20070606

• Increased murine neonatal iron intake results in Parkinson-like neurodegeneration with age.

  Neurobiology of aging 20070601

• Quantitative diffusion tensor imaging detects dopaminergic neuronal degeneration in a murine model of Parkinson's disease.

  Neurobiology of disease 20070601

• Non-steroidal anti-inflammatory drugs in Parkinson's disease.

  Experimental neurology 20070601

• Activated microglia affect the nigro-striatal dopamine neurons differently in neonatal and aged mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

  Journal of neuroscience research 20070601

• Inhibition of glycogen synthase kinase-3beta protects dopaminergic neurons from MPTP toxicity.

  Neuropharmacology 20070601

• Mitochondrial nutrition as a strategy for neuroprotection in Parkinson's disease—research focus in the department of alternative medicine and experimental therapeutics at Hokuriku University.

  Evidence-based complementary and alternative medicine : eCAM 20070601

• Rasagiline - a novel MAO B inhibitor in Parkinson's disease therapy.

  Therapeutics and clinical risk management 20070601

• Fluoro-Jade C can specifically stain the degenerative neurons in the substantia nigra of the 1-methyl-4-phenyl-1,2,3,6-tetrahydro pyridine-treated C57BL/6 mice.

  Brain research 20070530

• Use-dependent behavioral and neurochemical asymmetry in MPTP mice.

  Neuroscience letters 20070518

• Mangiferin protects against 1-methyl-4-phenylpyridinium toxicity mediated by oxidative stress in N2A cells.

  Neuroscience letters 20070517

• Effects of treadmill exercise on dopaminergic transmission in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse model of basal ganglia injury.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20070516

• Pre-training to find a hidden platform in the Morris water maze can compensate for a deficit to find a cued platform in a rat model of Parkinson's disease.

  Neurobiology of learning and memory 20070501

• Does ORP150/HSP12A protect dopaminergic neurons against MPTP/MPP(+)-induced neurotoxicity?

  Antioxidants & redox signaling 20070501

• The selective kappa-opioid receptor agonist U50,488 reduces L-dopa-induced dyskinesias but worsens parkinsonism in MPTP-treated primates.

  Experimental neurology 20070501

• MPTP and DSP-4 susceptibility of substantia nigra and locus coeruleus catecholaminergic neurons in mice is independent of parkin activity.

  Neurobiology of disease 20070501

• A highly sensitive automated complex running wheel test to detect latent motor deficits in the mouse MPTP model of Parkinson's disease.

  Experimental neurology 20070501

• Altered D(1) dopamine receptor trafficking in parkinsonian and dyskinetic non-human primates.

  Neurobiology of disease 20070501

• Modification of the number and phenotype of striatal dopaminergic cells by carotid body graft.

  Brain : a journal of neurology 20070501

• Does thioredoxin-1 prevent mitochondria- and endoplasmic reticulum-mediated neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine?

  Antioxidants & redox signaling 20070501

• N-methyltetrahydro-beta-carboline analogs of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxin are oxidized to neurotoxic beta-carbolinium cations by heme peroxidases.

  Biochemical and biophysical research communications 20070427

• Antioxidant responses and lipid peroxidation following intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration in rats: increased susceptibility of olfactory bulb.

  Life sciences 20070424

• An orally active catalytic metalloporphyrin protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity in vivo.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20070418

• Antiparkinsonian activity of L-propyl-L-leucyl-glycinamide or melanocyte-inhibiting factor in MPTP-treated common marmosets.

  Movement disorders : official journal of the Movement Disorder Society 20070415

• Attenuation of 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine induced nigrostriatal toxicity in mice by N-acetyl cysteine.

  Cellular and molecular biology (Noisy-le-Grand, France) 20070415

• The COX-2 inhibitor parecoxib produces neuroprotective effects in MPTP-lesioned rats.

  European journal of pharmacology 20070410

• Chronic ferritin expression within murine dopaminergic midbrain neurons results in a progressive age-related neurodegeneration.

  Brain research 20070406

• Enhanced preproenkephalin-B-derived opioid transmission in striatum and subthalamic nucleus converges upon globus pallidus internalis in L-3,4-dihydroxyphenylalanine-induced dyskinesia.

  Biological psychiatry 20070401

• TNF-alpha knockout and minocycline treatment attenuates blood-brain barrier leakage in MPTP-treated mice.

  Neurobiology of disease 20070401

• Aging-related changes in the nigrostriatal dopamine system and the response to MPTP in nonhuman primates: diminished compensatory mechanisms as a prelude to parkinsonism.

  Neurobiology of disease 20070401

• Oxidative damage in nucleic acids and Parkinson's disease.

  Journal of neuroscience research 20070401

• DJ-1 and Parkin modulate dopamine-dependent behavior and inhibit MPTP-induced nigral dopamine neuron loss in mice.

  Molecular therapy : the journal of the American Society of Gene Therapy 20070401

• Neuroprotection by estrogen against MPP+-induced dopamine neuron death is mediated by ERalpha in primary cultures of mouse mesencephalon.

  Experimental neurology 20070401

• Motor cortex stimulation: mild transient benefit in a primate model of Parkinson disease.

  Journal of neurosurgery 20070401

• Epidemiology of Parkinson's disease.

  Disease-a-month : DM 20070401

• Long-lasting reactive changes observed in microglia in the striatal and substantia nigral of mice after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

  Brain research 20070323

• Involvement of interferon-gamma in microglial-mediated loss of dopaminergic neurons.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20070321

• Temporal mRNA profiles of inflammatory mediators in the murine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine model of Parkinson's disease.

  Neuroscience 20070316

• Lipid-lowering drugs in the MPTP mouse model of Parkinson's disease: fenofibrate has a neuroprotective effect, whereas bezafibrate and HMG-CoA reductase inhibitors do not.

  Brain research 20070302

• Subthalamic glutamic acid decarboxylase gene therapy: changes in motor function and cortical metabolism.

  Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 20070301

• Changes in the neuronal activity in the pedunculopontine nucleus in chronic MPTP-treated primates: an in situ hybridization study of cytochrome oxidase subunit I, choline acetyl transferase and substance P mRNA expression.

  Journal of neural transmission (Vienna, Austria : 1996) 20070301

• Decreased expression of l-dopa-induced dyskinesia by switching to ropinirole in MPTP-treated common marmosets.

  Experimental neurology 20070301

• Neuroprotective efficacy of the peroxisome proliferator-activated receptor delta-selective agonists in vitro and in vivo.

  The Journal of pharmacology and experimental therapeutics 20070301

• The isolation of neural stem cells from the olfactory bulb of Parkinson's disease model.

  Neuroscience research 20070301

• Absence of Ret signaling in mice causes progressive and late degeneration of the nigrostriatal system.

  PLoS biology 20070301

• Impact of chronic subthalamic high-frequency stimulation on metabolic basal ganglia activity: a 2-deoxyglucose uptake and cytochrome oxidase mRNA study in a macaque model of Parkinson's disease.

  The European journal of neuroscience 20070301

• Manganese does not alter the severe neurotoxicity of MPTP.

  Human & experimental toxicology 20070301

• Acupuncture inhibits microglial activation and inflammatory events in the MPTP-induced mouse model.

  Brain research 20070202

• The novel squamosamide derivative (compound FLZ) attenuated 1-methyl, 4-phenyl-pyridinium ion (MPP+)-induced apoptosis and alternations of related signal transduction in SH-SY5Y cells.

  Neuropharmacology 20070201

• Tamoxifen effect on L-DOPA induced response complications in parkinsonian rats and primates.

  Neuropharmacology 20070201

• GDNF applied to the MPTP-lesioned nigrostriatal system requires TGF-beta for its neuroprotective action.

  Neurobiology of disease 20070201

• CD4+ T cells from Copolymer-1 immunized mice protect dopaminergic neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.

  Journal of neuroimmunology 20070201

• Prodromal non-motor symptoms of Parkinson's disease.

  Neuropsychiatric disease and treatment 20070201

• Chemokines in the MPTP model of Parkinson's disease: absence of CCL2 and its receptor CCR2 does not protect against striatal neurodegeneration.

  Brain research 20070112

• Cytotoxicity of 17 tetrahydroisoquinoline derivatives in SH-SY5Y human neuroblastoma cells is related to mitochondrial NADH-ubiquinone oxidoreductase inhibition.

  Neurotoxicology 20070101

• Evaluation of acute antiapoptotic effects of Li+ in neuronal cell cultures.

  Journal of neural transmission (Vienna, Austria : 1996) 20070101

• Dopaminergic neuronal loss in transgenic mice expressing the Parkinson's disease-associated UCH-L1 I93M mutant.

  Neurochemistry international 20070101

• Methoxyflavones protect cells against endoplasmic reticulum stress and neurotoxin.

  American journal of physiology. Cell physiology 20070101

• Divergent mechanisms of paraquat, MPP+, and rotenone toxicity: oxidation of thioredoxin and caspase-3 activation.

  Toxicological sciences : an official journal of the Society of Toxicology 20070101

• Obligatory role for complex I inhibition in the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

  Toxicological sciences : an official journal of the Society of Toxicology 20070101

• Activation of tyrosine kinase receptor signaling pathway by rasagiline facilitates neurorescue and restoration of nigrostriatal dopamine neurons in post-MPTP-induced parkinsonism.

  Neurobiology of disease 20070101

• Transglutaminase 2 ablation leads to defective function of mitochondrial respiratory complex I affecting neuronal vulnerability in experimental models of extrapyramidal disorders.

  Journal of neurochemistry 20070101

• Striatal delta opioid receptor binding in experimental models of Parkinson's disease and dyskinesia.

  Movement disorders : official journal of the Movement Disorder Society 20070101

• A pivotal role of matrix metalloproteinase-3 activity in dopaminergic neuronal degeneration via microglial activation.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20070101

• Levodopa-induced hyperactivity in mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

  Movement disorders : official journal of the Movement Disorder Society 20070101

• Metabolic activity of cerebellar and basal ganglia-thalamic neurons is reduced in parkinsonism.

  Brain : a journal of neurology 20070101

• Regulation of autophagy by extracellular signal-regulated protein kinases during 1-methyl-4-phenylpyridinium-induced cell death.

  The American journal of pathology 20070101

• Prostaglandin E2 receptor subtype 2 (EP2) regulates microglial activation and associated neurotoxicity induced by aggregated alpha-synuclein.

  Journal of neuroinflammation 20070101

• Angiotensin type 1 receptor antagonist losartan, reduces MPTP-induced degeneration of dopaminergic neurons in substantia nigra.

  Molecular neurodegeneration 20070101

• Neuroprotective effect of ketamine/xylazine on two rat models of Parkinson's disease.

  Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas 20070101

• Alloimmunisation to donor antigens and immune rejection following foetal neural grafts to the brain in patients with Huntington's disease.

  PloS one 20070101

• Differential gene expression patterns in cyclooxygenase-1 and cyclooxygenase-2 deficient mouse brain.

  Genome biology 20070101

• Role of mitochondrial dysfunction in Parkinson's disease: Implications for treatment.

  Drugs & aging 20070101

• Dominant inheritance of retinal ganglion cell resistance to optic nerve crush in mice.

  BMC neuroscience 20070101

• XIAP protection of photoreceptors in animal models of retinitis pigmentosa.

  PloS one 20070101

• Protocol for the MPTP mouse model of Parkinson's disease.

  Nature protocols 20070101

• Modulating effect of Hypericum perforatum extract on astrocytes in MPTP induced Parkinson's disease in mice.

  European review for medical and pharmacological sciences 20070101

• The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention.

  Molecular cancer 20070101

• The neuroprotective effect of Withania somnifera root extract in MPTP-intoxicated mice: an analysis of behavioral and biochemical variables.

  Cellular & molecular biology letters 20070101

• Absence of dopaminergic neuronal degeneration and oxidative damage in aged DJ-1-deficient mice.

  Molecular neurodegeneration 20070101

• The role of the substantia nigra pars compacta in regulating sleep patterns in rats.

  PloS one 20070101

• Antioxidative and anti-inflammatory effects of four cysteine-containing agents in striatum of MPTP-treated mice.

  Nutrition (Burbank, Los Angeles County, Calif.) 20070101

• Inflammation in Parkinson's diseases and other neurodegenerative diseases: cause and therapeutic implications.

  Current pharmaceutical design 20070101

• [Involvement of the brain dopaminergic systems in the development of the MPTP-induced depressive state in rats].

  Zhurnal vysshei nervnoi deiatelnosti imeni I P Pavlova 20070101

• Inflammation in Parkinson's disease: causative or epiphenomenal?

  Sub-cellular biochemistry 20070101

• Minocycline delayed photoreceptor death in rds mice through iNOS-dependent mechanism.

  Molecular vision 20070101

• Minocycline and sulforaphane inhibited lipopolysaccharide-mediated retinal microglial activation.

  Molecular vision 20070101

• Identification of novel proteins affected by rotenone in mitochondria of dopaminergic cells.

  BMC neuroscience 20070101

• Nonhuman primate models of Parkinson's disease.

  ILAR journal 20070101

• Enhanced astrocytic nitric oxide production and neuronal modifications in the neocortex of a NOS2 mutant mouse.

  PloS one 20070101

• A unified framework for finding differentially expressed genes from microarray experiments.

  BMC bioinformatics 20070101

• Sinomenine, a natural dextrorotatory morphinan analog, is anti-inflammatory and neuroprotective through inhibition of microglial NADPH oxidase.

  Journal of neuroinflammation 20070101

• Agmatine protects retinal ganglion cells from hypoxia-induced apoptosis in transformed rat retinal ganglion cell line.

  BMC neuroscience 20070101

• CYP 2E1 mutant mice are resistant to DDC-induced enhancement of MPTP toxicity.

  Journal of neural transmission. Supplementum 20070101

• A model of MPTP-induced Parkinson's disease in the goldfish.

  Nature protocols 20070101

• Multilineage potential of stable human mesenchymal stem cell line derived from fetal marrow.

  PloS one 20070101

• [Daphnia magna (straus): a new test object for modeling of dopaminergic neurotransmission deficiency induced by the selective neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine].

  Eksperimental'naia i klinicheskaia farmakologiia 20070101

• PET 6-[F]fluoro-L-m-tyrosine Studies of Dopaminergic Function in Human and Nonhuman Primates.

  Frontiers in human neuroscience 20070101

• Human bone marrow-derived mesenchymal stem cells.

  The Libyan journal of medicine 20070101

• Identification of genes related to Parkinson's disease using expressed sequence tags.

  DNA research : an international journal for rapid publication of reports on genes and genomes 20061231

• Intrastriatal infusion of the Parkinsonian neurotoxin, MPP(+), induces damage of striatal cell nuclei in Sprague-Dawley rats.

  Journal of chemical neuroanatomy 20061201

• Neuroanatomical mapping of DNA repair and antioxidative responses in mouse brain: Effects of a single dose of MPTP.

  Neurotoxicology 20061201

• The risk is in the air: Intranasal administration of MPTP to rats reproducing clinical features of Parkinson's disease.

  Experimental neurology 20061201

• In vivo modulation of the Parkinsonian phenotype by Nrf2.

  Neurotoxicology 20061201

• In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with\ increased motor disability.

  The Journal of pharmacology and experimental therapeutics 20061201

• Subthalamic nucleus neurones in slices from 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mice show irregular, dopamine-reversible firing pattern changes, but without synchronous activity.

  Neuroscience 20061201

• Metabolic aromatization of N-alkyl-1,2,3,4-tetrahydroquinoline substructures to quinolinium by human liver microsomes and horseradish peroxidase.

  Drug metabolism and disposition: the biological fate of chemicals 20061201

• Antiparkinsonian effects of the novel D3/D2 dopamine receptor agonist, S32504, in MPTP-lesioned marmosets: Mediation by D2, not D3, dopamine receptors.

  Movement disorders : official journal of the Movement Disorder Society 20061201

• Mitochondrial complex-1 in Parkinson's disease.

  Neurology India 20061201

• Mass spectrometric studies on 4-aryl-1-cyclopropyl-1,2-dihydropyridinyl derivatives: an examination of a novel fragmentation pathway.

  Journal of mass spectrometry : JMS 20061201

• 3-Hydroxymorphinan, a metabolite of dextromethorphan, protects nigrostriatal pathway against MPTP-elicited damage both in vivo and in vitro.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20061201

• alpha-Synuclein, oxidative stress and apoptosis from the perspective of a yeast model of Parkinson's disease.

  FEMS yeast research 20061201

• Neuroprotection in Parkinson models varies with toxin administration protocol.

  The European journal of neuroscience 20061201

• Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys.

  Annals of neurology 20061201

• Place learning strategy of substantia nigra pars compacta-lesioned rats.

  Behavioral neuroscience 20061201

• 1alpha,25-Dihydroxyvitamin D(3) Protects Dopaminergic Neurons in Rodent Models of Parkinson's Disease through Inhibition of Microglial Activation.

  Journal of clinical neurology (Seoul, Korea) 20061201

• Enhanced neuroprotective effect by combination of bromocriptine and Hypericum perforatum extract against MPTP-induced neurotoxicity in mice.

  Journal of the neurological sciences 20061115

• Ebselen effects on MPTP-induced neurotoxicity.

  Brain research 20061106

• DHEA improves symptomatic treatment of moderately and severely impaired MPTP monkeys.

  Neurobiology of aging 20061101

• Wld(S) mice are protected against the Parkinsonian mimetic MPTP.

  Experimental neurology 20061101

• Comparative aromatic hydroxylation and N-demethylation of MPTP neurotoxin and its analogs, N-methylated beta-carboline and isoquinoline alkaloids, by human cytochrome P450 2D6.

  Toxicology and applied pharmacology 20061101

• HSV-mediated delivery of erythropoietin restores dopaminergic function in MPTP-treated mice.

  Molecular therapy : the journal of the American Society of Gene Therapy 20061101

• Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease.

  Movement disorders : official journal of the Movement Disorder Society 20061101

• Tetrandrine selectively protects against amyloid-beta protein - but not against MPTP-induced cytotoxicity in SK-N-SH neuroblastoma cells.

  Planta medica 20061101

• Recombinant human granulocyte colony-stimulating factor protects against MPTP-induced dopaminergic cell death in mice by altering Bcl-2/Bax expression levels.

  Journal of neurochemistry 20061101

• Implications for estrogens in Parkinson's disease: an epidemiological approach.

  Annals of the New York Academy of Sciences 20061101

• Activities of prolyl endopeptidase and dipeptidyl peptidase IV in brain structures of rats with dopamine deficiency-dependent MPTP-induced depressive syndrome.

  Bulletin of experimental biology and medicine 20061101

• Dynamic modeling of alpha-synuclein aggregation for the sporadic and genetic forms of Parkinson's disease.

  Neuroscience 20061027

• Distinct structure and activity of monoamine oxidase in the brain of zebrafish (Danio rerio).

  The Journal of comparative neurology 20061010

• Dopamine turnover is upregulated in the caudate/putamen of asymptomatic MPTP-treated rhesus monkeys.

  Neurochemistry international 20061001

• Does increased excitatory drive from the subthalamic nucleus contribute to dopaminergic neuronal death in Parkinson's disease?

  Experimental neurology 20061001

• Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC.

  Molecular therapy : the journal of the American Society of Gene Therapy 20061001

• Behavioral models of Parkinson's disease in rodents: a new look at an old problem.

  Movement disorders : official journal of the Movement Disorder Society 20061001

• Partial recovery of striatal nicotinic receptors in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned monkeys with chronic oral nicotine.

  The Journal of pharmacology and experimental therapeutics 20061001

• Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies: keys to success and roads to failure.

  Movement disorders : official journal of the Movement Disorder Society 20061001

• Persistent penetration of MPTP through the nasal route induces Parkinson's disease in mice.

  The European journal of neuroscience 20061001

• Effects of nicotinic therapies on attention and executive functions in chronic low-dose MPTP-treated monkeys.

  The European journal of neuroscience 20061001

• Further validation of LABORAS using various dopaminergic manipulations in mice including MPTP-induced nigro-striatal degeneration.

  Journal of neuroscience methods 20060930

• The novel adenosine A2a receptor antagonist ST1535 potentiates the effects of a threshold dose of L-DOPA in MPTP treated common marmosets.

  European journal of pharmacology 20060928

• Nitric oxide and MPP+-induced hydroxyl radical generation.

  Journal of neural transmission (Vienna, Austria : 1996) 20060901

• Potentiating effect of the ATP-sensitive potassium channel blocker glibenclamide on complex I inhibitor neurotoxicity in vitro and in vivo.

  Neurotoxicology 20060901

• Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: effect on adenosine A2A receptors.

  Synapse (New York, N.Y.) 20060901

• 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced acute transient dystonia in monkeys associated with low striatal dopamine.

  Neuroscience 20060901

• Genetic vitamin E deficiency does not affect MPTP susceptibility in the mouse brain.

  Journal of neurochemistry 20060901

• Chronic oral nicotine treatment protects against striatal degeneration in MPTP-treated primates.

  Journal of neurochemistry 20060901

• A call for clinically driven experimental design in assessing neuroprotection in experimental Parkinsonism.

  Behavioural pharmacology 20060901

• Neuroprotective effects of modafinil in a marmoset Parkinson model: behavioral and neurochemical aspects.

  Behavioural pharmacology 20060901

• Parkinson's disease-like syndrome in rats induced by 2,9-dimethyl-beta-carbolinium ion, a beta-carboline occurring in the human brain.

  Behavioural pharmacology 20060901

• Evidence of apoptosis in the subventricular zone and rostral migratory stream in the MPTP mouse model of Parkinson disease.

  Journal of neuropathology and experimental neurology 20060901

• Dopamine receptor agonists and levodopa and inducing psychosis-like behavior in the MPTP primate model of Parkinson disease.

  Archives of neurology 20060901

• Mathematical modeling identifies inhibitors of apoptosis as mediators of positive feedback and bistability.

  PLoS computational biology 20060901

• Alterations of the expression and activity of midbrain nitric oxide synthase and soluble guanylyl cyclase in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice.

  Neuroscience 20060825

• Localization of nerve growth factor, neurotrophin-3, and glial cell line-derived neurotrophic factor in nestin-expressing reactive astrocytes in the caudate-putamen of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated C57/Bl mice.

  The Journal of comparative neurology 20060820

• Dopamine replacement therapy does not restore the full spectrum of normal pallidal activity in the 1-methyl-4-phenyl-1,2,3,6-tetra-hydropyridine primate model of Parkinsonism.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20060802

• The GT to GC single nucleotide polymorphism at the beginning of an alternative exon 2C of human MTH1 gene confers an amino terminal extension that functions as a mitochondrial targeting signal.

  Journal of molecular medicine (Berlin, Germany) 20060801

• Synthetic bovine proline-rich-polypeptides generate hydroxyl radicals and fail to protect dopaminergic neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity in mice.

  Neuropeptides 20060801

• Basal ganglia lesions after MPTP administration in rhesus monkeys.

  Neurobiology of disease 20060801

• Developmental exposure to the pesticide dieldrin alters the dopamine system and increases neurotoxicity in an animal model of Parkinson's disease.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20060801

• Convergent roles of alpha-synuclein, DA metabolism, and the ubiquitin-proteasome system in nigrostriatal toxicity.

  Annals of the New York Academy of Sciences 20060801

• Inclusion dynamics in PC12 is comparable between amphetamines and MPTP.

  Annals of the New York Academy of Sciences 20060801

• Calpain activation in apoptosis of motoneurons in cell culture models of experimental parkinsonism.

  Annals of the New York Academy of Sciences 20060801

• gamma-Tocopherol attenuates MPTP-induced dopamine loss more efficiently than alpha-tocopherol in mouse brain.

  Neuroscience letters 20060731

• Pharmacological activation of mGlu4 metabotropic glutamate receptors reduces nigrostriatal degeneration in mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20060705

• Endogenously nitrated proteins in mouse brain: links to neurodegenerative disease.

  Biochemistry 20060704

• 5-HT1A receptor agonist-mediated protection from MPTP toxicity in mouse and macaque models of Parkinson's disease.

  Neurobiology of disease 20060701

• Reduction of dopaminergic degeneration and oxidative stress by inhibition of angiotensin converting enzyme in a MPTP model of parkinsonism.

  Neuropharmacology 20060701

• Differential protection against MPTP or methamphetamine toxicity in dopamine neurons by deletion of ppN/OFQ expression.

  Journal of neurochemistry 20060701

• Parkinsonism-preventing activity of 1-methyl-1,2,3,4-tetrahydroisoquinoline derivatives in C57BL mouse in vivo.

  Biological & pharmaceutical bulletin 20060701

• Comparison of [18F]FDOPA, [18F]FMT and [18F]FECNT for imaging dopaminergic neurotransmission in mice.

  Nuclear medicine and biology 20060701

• (-)-Epigallocatechin gallate regulates dopamine transporter internalization via protein kinase C-dependent pathway.

  Brain research 20060630

• Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.

  Neuroscience 20060619

• Age-related severity of dopaminergic neurodegeneration to MPTP neurotoxicity causes motor dysfunction in C57BL/6 mice.

  Neuroscience letters 20060619

• Doxycycline-regulated co-expression of GDNF and TH in PC12 cells.

  Neuroscience letters 20060619

• Identification of far upstream element-binding protein-1 as an authentic Parkin substrate.

  The Journal of biological chemistry 20060616

• Potential neuroprotective effect of low dose whole-body gamma-irradiation against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic toxicity in C57 mice.

  Neuroscience letters 20060612

• Increased sensitivity to MPTP in human alpha-synuclein A30P transgenic mice.

  Neurobiology of aging 20060601

• Discordant regulatory changes in monocrotaline-induced megalocytosis of lung arterial endothelial and alveolar epithelial cells.

  American journal of physiology. Lung cellular and molecular physiology 20060601

• Lesions in monkey globus pallidus externus exacerbate parkinsonian symptoms.

  Experimental neurology 20060601

• Histamine H3 receptor agonists reduce L-dopa-induced chorea, but not dystonia, in the MPTP-lesioned nonhuman primate model of Parkinson's disease.

  Movement disorders : official journal of the Movement Disorder Society 20060601

• Paeoniflorin attenuates neuroinflammation and dopaminergic neurodegeneration in the MPTP model of Parkinson's disease by activation of adenosine A1 receptor.

  British journal of pharmacology 20060601

• Histological effects of intraputaminal infusion of glial cell line-derived neurotrophic factor in Parkinson disease model macaque monkeys.

  Neurologia medico-chirurgica 20060601

• Adaptive acetylcholinesterase splicing patterns attenuate 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice.

  The European journal of neuroscience 20060601

• In vivo complementation of complex I by the yeast Ndi1 enzyme. Possible application for treatment of Parkinson disease.

  The Journal of biological chemistry 20060519

• Isolation and characterization of a monoamine oxidase B selective inhibitor from tobacco smoke.

  Bioorganic & medicinal chemistry 20060515

• Local shuffling of spike trains boosts the accuracy of spike train spectral analysis.

  Journal of neurophysiology 20060501

• Clozapine modulates aromatic L-amino acid decarboxylase activity in mouse striatum.

  The Journal of pharmacology and experimental therapeutics 20060501

• Enhanced de novo neurogenesis and dopaminergic neurogenesis in the substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease-like mice.

  Stem cells (Dayton, Ohio) 20060501

• New striatal dopamine neurons in MPTP-treated macaques result from a phenotypic shift and not neurogenesis.

  Brain : a journal of neurology 20060501

• Granulocyte-colony stimulating factor is neuroprotective in a model of Parkinson's disease.

  Journal of neurochemistry 20060501

• Attenuation of MPTP-induced neurotoxicity and locomotor dysfunction in Nucling-deficient mice via suppression of the apoptosome pathway.

  Journal of neurochemistry 20060501

• [125I]Iodomethyllycaconitine binds to alpha7 nicotinic acetylcholine receptors in monkey brain.

  The European journal of neuroscience 20060501

• Neuroprotection by transgenic expression of glucose-6-phosphate dehydrogenase in dopaminergic nigrostriatal neurons of mice.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20060426

• Chronic oral nicotine normalizes dopaminergic function and synaptic plasticity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20060426

• Pedunculopontine nucleus electric stimulation alleviates akinesia independently of dopaminergic mechanisms.

  Neuroreport 20060424

• Estrogen down-regulates glial activation in male mice following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine intoxication.

  Brain research 20060421

• Proteomic analysis of microglial contribution to mouse strain-dependent dopaminergic neurotoxicity.

  Glia 20060415

• Rifampicin attenuates the MPTP-induced neurotoxicity in mouse brain.

  Brain research 20060412

• Application of a blood-brain-barrier-penetrating form of GDNF in a mouse model for Parkinson's disease.

  Brain research 20060412

• MTH1, an oxidized purine nucleoside triphosphatase, protects the dopamine neurons from oxidative damage in nucleic acids caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

  Cell death and differentiation 20060401

• Neuronal firing before and after burst discharges in the monkey basal ganglia is predictably patterned in the normal state and altered in parkinsonism.

  Journal of neurophysiology 20060401

• Implication of the phosphatidylinositol-3 kinase/protein kinase B signaling pathway in the neuroprotective effect of estradiol in the striatum of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice.

  Molecular pharmacology 20060401

• Synaptic microcircuitry of tyrosine hydroxylase-containing neurons and terminals in the striatum of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys.

  The Journal of comparative neurology 20060401

• Deficiency of TNF receptors suppresses microglial activation and alters the susceptibility of brain regions to MPTP-induced neurotoxicity: role of TNF-alpha.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20060401

• MPTP treatment of common marmosets impairs proteasomal enzyme activity and decreases expression of structural and regulatory elements of the 26S proteasome.

  The European journal of neuroscience 20060401

• Dopamine-dependent non-linear correlation between subthalamic rhythms in Parkinson's disease.

  The Journal of physiology 20060315

• Norharman-induced motoric impairment in mice: neurodegeneration and glial activation in substantia nigra.

  Journal of neural transmission (Vienna, Austria : 1996) 20060301

• Transforming growth factor beta2 haploinsufficient mice develop age-related nigrostriatal dopamine deficits.

  Neurobiology of disease 20060301

• The neurotoxin 2'-NH2-MPTP degenerates serotonin axons and evokes increases in hippocampal BDNF.

  Neuropharmacology 20060301

• Neuroprotective effect of arundic acid, an astrocyte-modulating agent, in mouse brain against MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity.

  Neuropharmacology 20060301

• Tetrahydrobiopterin causes mitochondrial dysfunction in dopaminergic cells: implications for Parkinson's disease.

  Neurochemistry international 20060301

• Effect of age on markers for monoaminergic neurons of normal and MPTP-lesioned rhesus monkeys: a multi-tracer PET study.

  NeuroImage 20060301

• Role of extracellular-regulated kinase and c-Jun NH2-terminal kinase in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurofilament phosphorylation.

  Journal of neuroscience research 20060301

• Pramipexole protects against MPTP toxicity in non-human primates.

  Journal of neurochemistry 20060301

• Convection-enhanced delivery of adeno-associated virus type 2 (AAV2) into the striatum and transport of AAV2 within monkey brain.

  Human gene therapy 20060301

• FGF-2 deficiency does not alter vulnerability of the dopaminergic nigrostriatal system towards MPTP intoxication in mice.

  The European journal of neuroscience 20060301

• The potentiating effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on paraquat-induced neurochemical and behavioral changes in mice.

  Pharmacology, biochemistry, and behavior 20060301

• Therapeutic effects of caloric stimulation and optokinetic stimulation on hemispatial neglect.

  Journal of clinical neurology (Seoul, Korea) 20060301

• Cerebellar neurotransmission in attention-deficit/hyperactivity disorder: does dopamine neurotransmission occur in the cerebellar vermis?

  Journal of neuroscience methods 20060215

• Divergent role of calcium on Abeta- and MPTP-induced cell death in SK-N-SH neuroblastoma.

  Life sciences 20060209

• Adult and in utero exposure to cocaine alters sensitivity to the Parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

  Neuroscience 20060201

• Role of ICAM-1 in persisting inflammation in Parkinson disease and MPTP monkeys.

  Experimental neurology 20060201

• Behavioral motor recovery in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned squirrel monkey (Saimiri sciureus): changes in striatal dopamine and expression of tyrosine hydroxylase and dopamine transporter proteins.

  Journal of neuroscience research 20060201

• Minocycline attenuates microglial activation but fails to mitigate striatal dopaminergic neurotoxicity: role of tumor necrosis factor-alpha.

  Journal of neurochemistry 20060201

• Compensation in pre-synaptic dopaminergic function following nigrostriatal damage in primates.

  Journal of neurochemistry 20060201

• Docosahexaenoic acid reduces levodopa-induced dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys.

  Annals of neurology 20060201

• Pesticides and Parkinson's disease--is there a link?

  Environmental health perspectives 20060201

• Decreased striatal levels of PEP-19 following MPTP lesion in the mouse.

  Journal of proteome research 20060201

• H MRS identifies lactate rise in the striatum of MPTP-treated C57BL/6 mice.

  The European journal of neuroscience 20060201

• Molecular biology, pharmacology and functional role of the plasma membrane dopamine transporter.

  CNS & neurological disorders drug targets 20060201

• Ameliorating effect of dimethylsulfoniopropionate on the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease of mice.

  Journal of nutritional science and vitaminology 20060201

• Dopamine release in human neocortical slices: characterization of inhibitory autoreceptors and of nicotinic acetylcholine receptor-evoked release.

  Brain research bulletin 20060130

• Estrogen prevents neuroprotection by caffeine in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20060111

• Prevention of levodopa-induced dyskinesias by a selective NR1A/2B N-methyl-D-aspartate receptor antagonist in parkinsonian monkeys: implication of preproenkephalin.

  Movement disorders : official journal of the Movement Disorder Society 20060101

• Estrogen, neuroinflammation and neuroprotection in Parkinson's disease: glia dictates resistance versus vulnerability to neurodegeneration.

  Neuroscience 20060101

• cDNA array reveals increased expression of glucose-dependent insulinotropic polypeptide following chronic clozapine treatment: role in atypical antipsychotic drug-induced adverse metabolic effects.

  The pharmacogenomics journal 20060101

• Mutagenic activity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

  Journal of applied genetics 20060101

• Serum antibodies from Parkinson's disease patients react with neuronal membrane proteins from a mouse dopaminergic cell line and affect its dopamine expression.

  Journal of neuroinflammation 20060101

• Reduced 125I-meta-iodobenzylguanidine uptake and norepinephrine transporter density in the hearts of mice with MPTP-induced parkinsonism.

  Nuclear medicine and biology 20060101

• Cyclooxygenase-2 mediates microglial activation and secondary dopaminergic cell death in the mouse MPTP model of Parkinson's disease.

  Journal of neuroinflammation 20060101

• N-acetyltransferase 2 (NAT2) gene polymorphisms in Parkinson's disease.

  BMC medical genetics 20060101

• A ketogenic diet as a potential novel therapeutic intervention in amyotrophic lateral sclerosis.

  BMC neuroscience 20060101

• Melatonin in Alzheimer's disease and other neurodegenerative disorders.

  Behavioral and brain functions : BBF 20060101

• Coenzyme Q(10) provides neuroprotection in iron-induced apoptosis in dopaminergic neurons.

  Journal of molecular neuroscience : MN 20060101

• Can a single subunit yeast NADH dehydrogenase (Ndi1) remedy diseases caused by respiratory complex I defects?

  Rejuvenation research 20060101

• Progressive dopamine neuron loss in Parkinson's disease: the multiple hit hypothesis.

  Cell transplantation 20060101

• Neural repair strategies for Parkinson's disease: insights from primate models.

  Cell transplantation 20060101

• Switching from levodopa to the long-acting dopamine D2/D3 agonist piribedil reduces the expression of dyskinesia while maintaining effective motor activity in MPTP-treated primates.

  Clinical neuropharmacology 20060101

• Phosphatidylinositol transfer protein expression altered by aging and Parkinson disease.

  Cellular and molecular neurobiology 20060101

• Curcumin protects mouse brain from oxidative stress caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

  European review for medical and pharmacological sciences 20060101

• [Dependence of electromyographic reaction indices of the muscles-antagonists and stiffness of the elbow joint on its extension velocity before and after the injection of neurotoxin].

  Fiziolohichnyi zhurnal (Kiev, Ukraine : 1994) 20060101

• Toxicity and metabolism of the chloral-derived mammalian alkaloid 1-trichloromethyl-1,2,3,4-tetrahydro-beta-carboline (TaClo) in PC12 cells.

  Zeitschrift fur Naturforschung. C, Journal of biosciences 20060101

• A short overview on the role of alpha-synuclein and proteasome in experimental models of Parkinson's disease.

  Journal of neural transmission. Supplementum 20060101

• Nongenetic causes of Parkinson's disease.

  Journal of neural transmission. Supplementum 20060101

• Cytochrome P450 and Parkinson's disease: protective role of neuronal CYP 2E1 from MPTP toxicity.

  Journal of neural transmission. Supplementum 20060101

• Controversies on new animal models of Parkinson's disease pro and con: the rotenone model of Parkinson's disease (PD).

  Journal of neural transmission. Supplementum 20060101

• M30, a novel multifunctional neuroprotective drug with potent iron chelating and brain selective monoamine oxidase-ab inhibitory activity for Parkinson's disease.

  Journal of neural transmission. Supplementum 20060101

• Anti-apoptotic gene therapy in Parkinson's disease.

  Journal of neural transmission. Supplementum 20060101

• Complement activation in the Parkinson's disease substantia nigra: an immunocytochemical study.

  Journal of neuroinflammation 20060101

• [Monoamine oxidase as a target for drug action].

  Postepy higieny i medycyny doswiadczalnej (Online) 20060101

• [Change of the nitric oxide synthase activity after administration of neurotoxic compounds in mice].

  Acta pharmaceutica Hungarica 20060101

• Spirulina maxima pretreatment partially protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity.

  Nutritional neuroscience 20060101

• Oxidative stress and 17-alpha- and 17-beta-estradiol modulate neurofilaments differently.

  Journal of molecular neuroscience : MN 20060101

• Molecular mechanism of the relation of monoamine oxidase B and its inhibitors to Parkinson's disease: possible implications of glial cells.

  Journal of neural transmission. Supplementum 20060101

• Marmoset monkey models of Parkinson's disease: which model, when and why?

  Brain research bulletin 20051230

• MPTP induces intranuclear rodlet formation in midbrain dopaminergic neurons.

  Brain research 20051220

• Morphological impairments in retinal neurons of the scotopic visual pathway in a monkey model of Parkinson's disease.

  The Journal of comparative neurology 20051212

• Geldanamycin induces heat shock protein 70 and protects against MPTP-induced dopaminergic neurotoxicity in mice.

  The Journal of biological chemistry 20051202

• The role of phospholipid methylation in 1-methyl-4-phenyl-pyridinium ion (MPP+)-induced neurotoxicity in PC12 cells.

  Neurotoxicology 20051201

• Changes in cytoskeletal gene expression linked to MPTP-treatment in Mice.

  Neurobiology of disease 20051201

• Promethazine protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity.

  Neurobiology of disease 20051201

• Altered gene expression profiles reveal similarities and differences between Parkinson disease and model systems.

  The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry 20051201

• K-ATP channels promote the differential degeneration of dopaminergic midbrain neurons.

  Nature neuroscience 20051201

• Down-regulation of metabotropic glutamate receptor 1alpha in globus pallidus and substantia nigra of parkinsonian monkeys.

  The European journal of neuroscience 20051201

• Hormones are key actors in gene x environment interactions programming the vulnerability to Parkinson's disease: glia as a common final pathway.

  Annals of the New York Academy of Sciences 20051201

• Neuroprotection of MPTP-induced toxicity in zebrafish dopaminergic neurons.

  Brain research. Molecular brain research 20051130

• Heat shock proteins protect both MPP(+) and paraquat neurotoxicity.

  Brain research bulletin 20051130

• Drosophila DJ-1 mutants show oxidative stress-sensitive locomotive dysfunction.

  Gene 20051121

• Expression of GAD65 and GAD67 immunoreactivity in MPTP-treated monkeys with or without L-DOPA administration.

  Neurobiology of disease 20051101

• Glia cell number modulates sensitivity to MPTP in mice.

  Glia 20051101

• Role of the redox protein thioredoxin in cytoprotective mechanism evoked by (-)-deprenyl.

  Molecular pharmacology 20051101

• CHOP/GADD153 is a mediator of apoptotic death in substantia nigra dopamine neurons in an in vivo neurotoxin model of parkinsonism.

  Journal of neurochemistry 20051101

• Paraquat neurotoxicity is distinct from that of MPTP and rotenone.

  Toxicological sciences : an official journal of the Society of Toxicology 20051101

• Increased plasma levels of TNF-alpha but not of IL1-beta in MPTP-treated monkeys one year after the MPTP administration.

  Parkinsonism & related disorders 20051101

• Cell survival patterns in the pedunculopontine tegmental nucleus of methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys and 6OHDA-lesioned rats: evidence for differences to idiopathic Parkinson disease patients?

  Anatomy and embryology 20051101

• Dopamine D3 receptor-preferring agonists induce neurotrophic effects on mesencephalic dopamine neurons.

  The European journal of neuroscience 20051101

• Effects of mitochondrial toxins on the brain amino acid concentrations.

  Neurochemical research 20051101

• [Effects of yinxing pingchan recipe and its components on activity of mitochondrial enzyme complex in brain of mice with Parkinson's disease].

  Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine 20051101

• Blockade of nociceptin/orphanin FQ transmission attenuates symptoms and neurodegeneration associated with Parkinson's disease.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20051019

• Comparison of bilaterally 6-OHDA- and MPTP-lesioned rats as models of the early phase of Parkinson's disease: histological, neurochemical, motor and memory alterations.

  Journal of neuroscience methods 20051015

• A novel and selective monoamine oxidase B substrate.

  Bioorganic & medicinal chemistry 20051015

• Sepiapterin attenuates 1-methyl-4-phenylpyridinium-induced apoptosis in neuroblastoma cells transfected with neuronal NOS: role of tetrahydrobiopterin, nitric oxide, and proteasome activation.

  Free radical biology & medicine 20051015

• Dopamine depletion does not protect against acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in vivo.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20051012

• Intra-nigral MPTP lesion in rats: behavioral and autoradiography studies.

  Experimental neurology 20051001

• 4-Phenyl-1,2,3,6-tetrahydropyridine, an excellent fragment to improve the potency of PARP-1 inhibitors.

  Bioorganic & medicinal chemistry letters 20051001

• Subthalamic high frequency stimulation resets subthalamic firing and reduces abnormal oscillations.

  Brain : a journal of neurology 20051001

• Unraveling substantia nigra sequential gene expression in a progressive MPTP-lesioned macaque model of Parkinson's disease.

  Neurobiology of disease 20051001

• Formation of stacking complexes between caffeine (1,2,3-trimethylxanthine) and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine may attenuate biological effects of this neurotoxin.

  Bioorganic chemistry 20051001

• Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion.

  Journal of neurochemistry 20051001

• [Animal models of parkinsonism].

  Revue neurologique 20051001

• Neuroprotective therapy in Parkinson's disease: current status and new directions from experimental and genetic clues.

  Journal of clinical neurology (Seoul, Korea) 20051001

• Swim-test as a function of motor impairment in MPTP model of Parkinson's disease: a comparative study in two mouse strains.

  Behavioural brain research 20050908

• Decrease in alpha3*/alpha6* nicotinic receptors but not nicotine-evoked dopamine release in monkey brain after nigrostriatal damage.

  Molecular pharmacology 20050901

• The effects of a selective dopamine D2 receptor agonist on behavioral and pathological outcome in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated squirrel monkeys.

  The Journal of pharmacology and experimental therapeutics 20050901

• Early environmental origins of neurodegenerative disease in later life.

  Environmental health perspectives 20050901

• The role of early life environmental risk factors in Parkinson disease: what is the evidence?

  Environmental health perspectives 20050901

• Developmental pesticide models of the Parkinson disease phenotype.

  Environmental health perspectives 20050901

• Differential survival patterns among midbrain dopaminergic cells of MPTP-treated monkeys and 6OHDA-lesioned rats.

  Anatomy and embryology 20050901

• Apoptosis inducing factor mediates caspase-independent 1-methyl-4-phenylpyridinium toxicity in dopaminergic cells.

  Journal of neurochemistry 20050901

• Unilateral pallidotomy in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets exhibiting levodopa-induced dyskinesia.

  The European journal of neuroscience 20050901

• Cellular distribution of interleukin-1alpha-immunoreactivity after MPTP intoxication in mice.

  Brain research. Molecular brain research 20050818

• Role of mitochondrial re-energization and Ca2+ influx in reperfusion injury of metabolically inhibited cardiac myocytes.

  Cardiovascular research 20050801

• Dietary restriction affects striatal glutamate in the MPTP-induced mouse model of nigrostriatal degeneration.

  Synapse (New York, N.Y.) 20050801

• MPTP treatment in mice does not transmit and cause Parkinsonian neurotoxicity in non-treated cagemates through close contact.

  Neuroscience research 20050801

• Melatonin protects against MPTP/MPP+ -induced mitochondrial DNA oxidative damage in vivo and in vitro.

  Journal of pineal research 20050801

• Naltrexone in the short-term decreases antiparkinsonian response to l-Dopa and in the long-term increases dyskinesias in drug-naïve parkinsonian monkeys.

  Neuropharmacology 20050801

• Oestrogens prevent loss of dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) in substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice.

  Journal of neuroendocrinology 20050801

• Synthesis and neurotoxicity of tetrahydroisoquinoline derivatives for studying Parkinson's disease.

  Biological & pharmaceutical bulletin 20050801

• In vivo models of multiple system atrophy.

  Movement disorders : official journal of the Movement Disorder Society 20050801

• Celastrol protects against MPTP- and 3-nitropropionic acid-induced neurotoxicity.

  Journal of neurochemistry 20050801

• Effects of metabolic modifiers such as carnitines, coenzyme Q10, and PUFAs against different forms of neurotoxic insults: metabolic inhibitors, MPTP, and methamphetamine.

  Annals of the New York Academy of Sciences 20050801

• Pinhole SPECT imaging of dopamine transporters correlates with dopamine transporter immunohistochemical analysis in the MPTP mouse model of Parkinson's disease.

  NeuroImage 20050715

• Pig brain stereotaxic standard space: mapping of cerebral blood flow normative values and effect of MPTP-lesioning.

  Brain research bulletin 20050715

• Ablation of the inflammatory enzyme myeloperoxidase mitigates features of Parkinson's disease in mice.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20050713

• MPP+-induced COX-2 activation and subsequent dopaminergic neurodegeneration.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20050701

• Acute repetitive transcranial magnetic stimulation reactivates dopaminergic system in lesion rats.

  Neuroscience letters 20050701

• A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20050701

• Possibility for neurogenesis in substantia nigra of parkinsonian brain.

  Annals of neurology 20050701

• Effect of kynurenine 3-hydroxylase inhibition on the dyskinetic and antiparkinsonian responses to levodopa in Parkinsonian monkeys.

  Movement disorders : official journal of the Movement Disorder Society 20050701

• Levodopa-induced dyskinesia in MPTP-treated macaques is not dependent on the extent and pattern of nigrostrial lesioning.

  The European journal of neuroscience 20050701

• The acute and the long-term effects of nigral lipopolysaccharide administration on dopaminergic dysfunction and glial cell activation.

  The European journal of neuroscience 20050701

• Study of antiparkinsonic activity of panavir on a model of Parkinson syndrome induced by systemic administration of MPTP to outbred rats and C57Bl/6 mice.

  Bulletin of experimental biology and medicine 20050701

• Toxin-induced models of Parkinson's disease.

  NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics 20050701

• MPTP-induced models of Parkinson's disease in mice and non-human primates.

  Current protocols in pharmacology 20050701

• The Webcam system: a simple, automated, computer-based video system for quantitative measurement of movement in nonhuman primates.

  Journal of neuroscience methods 20050630

• Written in our genes?

  Science (New York, N.Y.) 20050617

• Possible mechanisms of the protection of ginsenoside Re against MPTP-induced apoptosis in substantia nigra neurons of Parkinson's disease mouse model.

  Journal of Asian natural products research 20050601

• Oxidative stress and inflammation in Parkinson's disease: is there a causal link?

  Experimental neurology 20050601

• Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors.

  Parkinsonism & related disorders 20050601

• Neuroinflammatory processes in Parkinson's disease.

  Parkinsonism & related disorders 20050601

• [Effect of the oil from ganoderma lucidum spores on pathological changes in the substantia nigra and behaviors of MPTP-treated mice].

  Di 1 jun yi da xue xue bao = Academic journal of the first medical college of PLA 20050601

• Immunoautoradiographic analysis of NMDA receptor subunits and associated postsynaptic density proteins in the brain of dyskinetic MPTP-treated common marmosets.

  The European journal of neuroscience 20050601

• Neuroprotection by adenosine in the brain: From A(1) receptor activation to A (2A) receptor blockade.

  Purinergic signalling 20050601

• In mice, production of plasma IL-1 and IL-6 in response to MPTP is related to behavioral lateralization.

  Brain research 20050531

• Mutation of surface cysteine 374 to alanine in monoamine oxidase A alters substrate turnover and inactivation by cyclopropylamines.

  Bioorganic & medicinal chemistry 20050516

• Temporal evolution of mouse striatal gene expression following MPTP injury.

  Neurobiology of aging 20050501

• [Kinetic changes of plasma IL-1 and IL-6 levels in MPTP-induced Parkinson's disease model mice and their relationship with brain asymmetry].

  Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology 20050501

• Induction of thioredoxin and mitochondrial survival proteins mediates preconditioning-induced cardioprotection and neuroprotection.

  Annals of the New York Academy of Sciences 20050501

• LC-MS determination of MPTP at sub-ppm level in pethidine hydrochloride.

  Journal of pharmaceutical and biomedical analysis 20050429

• Differential inflammatory activation of IL-6 (-/-) astrocytes.

  Cytokine 20050421

• Selective glial cell line-derived neurotrophic factor production in adult dopaminergic carotid body cells in situ and after intrastriatal transplantation.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20050420

• Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine (MPTP) and oxidative stress.

  Proceedings of the National Academy of Sciences of the United States of America 20050405

• Regulation of striatal preproenkephalin mRNA levels in MPTP-lesioned mice treated with estradiol.

  Journal of neuroscience research 20050401

• Uncoupling protein 2 protects dopaminergic neurons from acute 1,2,3,6-methyl-phenyl-tetrahydropyridine toxicity.

  Journal of neurochemistry 20050401

• Glucocorticoid receptor-nitric oxide crosstalk and vulnerability to experimental parkinsonism: pivotal role for glia-neuron interactions.

  Brain research. Brain research reviews 20050401

• Comparison of the Protective Effect of Indole beta-carbolines and R-(-)-deprenyl Against Nitrogen Species-Induced Cell Death in Experimental Culture Model of Parkinson's Disease.

  Journal of clinical neurology (Seoul, Korea) 20050401

• The MPTP model of Parkinson's disease.

  Brain research. Molecular brain research 20050324

• Absence of inclusion body formation in the MPTP mouse model of Parkinson's disease.

  Brain research. Molecular brain research 20050324

• Quantitative proteomic analysis of mitochondrial proteins: relevance to Lewy body formation and Parkinson's disease.

  Brain research. Molecular brain research 20050324

• Environmental enrichment in adulthood eliminates neuronal death in experimental Parkinsonism.

  Brain research. Molecular brain research 20050324

• Regulation of mitochondrial NADP+-dependent isocitrate dehydrogenase activity by glutathionylation.

  The Journal of biological chemistry 20050318

• Chronic implantation of deep brain stimulation leads in animal models of neurological disorders.

  Journal of neuroscience methods 20050315

• Enhanced susceptibility to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity in high-fat diet-induced obesity.

  Free radical biology & medicine 20050315

• Simvastatin prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced striatal dopamine depletion and protein tyrosine nitration in mice.

  Brain research 20050310

• A synthetic human proline-rich-polypeptide enhances hydroxyl radical generation and fails to protect dopaminergic neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced toxicity in mice.

  Neuroscience letters 20050303

• Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates.

  Movement disorders : official journal of the Movement Disorder Society 20050301

• Continuous dopaminergic stimulation reduces risk of motor complications in parkinsonian primates.

  Experimental neurology 20050301

• Lesion of the substantia nigra, pars compacta impairs delayed alternation in a Y-maze in rats.

  Experimental neurology 20050301

• Neural mechanisms underlying motor dysfunction as detected by the tail suspension test in MPTP-treated C57BL/6 mice.

  Neuroscience research 20050301

• Disruption of lateral olivocochlear neurons via a dopaminergic neurotoxin depresses sound-evoked auditory nerve activity.

  Journal of the Association for Research in Otolaryngology : JARO 20050301

• Viral vector mediated overexpression of human alpha-synuclein in the nigrostriatal dopaminergic neurons: a new model for Parkinson's disease.

  CNS spectrums 20050301

• KW-6002 protects from MPTP induced dopaminergic toxicity in the mouse.

  Neuropharmacology 20050301

• Zebrafish embryos are susceptible to the dopaminergic neurotoxin MPTP.

  The European journal of neuroscience 20050301

• Tumor necrosis factor-alpha receptor ablation in a chronic MPTP mouse model of Parkinson's disease.

  Neuroscience letters 20050227

• Acanthopanax senticosus Harms as a prophylactic for MPTP-induced Parkinson's disease in rats.

  Journal of ethnopharmacology 20050227

• Quantitative 1H magnetic resonance spectroscopic imaging determines therapeutic immunization efficacy in an animal model of Parkinson's disease.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20050216

• Thalamic neuronal activity in dopamine-depleted primates: evidence for a loss of functional segregation within basal ganglia circuits.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20050209

• Striatal trophic factor activity in aging monkeys with unilateral MPTP-induced parkinsonism.

  Experimental neurology 20050201

• A novel thiol antioxidant that crosses the blood brain barrier protects dopaminergic neurons in experimental models of Parkinson's disease.

  The European journal of neuroscience 20050201

• A modified MPTP treatment regime produces reproducible partial nigrostriatal lesions in common marmosets.

  The European journal of neuroscience 20050201

• Measurement of mitochondrial respiration in permeabilized murine neuroblastoma (N-2alpha) cells, a simple and rapid in situ assay to investigate mitochondrial toxins.

  Journal of biochemical and biophysical methods 20050131

• Dietary polyphenols protect dopamine neurons from oxidative insults and apoptosis: investigations in primary rat mesencephalic cultures.

  Biochemical pharmacology 20050115

• Uncoupling protein-2 is critical for nigral dopamine cell survival in a mouse model of Parkinson's disease.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20050105

• Dopaminergic neurons generated from monkey embryonic stem cells function in a Parkinson primate model.

  The Journal of clinical investigation 20050103

• Subunit composition of nicotinic receptors in monkey striatum: effect of treatments with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine or L-DOPA.

  Molecular pharmacology 20050101

• Selective alterations of gene expression in mice induced by MPTP.

  Synapse (New York, N.Y.) 20050101

• Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia.

  Annals of neurology 20050101

• Effect of angiotensin-converting enzyme inhibitor perindopril on interneurons in MPTP-treated mice.

  European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 20050101

• Physiological studies of information processing in the normal and Parkinsonian basal ganglia: pallidal activity in Go/No-Go task and following MPTP treatment.

  Progress in brain research 20050101

• Hsp70 gene transfer by adeno-associated virus inhibits MPTP-induced nigrostriatal degeneration in the mouse model of Parkinson disease.

  Molecular therapy : the journal of the American Society of Gene Therapy 20050101

• Interleukine-1beta and interleukine-6 levels in striatum and other brain structures after MPTP treatment: influence of behavioral lateralization.

  Journal of neuroimmunology 20050101

• A novel azulenyl nitrone antioxidant protects against MPTP and 3-nitropropionic acid neurotoxicities.

  Experimental neurology 20050101

• Differential effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the olfactory bulb and the striatum in mice.

  Neuroscience research 20050101

• Beta-carbolines induce apoptosis in cultured cerebellar granule neurons via the mitochondrial pathway.

  Neuropharmacology 20050101

• Autotoxicity, methylation and a road to the prevention of Parkinson's disease.

  Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 20050101

• Recovery from experimental Parkinson's disease in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride treated marmoset with the melatonin analogue ML-23.

  Pharmacology, biochemistry, and behavior 20050101

• Ginsenoside Rg1 reduces MPTP-induced substantia nigra neuron loss by suppressing oxidative stress.

  Acta pharmacologica Sinica 20050101

• Immunization with myelin oligodendrocyte glycoprotein and complete Freund adjuvant partially protects dopaminergic neurons from 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced damage in mouse model of Parkinson's disease.

  Neuroscience 20050101

• Pharmacological manipulation of ataxia-telangiectasia kinase activity as a treatment for Parkinson's disease.

  Medical hypotheses 20050101

• Potential neuroprotective effect of t-butylhydroquinone against neurotoxicity-induced by 1-methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydropyridine (2'-methyl-MPTP) in mice.

  Journal of biochemical and molecular toxicology 20050101

• The chemistry and pharmacology of tetrahydropyridines.

  Current medicinal chemistry 20050101

• Inflammatory process in Parkinson's disease: role for cytokines.

  Current pharmaceutical design 20050101

• Enhanced striatal opioid receptor-mediated G-protein activation in L-DOPA-treated dyskinetic monkeys.

  Neuroscience 20050101

• Dyskinesias occur in response to saline and naltrexone alone after priming with combination of dopaminergic agents and naltrexone in the MPTP parkinsonian monkeys.

  Neurobiology of disease 20050101

• LY503430: pharmacology, pharmacokinetics, and effects in rodent models of Parkinson's disease.

  CNS drug reviews 20050101

• Reactive oxygen and nitrogen species: weapons of neuronal destruction in models of Parkinson's disease.

  Antioxidants & redox signaling 20050101

• MPTP and SNpc DA neuronal vulnerability: role of dopamine, superoxide and nitric oxide in neurotoxicity. Minireview.

  Neurotoxicity research 20050101

• [Neurodegenerative alterations induced by MPTP neurotoxin in senescence accelerated mice essay].

  Uspekhi fiziologicheskikh nauk 20050101

• Neural stem cells implanted into MPTP-treated monkeys increase the size of endogenous tyrosine hydroxylase-positive cells found in the striatum: a return to control measures.

  Cell transplantation 20050101

• Microglial inflammation in the parkinsonian substantia nigra: relationship to alpha-synuclein deposition.

  Journal of neuroinflammation 20050101

• Influence of paraquat on dopaminergic transporter in the rat brain.

  Pharmacological reports : PR 20050101

• Adenosine-dopamine interactions revealed in knockout mice.

  Journal of molecular neuroscience : MN 20050101

• A microarray study of MPP+-treated PC12 Cells: Mechanisms of toxicity (MOT) analysis using bioinformatics tools.

  BMC bioinformatics 20050101

• Gait dynamics in mouse models of Parkinson's disease and Huntington's disease.

  Journal of neuroengineering and rehabilitation 20050101

• MAOA haplotypes associated with thrombocyte-MAO activity.

  BMC genetics 20050101

• Neurochemical evidence for agmatine modulation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity.

  Neurochemical research 20050101

• l-dopa-induced reversal in striatal glutamate following partial depletion of nigrostriatal dopamine with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

  Neuroscience 20050101

• [Evoked potentials of the somatic cortex, thalamus, and electromyographic reactions of the cat shoulder muscles elicited by elbow joint straightening in norm and after injection of neurotoxin].

  Fiziolohichnyi zhurnal (Kiev, Ukraine : 1994) 20050101

• MPTP treatment impairs tyrosine hydroxylase immunopositive fibers not only in the striatum, but also in the amygdala.

  Neuro-degenerative diseases 20050101

• Modeling neurodegenerative diseases in vivo review.

  Neuro-degenerative diseases 20050101

• Arundic acid, an astrocyte-modulating agent, protects dopaminergic neurons against MPTP neurotoxicity in mice.

  Brain research 20041224

• Effect of estrogen receptor agonists treatment in MPTP mice: evidence of neuroprotection by an ER alpha agonist.

  Neuropharmacology 20041201

• Lack of evidence of direct mitochondrial involvement in the neuroprotective effect of minocycline.

  European journal of pharmacology 20041128

• Striatal preprotachykinin gene expression reflects parkinsonian signs.

  Neuroreport 20041115

• Upregulation of guanylyl cyclase expression and activity in striatum of MPTP-induced parkinsonism in mice.

  Biochemical and biophysical research communications 20041105

• Effect of the D3 dopamine receptor partial agonist BP897 [N-[4-(4-(2-methoxyphenyl)piperazinyl)butyl]-2-naphthamide] on L-3,4-dihydroxyphenylalanine-induced dyskinesias and parkinsonism in squirrel monkeys.

  The Journal of pharmacology and experimental therapeutics 20041101

• Prolongation of levodopa responses by glycineB antagonists in parkinsonian primates.

  Annals of neurology 20041101

• Astroglial plasticity and glutamate function in a chronic mouse model of Parkinson's disease.

  Experimental neurology 20041101

• A novel systemically active caspase inhibitor attenuates the toxicities of MPTP, malonate, and 3NP in vivo.

  Neurobiology of disease 20041101

• Sensitivity to oxidative stress in DJ-1-deficient dopamine neurons: an ES- derived cell model of primary Parkinsonism.

  PLoS biology 20041101

• Detection and semi-quantitative determination of low abundance GFAP mRNA in mouse brain by capillary electrophoresis coupled with laser-induced fluorescence.

  Brain research. Brain research protocols 20041101

• Vigilance states in a parkinsonian model, the MPTP mouse.

  The European journal of neuroscience 20041101

• Effect of 5-HT1B/D receptor agonist and antagonist administration on motor function in haloperidol and MPTP-treated common marmosets.

  Pharmacology, biochemistry, and behavior 20041101

• Mapping dopamine function in primates using pharmacologic magnetic resonance imaging.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20041027

• Effects of blocking the dopamine biosynthesis and of neurotoxic dopamine depletion with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on voluntary wheel running in mice.

  Behavioural brain research 20041005

• Acoustic startle response, prepulse inhibition, and spontaneous locomotor activity in MPTP-treated mice.

  Behavioural brain research 20041005

• Discharge rate of substantia nigra pars reticulata neurons is reduced in non-parkinsonian monkeys with apomorphine-induced orofacial dyskinesia.

  Journal of neurophysiology 20041001

• Dexamethasone protects against dopaminergic neurons damage in a mouse model of Parkinson's disease.

  International immunopharmacology 20041001

• Identification of the protein disulfide isomerase family member PDIp in experimental Parkinson's disease and Lewy body pathology.

  Brain research 20041001

• PET imaging of implanted human retinal pigment epithelial cells in the MPTP-induced primate model of Parkinson's disease.

  Experimental neurology 20041001

• Regulation of dopamine receptor and neuropeptide expression in the basal ganglia of monkeys treated with MPTP.

  Experimental neurology 20041001

• 1-trichloromethyl-1,2,3,4-tetrahydro-beta-carboline-induced apoptosis in the human neuroblastoma cell line SK-N-SH.

  Journal of neurochemistry 20041001

• Involvement of cytochrome P450 2E1 in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse model of Parkinson's disease.

  Journal of neurochemistry 20041001

• Dopamine transporter: involvement in selective dopaminergic neurotoxicity and degeneration.

  Journal of neural transmission (Vienna, Austria : 1996) 20041001

• Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP.

  Cell and tissue research 20041001

• Role of mitochondrial dysfunction in neurotoxicity of MPP+: partial protection of PC12 cells by acetyl-L-carnitine.

  Annals of the New York Academy of Sciences 20041001

• 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned model of parkinson's disease, with emphasis on mice and nonhuman primates.

  Comparative medicine 20041001

• Increased GAD67 mRNA levels are correlated with in vivo GABA synthesis in the MPTP-treated catecholamine-depleted goldfish brain.

  Brain research. Molecular brain research 20040928

• The cytotoxic activity of lactoperoxidase: enhancement and inhibition by neuroactive compounds.

  Free radical biology & medicine 20040915

• Proteasome-dependent degradation of cyclin D1 in 1-methyl-4-phenylpyridinium ion (MPP+)-induced cell cycle arrest.

  The Journal of biological chemistry 20040910

• Cyclooxygenases mRNA and protein expression in striata in the experimental mouse model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration to mouse.

  Brain research 20040903

• Mice lacking alpha-synuclein have an attenuated loss of striatal dopamine following prolonged chronic MPTP administration.

  Neurotoxicology 20040901

• Iron-sulfur enzyme mediated mitochondrial superoxide toxicity in experimental Parkinson's disease.

  Journal of neurochemistry 20040901

• Identification of an N-methyl-4-phenylpyridinium-like metabolite of the antidiarrheal agent loperamide in human liver microsomes: underlying reason(s) for the lack of neurotoxicity despite the bioactivation event.

  Drug metabolism and disposition: the biological fate of chemicals 20040901

• The role of membrane and vesicular monoamine transporters in the neurotoxic and hypothermic effects of 1-methyl-4-(2'-aminophenyl)-1,2,3,6-tetrahydropyridine (2'-NH(2)-MPTP).

  Molecular pharmacology 20040901

• Comparison of two methods for the analysis of [18F]6-fluoro-L-m-tyrosine PET data.

  NeuroImage 20040901

• Neuroprotective effect of the angiotensin-converting enzyme inhibitor perindopril in MPTP-treated mice.

  Neurological research 20040901

• Attention and executive function deficits in chronic low-dose MPTP-treated non-human primates.

  The European journal of neuroscience 20040901

• Is the unilateral lesion of the left substantia nigra pars compacta sufficient to induce working memory impairment in rats?

  Neurobiology of learning and memory 20040901

• Coordinated behavior of mitochondria in both space and time: a reactive oxygen species-activated wave of mitochondrial depolarization.

  Biophysical journal 20040901

• Postmortem studies in Parkinson's disease.

  Dialogues in clinical neuroscience 20040901

• Biology of Parkinson's disease: pathogenesis and pathophysiology of a multisystem neurodegenerative disorder.

  Dialogues in clinical neuroscience 20040901

• High-performance liquid chromatography/tandem mass spectrometry assay for the determination of 1-methyl-4-phenyl pyridinium (MPP+) in brain tissue homogenates.

  Journal of neuroscience methods 20040830

• Dysregulation of gene expression in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse substantia nigra.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20040825

• Folate intake and risk of Parkinson's disease.

  American journal of epidemiology 20040815

• The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease.

  Experimental neurology 20040801

• Exercise-induced behavioral recovery and neuroplasticity in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse basal ganglia.

  Journal of neuroscience research 20040801

• Late onset loss of hippocampal 5-HT and NE is accompanied by increases in BDNF protein expression in mice co-expressing mutant APP and PS1.

  Neurobiology of disease 20040801

• Olfactory impairment and Parkinson's disease-like symptoms observed in the common marmoset following administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

  Acta oto-laryngologica. Supplementum 20040801

• Neuroprotective effects of Bak Foong Pill in 1-methyl-4-phenyl-1,2,3,6-tetrahyrdropyridine (MPTP)-induced Parkinson's disease model mice.

  Biological & pharmaceutical bulletin 20040801

• MPTP as a mitochondrial neurotoxic model of Parkinson's disease.

  Journal of bioenergetics and biomembranes 20040801

• Acetyl-L-carnitine prevents total body hydroxyl free radical and uric acid production induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the rat.

  Life sciences 20040723

• Role of external pallidal segment in primate parkinsonism: comparison of the effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism and lesions of the external pallidal segment.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20040721

• Attentional cueing reverses deficits in spatial working memory task performance in chronic low dose MPTP-treated monkeys.

  Behavioural brain research 20040709

• Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease.

  The Journal of pharmacology and experimental therapeutics 20040701

• The role of Ca2+ channel modulation in the neuroprotective actions of estrogen in beta-amyloid protein and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) cytotoxic models.

  Neurochemistry international 20040701

• Estrogen and neuroprotection: higher constitutive expression of glutaredoxin in female mice offers protection against MPTP-mediated neurodegeneration.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20040701

• Selective blockade of D(3) dopamine receptors enhances the anti-parkinsonian properties of ropinirole and levodopa in the MPTP-lesioned primate.

  Experimental neurology 20040701

• Relevance of the MPTP primate model in the study of dyskinesia priming mechanisms.

  Parkinsonism & related disorders 20040701

• Prolonged biologically active transgene expression driven by HSV LAP2 in brain in vivo.

  Molecular therapy : the journal of the American Society of Gene Therapy 20040701

• L-3-hydroxyacyl-CoA dehydrogenase II protects in a model of Parkinson's disease.

  Annals of neurology 20040701

• Recent failures of new potential symptomatic treatments for Parkinson's disease: causes and solutions.

  Movement disorders : official journal of the Movement Disorder Society 20040701

• An application of a new planar positron imaging system (PPIS) in a small animal: MPTP-induced parkinsonism in mouse.

  Annals of nuclear medicine 20040701

• Chemoarchitectonic heterogeneities in the primate zona incerta: clinical and functional implications.

  Journal of neurocytology 20040701

• Spike synchronization in the cortex/basal-ganglia networks of Parkinsonian primates reflects global dynamics of the local field potentials.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20040630

• The biogenic trace amine tyramine induces a pronounced hydroxyl radical production via a monoamine oxidase dependent mechanism: an in vivo microdialysis study in mouse striatum.

  Brain research 20040625

• S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity in comparison to ropinirole.

  The Journal of pharmacology and experimental therapeutics 20040601

• Neuroprotective effects of a novel poly(ADP-ribose) polymerase-1 inhibitor, 2-[3-[4-(4-chlorophenyl)-1-piperazinyl] propyl]-4(3H)-quinazolinone (FR255595), in an in vitro model of cell death and in mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.

  The Journal of pharmacology and experimental therapeutics 20040601

• Altered nitric oxide production in mouse brain after administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydro-pyridin or methamphetamine.

  Neurochemistry international 20040601

• Prevention of MPTP (N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) dopaminergic neurotoxicity in mice by chronic lithium: involvements of Bcl-2 and Bax.

  Neuropharmacology 20040601

• The role of NF-kappaB in 6-hydroxydopamine- and TNFalpha-induced apoptosis of PC12 cells.

  Naunyn-Schmiedeberg's archives of pharmacology 20040601

• Developmental loss and resistance to MPTP toxicity of dopaminergic neurones in substantia nigra pars compacta of gamma-synuclein, alpha-synuclein and double alpha/gamma-synuclein null mutant mice.

  Journal of neurochemistry 20040601

• Neuroprotective effects of phenylethanoid glycosides from Cistanches salsa against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic toxicity in C57 mice.

  Biological & pharmaceutical bulletin 20040601

• The opioid agonist morphine decreases the dyskinetic response to dopaminergic agents in parkinsonian monkeys.

  Neurobiology of disease 20040601

• Deleterious effects of minocycline in animal models of Parkinson's disease and Huntington's disease.

  The European journal of neuroscience 20040601

• Development of calorie restriction mimetics as a prolongevity strategy.

  Annals of the New York Academy of Sciences 20040601

• The levels of plasma IL-1beta, IL-6 of C57BL/6J mice treated with MPTP and brain lateralization.

  Cellular & molecular immunology 20040601

• Striatal tyrosine hydroxylase immunoreactive neurons are induced by L-dihydroxyphenylalanine and nerve growth factor treatment in 6-hydroxydopamine lesioned rats.

  Neuroscience letters 20040520

• Tyrosine hydroxylase and dopamine transporter expression following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration of the mouse nigrostriatal pathway.

  Journal of neuroscience research 20040515

• Induction of gp130-related cytokines and activation of JAK2/STAT3 pathway in astrocytes precedes up-regulation of glial fibrillary acidic protein in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of neurodegeneration: key signaling pathway for astrogliosis in vivo?

  The Journal of biological chemistry 20040507

• The neuroprotective effects of estrogen in SK-N-SH neuroblastoma cell cultures.

  Neurochemistry international 20040501

• Immunofluorescent labeling of increased calpain expression and neuronal death in the spinal cord of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice.

  Brain research 20040501

• Differential expression and ser897 phosphorylation of striatal N-methyl-d-aspartate receptor subunit NR1 in animal models of Parkinson's disease.

  Experimental neurology 20040501

• Antiparkinsonian activity of Ro 25-6981, a NR2B subunit specific NMDA receptor antagonist, in animal models of Parkinson's disease.

  Experimental neurology 20040501

• Dopamine transporter-mediated cytotoxicity of beta-carbolinium derivatives related to Parkinson's disease: relationship to transporter-dependent uptake.

  Journal of neurochemistry 20040501

• Brain inflammation enhances 1-methyl-4-phenylpyridinium-evoked neurotoxicity in rats.

  Toxicology and applied pharmacology 20040501

• Evidence of active microglia in substantia nigra pars compacta of parkinsonian monkeys 1 year after MPTP exposure.

  Glia 20040501

• Early administration of nicotinamide prevents learning and memory impairment in mice induced by 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine.

  Pharmacology, biochemistry, and behavior 20040501

• The neuroprotective effects of Semax in conditions of MPTP-induced lesions of the brain dopaminergic system.

  Neuroscience and behavioral physiology 20040501

• 1-Methyl-4-phenylpyridinium-induced apoptosis in cerebellar granule neurons is mediated by transferrin receptor iron-dependent depletion of tetrahydrobiopterin and neuronal nitric-oxide synthase-derived superoxide.

  The Journal of biological chemistry 20040430

• Aging of the nigrostriatal system in the squirrel monkey.

  The Journal of comparative neurology 20040412

• Acetaminophen and aspirin inhibit superoxide anion generation and lipid peroxidation, and protect against 1-methyl-4-phenyl pyridinium-induced dopaminergic neurotoxicity in rats.

  Neurochemistry international 20040401

• Commentary on 'Alpha-synuclein and mitochondria: a tangled skein'.

  Experimental neurology 20040401

• Enhanced substantia nigra mitochondrial pathology in human alpha-synuclein transgenic mice after treatment with MPTP.

  Experimental neurology 20040401

• Abnormal alpha-synuclein interactions with Rab proteins in alpha-synuclein A30P transgenic mice.

  Journal of neuropathology and experimental neurology 20040401

• Measurement of motor disability in MPTP-treated macaques using a telemetry system for estimating circadian motor activity.

  Journal of neuroscience methods 20040315

• Differences in alpha7 nicotinic acetylcholine receptor binding in motor symptomatic and asymptomatic MPTP-treated monkeys.

  Brain research 20040305

• Neuroprotective effect of dextromethorphan in the MPTP Parkinson's disease model: role of NADPH oxidase.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20040301

• Effect of melatonin on temporal changes of reactive oxygen species and glutathione after MPP(+) treatment in human astrocytoma U373MG cells.

  Journal of pineal research 20040301

• Deep brain stimulation for Parkinson's disease: potential risk of tissue damage associated with external stimulation.

  Annals of neurology 20040301

• Neuroprotective mechanism of modafinil on Parkinson disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

  Acta pharmacologica Sinica 20040301

• Effect of a selective glutamate antagonist on L-dopa-induced dyskinesias in drug-naive parkinsonian monkeys.

  Neurobiology of disease 20040301

• Mice deficient in dihydrolipoamide dehydrogenase show increased vulnerability to MPTP, malonate and 3-nitropropionic acid neurotoxicity.

  Journal of neurochemistry 20040301

• Protective effects of neuronal nitric oxide synthase inhibitor in mouse brain against MPTP neurotoxicity: an immunohistological study.

  European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 20040301

• [Inflammation and Parkinson's disease].

  Revista de neurologia 20040301

• Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28.

  Annals of the New York Academy of Sciences 20040301

• The role of the substantia nigra in cognitive activity in cats.

  Neuroscience and behavioral physiology 20040301

• Differing response to antipsychotic therapy in schizophrenia: pharmacogenomic aspects.

  Dialogues in clinical neuroscience 20040301

• Caspase-11 mediates inflammatory dopaminergic cell death in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20040225

• Regulation of dopaminergic loss by Fas in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20040225

• Neurotrophic actions of the novel AMPA receptor potentiator, LY404187, in rodent models of Parkinson's disease.

  European journal of pharmacology 20040220

• Levetiracetam improves choreic levodopa-induced dyskinesia in the MPTP-treated macaque.

  European journal of pharmacology 20040206

• SP600125, a new JNK inhibitor, protects dopaminergic neurons in the MPTP model of Parkinson's disease.

  Neuroscience research 20040201

• Long-term retention of neurotoxic beta-carbolines in brain neuromelanin.

  Journal of neural transmission (Vienna, Austria : 1996) 20040201

• Dopamine agonist 3-PPP fails to protect against MPTP-induced toxicity.

  Neurochemical research 20040201

• Neurokinin peptides and neurokinin receptors as potential therapeutic intervention targets of basal ganglia in the prevention and treatment of Parkinson's disease.

  Current drug targets 20040201

• Immunization of rats with conjugates of dopamine and serotonin with bovine serum albumin prevents the development of experimental MPTP-induced depressive syndrome (electrophysiological parameters).

  Neuroscience and behavioral physiology 20040201

• Preclinical models of Parkinson's disease.

  Current protocols in toxicology 20040201

• Endogenous activation of mGlu5 metabotropic glutamate receptors contributes to the development of nigro-striatal damage induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20040128

• Behavioural and neurochemical effects of phosphatidylserine in MPTP lesion of the substantia nigra of rats.

  European journal of pharmacology 20040126

• TorsinA, the gene linked to early-onset dystonia, is upregulated by the dopaminergic toxin MPTP in mice.

  Neuroscience letters 20040123

• Avoidance of dyskinesia: preclinical evidence for continuous dopaminergic stimulation.

  Neurology 20040113

• Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment.

  Neurology 20040113

• Modafinil prevents the MPTP-induced increase in GABAA receptor binding in the internal globus pallidus of MPTP-treated common marmosets.

  Neuroscience letters 20040102

• Differential effects of carboxyfullerene on MPP+/MPTP-induced neurotoxicity.

  Neurochemistry international 20040101

• Glucocorticoid receptor deficiency increases vulnerability of the nigrostriatal dopaminergic system: critical role of glial nitric oxide.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20040101

• Melatonin protects against oxidative stress caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the mouse nigrostriatum.

  Journal of pineal research 20040101

• Depressed contractile function and adrenergic responsiveness of cardiac myocytes in an experimental model of Parkinson disease, the MPTP-treated mouse.

  Neurobiology of aging 20040101

• Estrogen interacts with the IGF-1 system to protect nigrostriatal dopamine and maintain motoric behavior after 6-hydroxdopamine lesions.

  Journal of neuroscience research 20040101

• Neurochemical and behavioural changes in zebrafish Danio rerio after systemic administration of 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

  Journal of neurochemistry 20040101

• Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation.

  Journal of neurochemistry 20040101

• MPTP potentiates 3-nitropropionic acid-induced striatal damage in mice: reference to striatonigral degeneration.

  Experimental neurology 20040101

• (-)-Deprenyl, a selective MAO-B inhibitor, with apoptotic and anti-apoptotic properties.

  Neurotoxicology 20040101

• Tobacco leaf, smoke and smoking, MAO inhibitors, Parkinson's disease and neuroprotection; are there links?

  Neurotoxicology 20040101

• Characterization of novel dihydrothienopyridinium and thienopyridinium metabolites of ticlopidine in vitro: role of peroxidases, cytochromes p450, and monoamine oxidases.

  Drug metabolism and disposition: the biological fate of chemicals 20040101

• Disruption of self-organized actions in monkeys with progressive MPTP-induced parkinsonism. I. Effects of task complexity.

  The European journal of neuroscience 20040101

• Disruption of self-organized actions in monkeys with progressive MPTP-induced parkinsonism: II. Effects of reward preference.

  The European journal of neuroscience 20040101

• The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP-treated primates.

  Movement disorders : official journal of the Movement Disorder Society 20040101

• Neurogenesis in olfactory bulb identified by retroviral labeling in normal and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated adult mice.

  Neuroscience 20040101

• Time-course evaluation of whole blood phagocytosis in mice treated with the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

  Inflammopharmacology 20040101

• Matrix metalloproteinase-9 is elevated in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice.

  Neuromolecular medicine 20040101

• [Estimation of the protective effect of the novel potential antiparkinsonian agent himantane against MPTP neurotoxicity].

  Eksperimental'naia i klinicheskaia farmakologiia 20040101

• Effects of high frequency deep brain stimulation on urine storage and voiding function in conscious minipigs.

  Neurourology and urodynamics 20040101

• Low dose intravenous minocycline is neuroprotective after middle cerebral artery occlusion-reperfusion in rats.

  BMC neurology 20040101

• Terminally differentiated SH-SY5Y cells provide a model system for studying neuroprotective effects of dopamine agonists.

  Neurotoxicity research 20040101

• [Comparative study of neurophysiological effects of adamantane derivatives in the experimental parkinsonism model].

  Eksperimental'naia i klinicheskaia farmakologiia 20040101

• Decreased expression of kynurenine aminotransferase-I (KAT-I) in the substantia nigra of mice after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treatment.

  Neuroscience 20040101

• Identification of brain-derived neurotrophic factor in nestin-expressing astroglial cells in the neostriatum of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice.

  Neuroscience 20040101

• Dopamine transporter as a marker of neuroprotection in methamphetamine-lesioned mice treated acutely with estradiol.

  Neuroendocrinology 20040101

• Selective recovery of striatal 125I-alpha-conotoxinmii nicotinic receptors after nigrostriatal damage in monkeys.

  Neuroscience 20040101

• The strong inhibition of triosephosphate isomerase by the natural beta-carbolines may explain their neurotoxic actions.

  Neuroscience 20040101

• Interleukin-18 null mice show diminished microglial activation and reduced dopaminergic neuron loss following acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment.

  Neuroscience 20040101

• Sensitivity of zebrafish to environmental toxins implicated in Parkinson's disease.

  Neurotoxicology and teratology 20040101

• Low dose pramipexole is neuroprotective in the MPTP mouse model of Parkinson's disease, and downregulates the dopamine transporter via the D3 receptor.

  BMC biology 20040101

• 1-amino-4-phenyl-1,2,3,6-tetrahydropyridine and 1-amino-4-phenylpyridinium salt, the 1-amino analogues of neurotoxins, MPTP and MPP+, induce apoptosis in PC12 cells: detection of apoptotic cells by Comet assay and flow cytometric analysis.

  In vivo (Athens, Greece) 20040101

• Neuroprotective role of testosterone in the nervous system.

  Polish journal of pharmacology 20040101

• Neuroprotective effects of phenylbutyrate against MPTP neurotoxicity.

  Neuromolecular medicine 20040101

• Iron and alpha-synuclein in the substantia nigra of MPTP-treated mice: effect of neuroprotective drugs R-apomorphine and green tea polyphenol (-)-epigallocatechin-3-gallate.

  Journal of molecular neuroscience : MN 20040101

• MPTP-induced increase in c-Fos- and c-Jun-like immunoreactivity in the monkey cerebellum.

  European journal of histochemistry : EJH 20040101

• Neuroprotective effects of oral administration of triacetyluridine against MPTP neurotoxicity.

  Neuromolecular medicine 20040101

• Caenorhabditis elegans MPP+ model of Parkinson's disease for high-throughput drug screenings.

  Neuro-degenerative diseases 20040101

• Injury and strain-dependent dopaminergic neuronal degeneration in the substantia nigra of mice after axotomy or MPTP.

  Brain research 20031224

• Manganese complexes of curcumin and its derivatives: evaluation for the radical scavenging ability and neuroprotective activity.

  Free radical biology & medicine 20031215

• Heat shock protects PC12 cells against MPP+ toxicity.

  Brain research 20031212

• Modulation of GABAergic transmission in the striatopallidal system by adenosine A2A receptors: a potential mechanism for the antiparkinsonian effects of A2A antagonists.

  Neurology 20031209

• Neuroprotection by caffeine and more specific A2A receptor antagonists in animal models of Parkinson's disease.

  Neurology 20031209

• Monoamine oxidase B inhibition and neuroprotection: studies on selective adenosine A2A receptor antagonists.

  Neurology 20031209

• Translating A2A antagonist KW6002 from animal models to parkinsonian patients.

  Neurology 20031209

• Enriched environment confers resistance to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and cocaine: involvement of dopamine transporter and trophic factors.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20031203

• Neuronal and astroglial responses to the serotonin and norepinephrine neurotoxin: 1-methyl-4-(2'-aminophenyl)-1,2,3,6-tetrahydropyridine.

  The Journal of pharmacology and experimental therapeutics 20031201

• Opioid antagonists increase the dyskinetic response to dopaminergic agents in parkinsonian monkeys: interaction between dopamine and opioid systems.

  Neuropharmacology 20031201

• Behavioral effects of dopamine agonists and antagonists in MPTP-lesioned D3 receptor knockout mice.

  Pharmacology, biochemistry, and behavior 20031201

• Survival and differentiation of transplanted neural stem cells in mice brain with MPTP-induced Parkinson disease.

  Acta pharmacologica Sinica 20031201

• Chronic treatment with small doses of cabergoline prevents dopa-induced dyskinesias in parkinsonian monkeys.

  Movement disorders : official journal of the Movement Disorder Society 20031201

• Inactivation of acetylcholinesterase by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride.

  Molecular and cellular biochemistry 20031201

• Time-course of nigrostriatal degeneration in a progressive MPTP-lesioned macaque model of Parkinson's disease.

  Molecular neurobiology 20031201

• Microglial response is poorly correlated with neurodegeneration following chronic, low-dose MPTP administration in monkeys.

  Experimental neurology 20031201

• Diverse psychotomimetics act through a common signaling pathway.

  Science (New York, N.Y.) 20031121

• Synthesis and in vitro biological evaluation of fluoro-substituted-4-phenyl-1,2,3,6-tetrahydropyridines as monoamine oxidase B substrates.

  Bioorganic & medicinal chemistry 20031117

• Development of levodopa-induced dyskinesias in parkinsonian monkeys may depend upon rate of symptom onset and/or duration of symptoms.

  Brain research 20031114

• Brain-derived neurotrophic factor controls dopamine D3 receptor expression: therapeutic implications in Parkinson's disease.

  European journal of pharmacology 20031107

• PDNF, a human parasite-derived mimic of neurotrophic factors, prevents caspase activation, free radical formation, and death of dopaminergic cells exposed to the Parkinsonism-inducing neurotoxin MPP+.

  Brain research. Molecular brain research 20031106

• Synthesis and evaluation of chiral bicyclic proline FKBP12 ligands.

  Bioorganic & medicinal chemistry letters 20031103

• Synthesis, molecular modeling and biological evaluation of aza-proline and aza-pipecolic derivatives as FKBP12 ligands and their in vivo neuroprotective effects.

  Bioorganic & medicinal chemistry 20031103

• Behavioral changes are not directly related to striatal monoamine levels, number of nigral neurons, or dose of parkinsonian toxin MPTP in mice.

  Neurobiology of disease 20031101

• Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration.

  Annals of neurology 20031101

• A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease.

  Experimental neurology 20031101

• Neuroprotective effects of the novel D3/D2 receptor agonist and antiparkinson agent, S32504, in vitro against 1-methyl-4-phenylpyridinium (MPP+) and in vivo against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a comparison to ropinirole.

  Experimental neurology 20031101

• Neuroprotective actions of the ginseng extract G115 in two rodent models of Parkinson's disease.

  Experimental neurology 20031101

• Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset.

  Movement disorders : official journal of the Movement Disorder Society 20031101

• MPP+ induces the endoplasmic reticulum stress response in rabbit brain involving activation of the ATF-6 and NF-kappaB signaling pathways.

  Journal of neuropathology and experimental neurology 20031101

• COX-2-deficient mice are less prone to MPTP-neurotoxicity than wild-type mice.

  Neuroreport 20031027

• [Increased DMT1 expression and iron content in MPTP-treated C57BL/6 mice].

  Sheng li xue bao : [Acta physiologica Sinica] 20031025

• Minocycline enhances MPTP toxicity to dopaminergic neurons.

  Journal of neuroscience research 20031015

• The essentiality of Bcl-2, PKC and proteasome-ubiquitin complex activations in the neuroprotective-antiapoptotic action of the anti-Parkinson drug, rasagiline.

  Biochemical pharmacology 20031015

• Hprt(CAG)146 mice: age of onset of behavioral abnormalities, time course of neuronal intranuclear inclusion accumulation, neurotransmitter marker alterations, mitochondrial function markers, and susceptibility to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

  The Journal of comparative neurology 20031013

• Time-course of the expression of inflammatory cytokines and matrix metalloproteinases in the striatum and mesencephalon of mice injected with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, a dopaminergic neurotoxin.

  Neuroscience letters 20031009

• 3,4-methylenedioxymethamphetamine (ecstasy) inhibits dyskinesia expression and normalizes motor activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20031008

• D-deprenyl protects nigrostriatal neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity.

  Synapse (New York, N.Y.) 20031001

• Critical role of microglial NADPH oxidase-derived free radicals in the in vitro MPTP model of Parkinson's disease.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20031001

• Synergistic dopaminergic neurotoxicity of MPTP and inflammogen lipopolysaccharide: relevance to the etiology of Parkinson's disease.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20031001

• Cerebral alterations in a MPTP-mouse model of Parkinson's disease--an immunocytochemical study.

  Journal of neural transmission (Vienna, Austria : 1996) 20031001

• Primate models of Parkinson's disease.

  Experimental neurology 20031001

• Increased striatal pre-proenkephalin B expression is associated with dyskinesia in Parkinson's disease.

  Experimental neurology 20031001

• Mapping of brain function after MPTP-induced neurotoxicity in a primate Parkinson's disease model.

  NeuroImage 20031001

• Quantitative analysis of dopaminergic loss in relation to functional territories in MPTP-treated monkeys.

  The European journal of neuroscience 20031001

• Dipeptide analog of neurotensin active site prevents the development of experimental Parkinson's syndrome in mice.

  Bulletin of experimental biology and medicine 20031001

• NF-E2-related factor-2 mediates neuroprotection against mitochondrial complex I inhibitors and increased concentrations of intracellular calcium in primary cortical neurons.

  The Journal of biological chemistry 20030926

• The MPTP-treated primate as a model of motor complications in PD: primate model of motor complications.

  Neurology 20030923

• Compromised reactive microgliosis in MPTP-lesioned IL-6 KO mice.

  Brain research 20030919

• Determination of MPTP, a toxic impurity of pethidine.

  Journal of pharmaceutical and biomedical analysis 20030915

• Attenuation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity by the novel selective dopamine D3-receptor partial agonist FAUC 329 predominantly in the nucleus accumbens of mice.

  Biochemical pharmacology 20030915

• D-beta-hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson disease.

  The Journal of clinical investigation 20030915

• Cigarette smoke and nicotine protect dopaminergic neurons against the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Parkinsonian toxin.

  Brain research 20030912

• Chromosomal loci influencing the susceptibility to the parkinsonian neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20030910

• Sympathetic innervation in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine primate model of Parkinson's disease.

  The Journal of pharmacology and experimental therapeutics 20030901

• Dopaminergic cell death precedes iron elevation in MPTP-injected monkeys.

  Free radical biology & medicine 20030901

• Cerebrospinal fluid 3,4-dihydroxyphenylacetic acid level after tolcapone administration as an indicator of nigrostriatal degeneration.

  Experimental neurology 20030901

• Overlesioned hemiparkinsonian non human primate model: correlation between clinical, neurochemical and histochemical changes.

  Frontiers in bioscience : a journal and virtual library 20030901

• Profiling genes related to mitochondrial function in mice treated with N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

  Biochemical and biophysical research communications 20030815

• Pramipexole inhibits MPTP toxicity in mice by dopamine D3 receptor dependent and independent mechanisms.

  European journal of pharmacology 20030815

• Synthesis and antioxidant activity evaluation of novel antiparkinsonian agents, aminoadamantane derivatives of nitroxyl free radical.

  Bioorganic & medicinal chemistry 20030805

• LY503430, a novel alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor potentiator with functional, neuroprotective and neurotrophic effects in rodent models of Parkinson's disease.

  The Journal of pharmacology and experimental therapeutics 20030801

• Neuropathological and behavioral changes induced by various treatment paradigms with MPTP and 3-nitropropionic acid in mice: towards a model of striatonigral degeneration (multiple system atrophy).

  Acta neuropathologica 20030801

• Protective role of group-II metabotropic glutamate receptors against nigro-striatal degeneration induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice.

  Neuropharmacology 20030801

• Antidyskinetic effect of magnesium sulfate in MPTP-lesioned monkeys.

  Experimental neurology 20030801

• Effects of monoamine oxidase inhibitors on the diethyldithiocarbamate-induced enhancement of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in C57BL/6 mice.

  Journal of neural transmission (Vienna, Austria : 1996) 20030801

• Recovery of motor function and dopaminergic parameters in a mouse model of Parkinson's disease induced by co-administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and diethyldithiocarbamate.

  Journal of neural transmission (Vienna, Austria : 1996) 20030801

• Effect of manganese exposure on MPTP neurotoxicities.

  Neurotoxicology 20030801

• Circadian determinations of cortisol, prolactin and melatonin in chronic methyl-phenyl-tetrahydropyridine-treated monkeys.

  Neuroendocrinology 20030801

• Calcium channel agonist, (+/-)-Bay K8644, causes an immediate increase in the striatal 1-methyl-4-phenylpyridinium level following systemic administration of the dopaminergic neurotoxin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, in Balb/c mice.

  Neuroscience letters 20030731

• Acetyl-L-carnitine cytoprotection against 1-methyl-4-phenylpyridinium toxicity in neuroblastoma cells.

  Biochemical pharmacology 20030715

• The subtype-selective nicotinic acetylcholine receptor agonist SIB-1553A improves both attention and memory components of a spatial working memory task in chronic low dose 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys.

  The Journal of pharmacology and experimental therapeutics 20030701

• Coenzyme Q induces nigral mitochondrial uncoupling and prevents dopamine cell loss in a primate model of Parkinson's disease.

  Endocrinology 20030701

• Models of Parkinson's disease.

  Movement disorders : official journal of the Movement Disorder Society 20030701

• Kinetics of the uptake and distribution of the dopamine D(2,3) agonist (R)-N-[1-(11)C]n-propylnorapomorphine in brain of healthy and MPTP-treated Göttingen miniature pigs.

  Nuclear medicine and biology 20030701

• Attenuation of MPTP-induced dopaminergic neurotoxicity by TV3326, a cholinesterase-monoamine oxidase inhibitor.

  Journal of neurochemistry 20030701

• Alpha-1B adrenergic receptor knockout mice are protected against methamphetamine toxicity.

  Journal of neurochemistry 20030701

• Presymptomatic diagnosis of experimental Parkinsonism with 123I-PE2I SPECT.

  NeuroImage 20030701

• Adult neural stem/progenitor cells in neurodegenerative repair.

  Sheng li xue bao : [Acta physiologica Sinica] 20030625

• MPTP-induced reactive oxygen species promote cell death through a gradual activation of caspase-3 without expression of GRP78/Bip as a preventive measure against ER stress in PC12 cells.

  Life sciences 20030620

• Rapid reduction of ATP synthesis and lack of free radical formation by MPP+ in rat brain synaptosomes and mitochondria.

  Brain research 20030613

• The retina as a novel in vivo model for studying the role of molecules of the Bcl-2 family in relation to MPTP neurotoxicity.

  Neurochemical research 20030601

• Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function.

  Nature medicine 20030601

• Compensatory regulation of striatal neuropeptide gene expression occurs before changes in metabolic activity of basal ganglia nuclei.

  Neurobiology of disease 20030601

• Estradiol and dehydroepiandrosterone potentiate levodopa-induced locomotor activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys.

  Endocrine 20030601

• Role of dopamine transporter against MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity in mice.

  Metabolic brain disease 20030601

• The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model: a tool to explore the pathogenesis of Parkinson's disease.

  Annals of the New York Academy of Sciences 20030601

• COX-2 and neurodegeneration in Parkinson's disease.

  Annals of the New York Academy of Sciences 20030601

• Peroxynitrite and mitochondrial dysfunction in the pathogenesis of Parkinson's disease.

  Antioxidants & redox signaling 20030601

• [New aspects of neuroprotective effects of nonsteroidal anti-inflammatory drugs].

  Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology 20030601

• Interactions between environmental and genetic factors in the pathophysiology of Parkinson's disease.

  IUBMB life 20030601

• Nitric oxide and reactive oxygen species in Parkinson's disease.

  IUBMB life 20030601

• Dextromethorphan prevents the diethyldithiocarbamate enhancement of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in mice.

  Brain research 20030530

• Differential expression patterns of mGluR1 alpha in monkey nigral dopamine neurons.

  Neuroreport 20030523

• Inhibition of calpains prevents neuronal and behavioral deficits in an MPTP mouse model of Parkinson's disease.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20030515

• Human neural stem cell transplantation in the MPTP-lesioned mouse.

  Brain research 20030509

• Neuroprotective effect of vasoactive intestinal peptide (VIP) in a mouse model of Parkinson's disease by blocking microglial activation.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20030501

• Expression of S-100 protein is related to neuronal damage in MPTP-treated mice.

  Glia 20030501

• Evidence for the substantia nigra pars compacta as an essential component of a memory system independent of the hippocampal memory system.

  Neurobiology of learning and memory 20030501

• Influence of lipophilicity on the interactions of N-alkyl-4-phenyl-1,2,3,6-tetrahydropyridines and their positively charged N-alkyl-4-phenylpyridinium metabolites with cytochrome P450 2D6.

  Drug metabolism and disposition: the biological fate of chemicals 20030501

• Differential declines in striatal nicotinic receptor subtype function after nigrostriatal damage in mice.

  Molecular pharmacology 20030501

• Rest tremor in rhesus monkeys with MPTP-induced parkinsonism.

  Frontiers in bioscience : a journal and virtual library 20030501

• Increased synaptosomal dopamine content and brain concentration of paraquat produced by selective dithiocarbamates.

  Journal of neurochemistry 20030501

• Effect of pulsatile administration of levodopa on dyskinesia induction in drug-naïve MPTP-treated common marmosets: effect of dose, frequency of administration, and brain exposure.

  Movement disorders : official journal of the Movement Disorder Society 20030501

• Targeting programmed cell death in neurodegenerative diseases.

  Nature reviews. Neuroscience 20030501

• Dietary restriction does not protect the nigrostriatal dopaminergic pathway of older animals from low-dose MPTP-induced neurotoxicity.

  The journals of gerontology. Series A, Biological sciences and medical sciences 20030501

• Protection of dopaminergic neurons with a novel astrocyte modulating agent (R)-(-)-2-propyloctanoic acid (ONO-2506) in an MPTP-mouse model of Parkinson's disease.

  Journal of the neurological sciences 20030415

• Parkin binds to alpha/beta tubulin and increases their ubiquitination and degradation.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20030415

• Alterations in m-RNA expression for Cu,Zn-superoxide dismutase and glutathione peroxidase in the basal ganglia of MPTP-treated marmosets and patients with Parkinson's disease.

  Brain research 20030411

• Apoptotic mechanisms and antiapoptotic therapy in the MPTP model of Parkinson's disease.

  Toxicology letters 20030404

• Inhibition of monoamine oxidase B by selective adenosine A2A receptor antagonists.

  Bioorganic & medicinal chemistry 20030403

• Glutaredoxin is essential for maintenance of brain mitochondrial complex I: studies with MPTP.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20030401

• Prospects for antiapoptotic drug therapy of neurodegenerative diseases.

  Progress in neuro-psychopharmacology & biological psychiatry 20030401

• 1-Methyl-4-phenylpyridinium accumulates in cerebellar granule neurons via organic cation transporter 3.

  Journal of neurochemistry 20030401

• Protective action of recombinant neurturin on dopaminergic neurons in substantia nigra in a rhesus monkey model of Parkinson's disease.

  Neurological research 20030401

• Repeated estradiol treatment prevents MPTP-induced dopamine depletion in male mice.

  Neuroendocrinology 20030401

• Ironic fate: can a banned drug control metal heavies in neurodegenerative diseases?

  Neuron 20030327

• Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease.

  Neuron 20030327

• Grid performance test to measure behavioral impairment in the MPTP-treated-mouse model of parkinsonism.

  Journal of neuroscience methods 20030315

• Pattern of levodopa-induced striatal changes is different in normal and MPTP-lesioned mice.

  Journal of neurochemistry 20030301

• Stimulation of the subthalamic nucleus changes the firing pattern of pallidal neurons.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20030301

• Attenuation of MPTP-induced neurotoxicity and behavioural impairment in NSE-XIAP transgenic mice.

  Neurobiology of disease 20030301

• Acute and subchronic MPTP administration differentially affects striatal glutamate synaptic function.

  Experimental neurology 20030301

• Age-related microglial activation in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurodegeneration in C57BL/6 mice.

  Brain research 20030227

• The establishment of a reliable cytotoxic system with SK-N-SH neuroblastoma cell culture.

  Journal of neuroscience methods 20030215

• D-(+)-glucose rescue against 1-methyl-4-phenylpyridinium toxicity through anaerobic glycolysis in neuroblastoma cells.

  Brain research 20030207

• PF 9601N [N-(2-propynyl)-2-(5-benzyloxy-indolyl) methylamine], a new MAO-B inhibitor, attenuates MPTP-induced depletion of striatal dopamine levels in C57/BL6 mice.

  Neurochemistry international 20030201

• Pathogenic role of glial cells in Parkinson's disease.

  Movement disorders : official journal of the Movement Disorder Society 20030201

• Effects of some antioxidative aporphine derivatives on striatal dopaminergic transmission and on MPTP-induced striatal dopamine depletion in B6CBA mice.

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20030201

• Proton magnetic resonance imaging and spectroscopy identify metabolic changes in the striatum in the MPTP feline model of parkinsonism.

  Experimental neurology 20030201

• 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine pretreatment attenuates methamphetamine-induced dopamine toxicity.

  Pharmacology & toxicology 20030201

• Dehydroepiandrosterone (DHEA) such as 17beta-estradiol prevents MPTP-induced dopamine depletion in mice.

  Synapse (New York, N.Y.) 20030101

• Essential requirements for substrate binding affinity and selectivity toward human CYP2 family enzymes.

  Archives of biochemistry and biophysics 20030101

• Screening of novel pentacyclo-undecylamines for neuroprotective activity.

  European journal of pharmacology 20030101

• Both short- and long-acting D-1/D-2 dopamine agonists induce less dyskinesia than L-DOPA in the MPTP-lesioned common marmoset (Callithrix jacchus).

  Experimental neurology 20030101

• Experimental parkinsonism is associated with increased pallidal GAD gene expression and is reversed by site-directed antisense gene therapy.

  Movement disorders : official journal of the Movement Disorder Society 20030101

• The mouse MPTP model: gene expression changes in dopaminergic neurons.

  The European journal of neuroscience 20030101

• 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced lipid peroxidation and DNA damage in mouse bone marrow and blood.

  Environmental and molecular mutagenesis 20030101

• In vivo imaging of brain dopaminergic neurotransmission system in small animals with high-resolution single photon emission computed tomography.

  Analytical sciences : the international journal of the Japan Society for Analytical Chemistry 20030101

• Manganese ethylene-bis-dithiocarbamate and selective dopaminergic neurodegeneration in rat: a link through mitochondrial dysfunction.

  Journal of neurochemistry 20030101

• The contribution of the MPTP-treated primate model to the development of new treatment strategies for Parkinson's disease.

  Parkinsonism & related disorders 20030101

• Synergistic effects of melatonin and deprenyl against MPTP-induced mitochondrial damage and DA depletion.

  Neurobiology of aging 20030101

• Neuroprotective effects of inhibitors of dipeptidyl peptidase-iV in vitro and in vivo.

  Advances in experimental medicine and biology 20030101

• Role of alpha-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice.

  Neuroscience 20030101

• [Immunization of rats with bovine serum albumin conjugate with dopamine or 5-hydroxytryptamine prevents the development of experimental MPTP-induced depressive syndrome. An electrophysiological study].

  Zhurnal vysshei nervnoi deiatelnosti imeni I P Pavlova 20030101

• [Insufficiency of nigrostriatal dopaminergic system as a disregulation mechanism of dopamine-dependent depression syndrome].

  Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 20030101

• Exercise induces behavioral recovery and attenuates neurochemical deficits in rodent models of Parkinson's disease.

  Neuroscience 20030101

• Effects of acute administration of DA agonists on locomotor activity: MPTP versus neonatal intracerebroventricular 6-OHDA treatment.

  Neurotoxicity research 20030101

• A chemical genetic approach for the identification of direct substrates of protein kinases.

  Methods in molecular biology (Clifton, N.J.) 20030101

• BP 897, a selective dopamine D3 receptor ligand with therapeutic potential for the treatment of cocaine-addiction.

  CNS drug reviews 20030101

• Neuroprotective strategies in Parkinson's disease : an update on progress.

  CNS drugs 20030101

• What have we learnt from CDNA microarray gene expression studies about the role of iron in MPTP induced neurodegeneration and Parkinson's disease?

  Journal of neural transmission. Supplementum 20030101

• Animal models of Parkinson's disease in rodents induced by toxins: an update.

  Journal of neural transmission. Supplementum 20030101

• Experimental study on the protective effect of puerarin to Parkinson disease.

  Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban 20030101

• Neurobehavioural deficits following postnatal iron overload: I spontaneous motor activity.

  Neurotoxicity research 20030101

• Additive neuroprotective effects of creatine and a cyclooxygenase 2 inhibitor against dopamine depletion in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.

  Journal of molecular neuroscience : MN 20030101

• Noradrenergic drugs for levodopa-induced dyskinesia.

  Clinical neuropharmacology 20030101

• Overexpression of CYP2D6 attenuates the toxicity of MPP+ in actively dividing and differentiated PC12 cells.

  Gene expression 20030101

• MPP(+)-induced degeneration is potentiated by dicoumarol in cultures of the RCSN-3 dopaminergic cell line. Implications of neuromelanin in oxidative metabolism of dopamine neurotoxicity.

  Neurotoxicity research 20030101

• Green tea polyphenol (-)-epigallocatechin-3-gallate protects rat PC12 cells from apoptosis induced by serum withdrawal independent of P13-Akt pathway.

  Neurotoxicity research 20030101

• Zinc potentiates 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced dopamine depletion in caudate nucleus of mice brain.

  Neuroscience letters 20021219

• Dystonia is predictive of subsequent altered dopaminergic responsiveness in a chronic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine+3-nitropropionic acid model of striatonigral degeneration in monkeys.

  Neuroscience letters 20021219

• Dopamine, but not norepinephrine or serotonin, reuptake inhibition reverses motor deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates.

  The Journal of pharmacology and experimental therapeutics 20021201

• Homocysteine, folate deficiency, and Parkinson's disease.

  Nutrition reviews 20021201

• An inflammatory review of Parkinson's disease.

  Progress in neurobiology 20021201

• [Genetics and environmental factors of Parkinson disease].

  Revue neurologique 20021201

• Lysosomal malfunction accompanies alpha-synuclein aggregation in a progressive mouse model of Parkinson's disease.

  Brain research 20021122

• Impact of incorporating the 2C5 crystal structure into comparative models of cytochrome P450 2D6.

  Proteins 20021101

• Neural stem cells display an inherent mechanism for rescuing dysfunctional neurons.

  Nature biotechnology 20021101

• 2'-NH(2)-MPTP [1-methyl-4-(2'-aminophenyl)-1,2,3,6-tetrahydropyridine] depletes serotonin and norepinephrine in rats: a comparison with 2'-CH(3)-MPTP [1-methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydropyridine].

  The Journal of pharmacology and experimental therapeutics 20021101

• Declines in different beta2* nicotinic receptor populations in monkey striatum after nigrostriatal damage.

  The Journal of pharmacology and experimental therapeutics 20021101

• Reversal of akinesia in experimental parkinsonism by GABA antagonist microinjections in the pedunculopontine nucleus.

  Brain : a journal of neurology 20021101

• Disruption of the proprioceptive mapping in the medial wall of parkinsonian monkeys.

  Annals of neurology 20021101

• p53 inhibitors preserve dopamine neurons and motor function in experimental parkinsonism.

  Annals of neurology 20021101

• Neural stem cells, scaffolds, and chaperones.

  Nature biotechnology 20021101

• Detection of behavioral impairments correlated to neurochemical deficits in mice treated with moderate doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

  Experimental neurology 20021101

• Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease.

  Movement disorders : official journal of the Movement Disorder Society 20021101

• Beginning-of-dose and rebound worsening in MPTP-treated common marmosets treated with levodopa.

  Movement disorders : official journal of the Movement Disorder Society 20021101

• Activation of the c-Jun N terminal kinase pathway in an animal model of Parkinson's disease.

  Annals of the New York Academy of Sciences 20021101

• Neuroprotective effect of estradiol and phytoestrogens on MPP+-induced cytotoxicity in neuronal PC12 cells.

  Journal of neuroscience research 20021001

• Increased vulnerability of dopaminergic neurons in MPTP-lesioned interleukin-6 deficient mice.

  Journal of neurochemistry 20021001

• A novel in vivo post-translational modification of p53 by PARP-1 in MPTP-induced parkinsonism.

  Journal of neurochemistry 20021001

• Overexpression of Parkinson's disease-associated alpha-synucleinA53T by recombinant adeno-associated virus in mice does not increase the vulnerability of dopaminergic neurons to MPTP.

  Journal of neurobiology 20021001

• Neuroimmunophilin ligand V-10,367 is neuroprotective after 24-hour delayed administration in a mouse model of diffuse traumatic brain injury.

  Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 20021001

• Naloxone reduces levodopa-induced dyskinesias and apomorphine-induced rotations in primate models of parkinsonism.

  Journal of neural transmission (Vienna, Austria : 1996) 20021001

• [Pesticide exposure and Parkinson's syndrome - the epidemiological and experimental evidence].

  Der Nervenarzt 20021001

• Role of nitric oxide synthase against MPTP neurotoxicity in mice.

  Neurological research 20021001

• Environmental factors in Parkinson's disease.

  Neurotoxicology 20021001

• Catecholaminergic neuronal degeneration in rainbow trout assessed by skin color change: a model system for identification of environmental risk factors.

  Neurotoxicology 20021001

• Acute mitochondrial and chronic toxicological effects of 1-methyl-4-phenylpyridinium in human neuroblastoma cells.

  Neurotoxicology 20021001

• L-DOPA does not cause neurotoxicity in VMAT2 heterozygote knockout mice.

  Neurotoxicology 20021001

• Quetiapine attenuates levodopa-induced motor complications in rodent and primate parkinsonian models.

  Experimental neurology 20021001

• Early and late gene changes in MPTP mice model of Parkinson's disease employing cDNA microarray.

  Neurochemical research 20021001

• 8-(3-Chlorostyryl)caffeine may attenuate MPTP neurotoxicity through dual actions of monoamine oxidase inhibition and A2A receptor antagonism.

  The Journal of biological chemistry 20020927

• Dopamine replacement therapy reverses abnormal synchronization of pallidal neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine primate model of parkinsonism.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20020915

• The neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induces apoptosis in mouse nigrostriatal glia. Relevance to nigral neuronal death and striatal neurochemical changes.

  The Journal of biological chemistry 20020913

• Dopamine reuptake inhibition and failure to evoke dyskinesia in MPTP-treated primates.

  European journal of pharmacology 20020913

• Dopamine efflux by MPTP and hydroxyl radical generation.

  Journal of neural transmission (Vienna, Austria : 1996) 20020901

• Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: implications for Parkinson's disease.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20020901

• Lack of effect of testosterone and dihydrotestosterone compared to 17beta-oestradiol in 1-methyl-4-phenyl-1,2,3,6, tetrahydropyridine-mice.

  Journal of neuroendocrinology 20020901

• In vivo receptor assay with multiple ligand concentrations: an equilibrium approach.

  Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 20020901

• Protective effect of ginsenoside Rg1 against MPTP-induced apoptosis in mouse substantia nigra neurons.

  Acta pharmacologica Sinica 20020901

• Therapeutic effect of neuronal nitric oxide synthase inhibitor (7-nitroindazole) against MPTP neurotoxicity in mice.

  Metabolic brain disease 20020901

• The monoamine reuptake blocker brasofensine reverses akinesia without dyskinesia in MPTP-treated and levodopa-primed common marmosets.

  Movement disorders : official journal of the Movement Disorder Society 20020901

• Repeated administration of piribedil induces less dyskinesia than L-dopa in MPTP-treated common marmosets: a behavioural and biochemical investigation.

  Movement disorders : official journal of the Movement Disorder Society 20020901

• The hyperkinetic abnormal movements scale: a tool for measuring levodopa-induced abnormal movements in squirrel monkeys.

  Movement disorders : official journal of the Movement Disorder Society 20020901

• Prevention of nitric oxide-mediated 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease in mice by tea phenolic epigallocatechin 3-gallate.

  Neurotoxicology 20020901

• Role of TNF-alpha receptors in mice intoxicated with the parkinsonian toxin MPTP.

  Experimental neurology 20020901

• Neuroprotective effect of the monoamine oxidase inhibitor PF 9601N [N-(2-propynyl)-2-(5-benzyloxy-indolyl) methylamine] on rat nigral neurons after 6-hydroxydopamine-striatal lesion.

  Neuroscience letters 20020830

• GABA(A) and mu-opioid receptor binding in the globus pallidus and endopeduncular nucleus of animals symptomatic for and recovered from experimental Parkinsonism.

  Brain research 20020830

• Pharmacological evaluation of a Br-76 analog of epibatidine: a potent ligand for studying brain nicotinic acetylcholine receptors.

  Synapse (New York, N.Y.) 20020801

• Synthesis of N-glyoxyl prolyl and pipecolyl amides and thioesters and evaluation of their in vitro and in vivo nerve regenerative effects.

  Journal of medicinal chemistry 20020801

• Synthesis of ketone analogues of prolyl and pipecolyl ester FKBP12 ligands.

  Journal of medicinal chemistry 20020801

• Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease.

  Journal of neurochemistry 20020801

• GABA-opioid interactions in the globus pallidus: [D-Ala2]-Met-enkephalinamide attenuates potassium-evoked GABA release after nigrostriatal lesion.

  Journal of neurochemistry 20020801

• Studies on the oxidation of 1,4-disubstituted-1,2,3,6-tetrahydropyridines.

  Drug metabolism reviews 20020801

• 1-Trichloromethyl-1,2,3,4-tetrahydro-beta-carboline (TaClo) and related derivatives: chemistry and biochemical effects on catecholamine biosynthesis.

  Bioorganic & medicinal chemistry 20020701

• Inhibition of the mitochondrial permeability transition by the nonimmunosuppressive cyclosporin derivative NIM811.

  Molecular pharmacology 20020701

• Biodistribution study of [99mTc] TRODAT-1 alone or combined with other dopaminergic drugs in mice with macroautoradiography.

  Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine 20020701

• Indomethacin protects against neurodegeneration caused by MPTP intoxication in mice.

  International immunopharmacology 20020701

• Lentivirally delivered glial cell line-derived neurotrophic factor increases the number of striatal dopaminergic neurons in primate models of nigrostriatal degeneration.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20020615

• Role of hydroxyl radical formation in neurotoxicity as revealed by in vivo free radical trapping.

  Toxicology letters 20020614

• Resistance to striatal dopamine depletion induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice expressing human mutant Cu,Zn superoxide dismutase.

  Neuroscience letters 20020607

• Peroxynitrite inactivates the human dopamine transporter by modification of cysteine 342: potential mechanism of neurotoxicity in dopamine neurons.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20020601

• Enhanced synchrony among primary motor cortex neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine primate model of Parkinson's disease.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20020601

• Morphological and biochemical evidence that apomorphine rescues striatal dopamine terminals and prevents methamphetamine toxicity.

  Annals of the New York Academy of Sciences 20020601

• Calpain upregulation and neuron death in spinal cord of MPTP-induced parkinsonism in mice.

  Annals of the New York Academy of Sciences 20020601

• Effect of MPTP on Dopamine metabolism in Ames dwarf mice.

  Neurochemical research 20020601

• Effect of tomato intake on striatal monoamine level in a mouse model of experimental Parkinson's disease.

  Journal of nutritional science and vitaminology 20020601

• Experimental depressive-pain syndrome in rats with initial various anxiety-phobic levels: a behavioral study.

  Bulletin of experimental biology and medicine 20020601

• The lesion of the rat substantia nigra pars compacta dopaminergic neurons as a model for Parkinson's disease memory disabilities.

  Cellular and molecular neurobiology 20020601

• Effects of fibroblast growth factor and glial-derived neurotrophic factor on akinesia, F-DOPA uptake and dopamine cells in parkinsonian primates.

  Parkinsonism & related disorders 20020601

• Solid-phase synthesis of FKBP12 inhibitors: N-sulfonyl and N-carbamoylprolyl/pipecolyl amides.

  Bioorganic & medicinal chemistry letters 20020520

• Biochemical and pharmacological characterization of 1-trichloromethyl-1,2,3,4-tetrahydro-beta-carboline: a biologically relevant neurotoxin?

  European journal of pharmacology 20020503

• Behavioral and neurochemical effects of wild-type and mutated human alpha-synuclein in transgenic mice.

  Experimental neurology 20020501

• Environmental estrogen-like chemicals and hydroxyl radicals induced by MPTP in the striatum: a review.

  Neurochemical research 20020501

• Modification of tyrosine hydroxylase activity by chloral derived beta-carbolines in vitro.

  Journal of neurochemistry 20020501

• Nitric oxide: an antioxidant and neuroprotector.

  Annals of the New York Academy of Sciences 20020501

• Impaired learning in a spatial working memory version and in a cued version of the water maze in rats with MPTP-induced mesencephalic dopaminergic lesions.

  Brain research bulletin 20020501

• Animal models of Parkinson's disease.

  BioEssays : news and reviews in molecular, cellular and developmental biology 20020401

• Dopaminergic cells of the carotid body: physiological significance and possible therapeutic applications in Parkinson's disease.

  Brain research bulletin 20020401

• Method for culturing postnatal substantia nigra as an in vitro model of experimental Parkinson's disease.

  Brain research. Brain research protocols 20020401

• Age-related alteration in hepatic disposition of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and pesticides.

  Pharmacology & toxicology 20020401

• [Possible mechanisms of the protective effect of ginsenoside Rg1 on apoptosis in substantia nigra neurons].

  Yao xue xue bao = Acta pharmaceutica Sinica 20020401

• Antioxidant compounds protect dopamine neurons from death due to oxidative stress in vitro.

  Brain research 20020329

• Caffeine's neuroprotection against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity shows no tolerance to chronic caffeine administration in mice.

  Neuroscience letters 20020329

• Association of homozygous 7048G7049 variant in the intron six of Nurr1 gene with Parkinson's disease.

  Neurology 20020326

• Erythropoietin restores glutathione peroxidase activity in 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine-induced neurotoxicity in C57BL mice and stimulates murine astroglial glutathione peroxidase production in vitro.

  Neuroscience letters 20020315

• Thioredoxin suppresses 1-methyl-4-phenylpyridinium-induced neurotoxicity in rat PC12 cells.

  Neuroscience letters 20020315

• The distribution of copper, zinc- and manganese-superoxide dismutase, and glutathione peroxidase messenger ribonucleic acid in rat basal ganglia.

  Biochemical pharmacology 20020315

• Striatal AMPA receptor binding is unaltered in the MPTP-lesioned macaque model of Parkinson's disease and dyskinesia.

  Experimental neurology 20020301

• Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20020301

• Continuous subcutaneous infusion of apomorphine rescues nigro-striatal dopaminergic terminals following MPTP injection in mice.

  Neuropharmacology 20020301

• Selective dopaminergic neurotoxicity of isoquinoline derivatives related to Parkinson's disease: studies using heterologous expression systems of the dopamine transporter.

  Biochemical pharmacology 20020301

• 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine has a transient proliferative effect on PC12h cells and nerve growth factor additively promotes this effect: possible involvement of distinct mechanisms of activation of MAP kinase family proteins.

  Brain research. Developmental brain research 20020227

• Pharmacology of dopamine agonists in the treatment of Parkinson's disease.

  Neurology 20020226

• Neuroprotection and dopamine agonists.

  Neurology 20020226

• Behavioral recovery in a primate model of Parkinson's disease by triple transduction of striatal cells with adeno-associated viral vectors expressing dopamine-synthesizing enzymes.

  Human gene therapy 20020210

• Effects of the prolyl endopeptidase inhibitor S 17092 on cognitive deficits in chronic low dose MPTP-treated monkeys.

  Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20020201

• Neuroprotective actions of selegiline.

  Journal of neuroscience research 20020201

• Slow oscillatory discharge in the primate basal ganglia.

  Journal of neurophysiology 20020201

• Significant reduction of 125 I-meta-iodobenzylguanidine accumulation directly caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydroxypyridine, a toxic agent for inducing experimental Parkinson's disease.

  Nuclear medicine communications 20020201

• The actions of a D-1 agonist in MPTP treated primates show dependence on both D-1 and D-2 receptor function and tolerance on repeated administration.

  Journal of neural transmission (Vienna, Austria : 1996) 20020201

• Disturbances of saccadic eye movements in monkeys during development of MPTP-induced syndrome.

  Bulletin of experimental biology and medicine 20020201

• Deprenyl protects from MPTP-induced Parkinson-like syndrome and glutathione oxidation in rat striatum.

  Toxicology 20020125

• Embryonic ventral mesencephalic grafts to the substantia nigra of MPTP-treated monkeys: feasibility relevant to multiple-target grafting as a therapy for Parkinson's disease.

  The Journal of comparative neurology 20020121

• Significant up-regulation of nestin protein in the neostriatum of MPTP-treated mice. Are the striatal astrocytes regionally activated after systemic MPTP administration?

  Brain research 20020118

• Effects of transient focal inactivation of the basal ganglia in parkinsonian primates.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20020115

• Loss of nicotinic receptors in monkey striatum after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment is due to a decline in alpha-conotoxin MII sites.

  Molecular pharmacology 20020101

• Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease.

  Journal of neurochemistry 20020101

• Neuroprotective effect of riluzole in a primate model of Parkinson's disease: behavioral and histological evidence.

  Movement disorders : official journal of the Movement Disorder Society 20020101

• Melatonin attenuates MPTP-induced dopaminergic neuronal injury associated with scavenging hydroxyl radical.

  Journal of pineal research 20020101

• Alteration of glutamate receptors in the striatum of dyskinetic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys following dopamine agonist treatment.

  Progress in neuro-psychopharmacology & biological psychiatry 20020101

• Neuroprotection by adenosine A2A receptor blockade in experimental models of Parkinson's disease.

  Journal of neurochemistry 20020101

• Differential vulnerability of snake species to MPTP: a behavioral and biochemical comparison in ratsnakes (Elaphe) and watersnakes (Nerodia).

  Neurotoxicology and teratology 20020101

• Brainstem motor loops in the control of movement.

  Movement disorders : official journal of the Movement Disorder Society 20020101

• [Experimental models of Parkinson's disease].

  Annales pharmaceutiques francaises 20020101

• Differential nicotinic receptor expression in monkey basal ganglia: effects of nigrostriatal damage.

  Neuroscience 20020101

• Increases in striatal preproenkephalin gene expression are associated with nigrostriatal damage but not L-DOPA-induced dyskinesias in the squirrel monkey.

  Neuroscience 20020101

• Amine-related neurotoxins in Parkinson's disease: past, present, and future.

  Neurotoxicology and teratology 20020101

• N-methylation underlying Parkinson's disease.

  Neurotoxicology and teratology 20020101

• Apoptotic molecules and MPTP-induced cell death.

  Neurotoxicology and teratology 20020101

• MPTP: insights into parkinsonian neurodegeneration.

  Neurotoxicology and teratology 20020101

• Aliphatic propargylamines as symptomatic and neuroprotective treatments for neurodegenerative diseases.

  Neurotoxicology and teratology 20020101

• Parkinson's disease.

  International review of neurobiology 20020101

• Exploration of the role of the upper brainstem in motor control.

  Stereotactic and functional neurosurgery 20020101

• Elevation of antioxidant potency in mice brain by low-dose X-ray irradiation and its effect on Fe-NTA-induced brain damage.

  Physiological chemistry and physics and medical NMR 20020101

• Endogenous risk factors in Parkinson's disease: dopamine and tetrahydroisoquinolines.

  Polish journal of pharmacology 20020101

• Caspase-9 activation results in downstream caspase-8 activation and bid cleavage in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20011215

• Mutation analysis of the human NR4A2 gene, an essential gene for midbrain dopaminergic neurogenesis, in schizophrenic patients.

  American journal of medical genetics 20011208

• Chronic administration of pharmacological levels of melatonin does not ameliorate the MPTP-induced degeneration of the nigrostriatal pathway.

  Brain research 20011207

• Intracerebral transplantation of bone marrow stromal cells in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.

  Neuroscience letters 20011201

• Protective effect and mechanism of Ginkgo biloba leaf extracts for Parkinson disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

  Acta pharmacologica Sinica 20011201

• L-Dopa restores striatal dopamine level but fails to reverse MPTP-induced memory deficits in rats.

  The international journal of neuropsychopharmacology 20011201

• Neurotoxicity of MPTP.

  Neuropathology : official journal of the Japanese Society of Neuropathology 20011201

• Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets.

  The European journal of neuroscience 20011201

• Profound astrogenesis in the striatum of adult mice following nigrostriatal dopaminergic lesion by repeated MPTP administration.

  Brain research. Developmental brain research 20011126

• Cell membrane transport of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the liver and systemic bioavailability.

  Biochemical and biophysical research communications 20011123

• Sequential up-regulation of the c-fos, c-jun and bax genes in the cortex, striatum and cerebellum induced by a single injection of a low dose of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in C57BL/6 mice.

  Neuroscience letters 20011113

• Impairment of the neuronal dopamine transporter activity in MPP(+)-treated rat was not prevented by treatments with nitric oxide synthase or poly(ADP-ribose) polymerase inhibitors.

  Neuroscience letters 20011113

• Neuroprotective effect of riluzole in MPTP-treated mice.

  Brain research 20011109

• Nicotine administration reduces striatal MPP+ levels in mice.

  Brain research 20011102

• Antiparkinsonian action of a delta opioid agonist in rodent and primate models of Parkinson's disease.

  Experimental neurology 20011101

• Behavioral phenotyping of the MPTP mouse model of Parkinson's disease.

  Behavioural brain research 20011101

• Evaluation of neurotoxicity of TIQ and MPTP and of parkinsonism-preventing effect of 1-MeTIQ by in vivo measurement of pre-synaptic dopamine transporters and post-synaptic dopamine D(2) receptors in the mouse striatum.

  Journal of neurochemistry 20011101

• Differential effects of D1 and D2 agonists in MPTP-treated primates: functional implications for Parkinson's disease. 1990.

  Neurology 20011101

• Acute exposure to organochlorine pesticides does not affect striatal dopamine in mice.

  Neurotoxicity research 20011101

• Adenosine A(2a) receptor antagonists: potential therapeutic and neuroprotective effects in Parkinson's disease.

  Neurotoxicity research 20011101

• Diversity in mechanisms of substrate oxidation by cytochrome P450 2D6. Lack of an allosteric role of NADPH-cytochrome P450 reductase in catalytic regioselectivity.

  The Journal of biological chemistry 20011026

• Assessment of motor behavior using a video system and a clinical rating scale in parkinsonian monkeys lesioned by MPTP.

  Journal of neuroscience methods 20011015

• Riluzole (2-amino-6-trifluoromethoxy benzothiazole) attenuates MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity in mice.

  Neuroscience letters 20011012

• Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease.

  Progress in neurobiology 20011001

• Molecular neurotoxicological models of Parkinsonism: focus on genetic manipulation of mice.

  Parkinsonism & related disorders 20011001

• Lidocaine and muscimol microinjections in subthalamic nucleus reverse Parkinsonian symptoms.

  Brain : a journal of neurology 20011001

• Memory disruption in rats with nigral lesions induced by MPTP: a model for early Parkinson's disease amnesia.

  Behavioural brain research 20010928

• Manganese mimics the action of 1-methyl-4-phenylpyridinium ion, a dopaminergic neurotoxin, in rat striatal tissue slices.

  Neuroscience letters 20010921

• Loss of metabolites from monkey striatum during PET with FDOPA.

  Synapse (New York, N.Y.) 20010901

• The parkinsonian neurotoxin, MPP+ induces phosphorylated c-Jun in dopaminergric neurons of mesencephalic cultures.

  Parkinsonism & related disorders 20010901

• Evidence for target-specific outgrowth from subpopulations of grafted human dopamine neurons.

  Microscopy research and technique 20010901

• Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20010901

• Mu- and delta-opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease.

  Experimental neurology 20010901

• Green tea polyphenol (-)-epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurodegeneration.

  Journal of neurochemistry 20010901

• 1-Methyl-4-phenyl-pyridinium increases S-adenosyl-L-methionine dependent phospholipid methylation.

  Pharmacology, biochemistry, and behavior 20010901

• Novel observations with FDOPA-PET imaging after early nigrostriatal damage.

  Movement disorders : official journal of the Movement Disorder Society 20010901

• Group I mGluR antagonist AIDA protects nigral DA cells from MPTP-induced injury.

  Neuroreport 20010828

• Dissociated functional recovery in parkinsonian monkeys following transplantation of astroglial cells.

  Brain research 20010824

• Nitric oxide enhances MPP(+) inhibition of complex I.

  FEBS letters 20010824

• Interactions of 1-methyl-4-phenylpyridinium and other compounds with P-glycoprotein: relevance to toxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

  Brain research 20010810

• Neuroprotective properties of 17beta-estradiol, progesterone, and raloxifene in MPTP C57Bl/6 mice.

  Synapse (New York, N.Y.) 20010801

• Protection of nigral neurons by GDNF-engineered marrow cell transplantation.

  Neuroscience research 20010801

• Vulnerability of 125I-alpha-conotoxin MII binding sites to nigrostriatal damage in monkey.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20010801

• Tyrosine hydroxylase and dopamine transporter expression in residual dopaminergic neurons: potential contributors to spontaneous recovery from experimental Parkinsonism.

  Journal of neuroscience research 20010801

• Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates.

  Pharmacogenetics 20010801

• Neurotrophic and neuroprotective actions of ginsenosides Rb(1) and Rg(1).

  Planta medica 20010801

• Biochemical and pathological study of endogenous 1-benzyl-1,2,3,4-tetrahydroisoquinoline-induced parkinsonism in the mouse.

  Brain research 20010713

• Expression of striatal preprotachykinin mRNA in symptomatic and asymptomatic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-exposed monkeys is related to parkinsonian motor signs.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20010701

• Differentiation of embryonic stem cell-derived dopaminergic neurons is enhanced by survival-promoting factors.

  Mechanisms of development 20010701

• Gene expression analysis in N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice model of Parkinson's disease using cDNA microarray: effect of R-apomorphine.

  Journal of neurochemistry 20010701

• Anatomic and biochemical correlates of the dopamine transporter ligand 11C-PE2I in normal and parkinsonian primates: comparison with 6-[18F]fluoro-L-dopa.

  Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 20010701

• Neuroimmunophilins: novel neuroprotective and neuroregenerative targets.

  Annals of neurology 20010701

• Antiparkinsonian activity and dyskinesia risk of ropinirole and L-DOPA combination therapy in drug naïve MPTP-lesioned common marmosets (Callithrix jacchus).

  Movement disorders : official journal of the Movement Disorder Society 20010701

• Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct: evidence from the effects of the alpha(2) adrenoceptor antagonist idazoxan.

  Movement disorders : official journal of the Movement Disorder Society 20010701

• Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease.

  Movement disorders : official journal of the Movement Disorder Society 20010701

• [Pathogenesis of idiopathic Parkinson's disease].

  Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics 20010701

• Administration of FGF-1 through transfected cells alleviates MPTP toxicity in mice.

  Neurotoxicity research 20010701

• Neuroprotective effects of pramipexole in young and aged MPTP-treated mice.

  Brain research 20010629

• Changes in striatal dopamine D3 receptor regulation during expression of and recovery from MPTP-induced parkinsonism.

  Brain research 20010629

• Toxic effects of MPP(+) and MPTP in PC12 cells independent of reactive oxygen species formation.

  Brain research 20010629

• Differential regulation of striatal G protein levels following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration in C57 BL/6 mice.

  Neuroscience letters 20010622

• Transport of choline and its relationship to the expression of the organic cation transporters in a rat brain microvessel endothelial cell line (RBE4).

  Biochimica et biophysica acta 20010606

• Effect of MPTP-induced denervation on basal ganglia GABA(B) receptors: correlation with dopamine concentrations and dopamine transporter.

  Synapse (New York, N.Y.) 20010601

• Parkinson's disease--redox mechanisms.

  Current medicinal chemistry 20010601

• Lack of protective effect by intermittent hypoxia on MPTP-induced neurotoxicity in mice.

  Annals of the New York Academy of Sciences 20010601

• Rescue of dying neurons by (R)-deprenyl in the MPTP-mouse model of Parkinson's disease does not include restoration of neostriatal dopamine.

  Annals of the New York Academy of Sciences 20010601

• Cannabinoid receptor agonist and antagonist effects on motor function in normal and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP)-treated non-human primates.

  Psychopharmacology 20010601

• Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20010515

• Participation of manganese-superoxide dismutase in the neuroprotection exerted by copper sulfate against 1-methyl 4-phenylpyridinium neurotoxicity.

  Brain research bulletin 20010515

• Experimental models of Parkinson's disease.

  Nature reviews. Neuroscience 20010501

• Sensitivity to MPTP is not increased in Parkinson's disease-associated mutant alpha-synuclein transgenic mice.

  Journal of neurochemistry 20010501

• Caffeine reverses the memory disruption induced by intra-nigral MPTP-injection in rats.

  Brain research bulletin 20010501

• Preclinical models of Parkinson's disease.

  Current protocols in neuroscience 20010501

• Nuclear factor-kappaB activation is not involved in a MPTP model of Parkinson's disease.

  Neuroreport 20010417

• Strain-dependent susceptibility to MPTP and MPP(+)-induced parkinsonism is determined by glia.

  Glia 20010415

• Dose-dependent protective effects of apomorphine against methamphetamine-induced nigrostriatal damage.

  Brain research 20010413

• Parkin immunoreactivity in the brain of human and non-human primates: an immunohistochemical analysis in normal conditions and in Parkinsonian syndromes.

  The Journal of comparative neurology 20010402

• Neuroprotective effects of (+/-)-kavain in the MPTP mouse model of Parkinson's disease.

  Synapse (New York, N.Y.) 20010401

• Transgenic ALS mice show increased vulnerability to the mitochondrial toxins MPTP and 3-nitropropionic acid.

  Experimental neurology 20010401

• Selective inhibition of MAO-B through chronic low-dose (R)-deprenyl treatment in C57BL/6 mice has no effect on basal neostriatal dopamine levels.

  Experimental neurology 20010401

• Caspase-8 is an effector in apoptotic death of dopaminergic neurons in Parkinson's disease, but pathway inhibition results in neuronal necrosis.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20010401

• Effects of R- and S-apomorphine on MPTP-induced nigro-striatal dopamine neuronal loss.

  Journal of neurochemistry 20010401

• Prosaptide D5, a retro-inverso 11-mer peptidomimetic, rescued dopaminergic neurons in a model of Parkinson's disease.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20010401

• Upregulation of striatal preproenkephalin gene expression occurs before the appearance of parkinsonian signs in 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine monkeys.

  Neurobiology of disease 20010401

• Protective role of melatonin against MPTP-induced mouse brain cell DNA fragmentation and apoptosis in vivo.

  Neuro endocrinology letters 20010401

• Pharmacological properties of the MPTP analog trans-1-methyl-4-[4-dimethylaminophenylethenyl]-1,2,3,6-tetrahydropyridine and its pyridinium metabolite in mouse brain synaptosomes: a potential visual marker for substrates of MPTP-induced neurotoxicity.

  Progress in neuro-psychopharmacology & biological psychiatry 20010401

• Serotonin 5-HT(1A) receptor expression is selectively enhanced in the striosomal compartment of chronic parkinsonian monkeys.

  Synapse (New York, N.Y.) 20010315

• A new in vitro approach for investigating the MPTP effect on DA uptake.

  Neurochemistry international 20010301

• Evidence for a dissociation between MPTP toxicity and tyrosinase activity based on congenic mouse strain susceptibility.

  Experimental neurology 20010301

• Systemic administration of the immunophilin ligand GPI 1046 in MPTP-treated monkeys.

  Experimental neurology 20010301

• Dopamine agonist-induced dyskinesias are correlated to both firing pattern and frequency alterations of pallidal neurones in the MPTP-treated monkey.

  Brain : a journal of neurology 20010301

• Nerve growth factor prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced cell death via the Akt pathway by suppressing caspase-3-like activity using PC12 cells: relevance to therapeutical application for Parkinson's disease.

  Journal of neuroscience research 20010301

• The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a technical review of its utility and safety.

  Journal of neurochemistry 20010301

• Gene therapy to the rescue in Parkinson's disease. Response from Kordower and Aebischer.

  Trends in pharmacological sciences 20010301

• Immunophilin ligands can prevent progressive dopaminergic degeneration in animal models of Parkinson's disease.

  The European journal of neuroscience 20010301

• Caspase-3 activation in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice.

  Movement disorders : official journal of the Movement Disorder Society 20010301

• Reliability and validity of a new global dyskinesia rating scale in the MPTP-lesioned non-human primate.

  Movement disorders : official journal of the Movement Disorder Society 20010301

• Eldepryl prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced nigral neuronal apoptosis in mice.

  Chinese medical journal 20010301

• SKF-38393, a dopamine receptor agonist, attenuates 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity.

  Brain research 20010223

• Erythropoietin exerts neuroprotection in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated C57/BL mice via increasing nitric oxide production.

  Neuroscience letters 20010202

• Nicotine, but not cotinine, partially protects dopaminergic neurons against MPTP-induced degeneration in mice.

  Brain research 20010202

• Effects of acute and repeated treatment with a novel dopamine D2 receptor ligand on L-DOPA-induced dyskinesias in MPTP monkeys.

  European journal of pharmacology 20010202

• Activity of pallidal and striatal tonically active neurons is correlated in mptp-treated monkeys but not in normal monkeys.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20010201

• Protection from MPTP-induced neurotoxicity in differentiating mouse N2a neuroblastoma cells.

  Journal of neurochemistry 20010201

• Antiparkinsonian and behavioral effects of inactivation of the substantia nigra pars reticulata in hemiparkinsonian primates.

  Experimental neurology 20010201

• GDNF reverses priming for dyskinesia in MPTP-treated, L-DOPA-primed common marmosets.

  The European journal of neuroscience 20010201

• Dopaminergic cell death induced by MPP(+), oxidant and specific neurotoxicants shares the common molecular mechanism.

  Journal of neurochemistry 20010201

• [Parkinsonism induced by MPTP and free radical generation].

  Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20010201

• Accumulation of the 1-methyl-4-phenylpyridinium ion in suncus (Suncus murinus) brain: implication for flavin-containing monooxygenase activity in brain microvessels.

  Chemical research in toxicology 20010201

• Nicotinamide-N-methyltransferase is higher in the lumbar cerebrospinal fluid of patients with Parkinson's disease.

  Neuroscience letters 20010126

• Glial cell line-derived neurotrophic factor concentration dependently improves disability and motor activity in MPTP-treated common marmosets.

  European journal of pharmacology 20010119

• Molecular characterization of monoamine oxidases A and B.

  Progress in nucleic acid research and molecular biology 20010101

• Biochemical and immunohistological changes in the brain of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mouse.

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20010101

• Mice with a partial deficiency of manganese superoxide dismutase show increased vulnerability to the mitochondrial toxins malonate, 3-nitropropionic acid, and MPTP.

  Experimental neurology 20010101

• Group II metabotropic glutamate receptor activation protects striatal dopaminergic nerve terminals against MPP+-induced neurotoxicity along with brain-derived neurotrophic factor induction.

  Journal of neurochemistry 20010101

• Oxidative post-translational modifications of alpha-synuclein in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.

  Journal of neurochemistry 20010101

• [Sensorimotor reactivity (acoustic startle response) in rats with experimental depressive syndrome].

  Zhurnal vysshei nervnoi deiatelnosti imeni I P Pavlova 20010101

• Pallidal border cells: an anatomical and electrophysiological study in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkey.

  Neuroscience 20010101

• Co-administration of memantine and amantadine with sub/suprathreshold doses of L-Dopa restores motor behaviour of MPTP-treated mice.

  Journal of neural transmission (Vienna, Austria : 1996) 20010101

• Ubiquinone (coenzyme q10) and mitochondria in oxidative stress of parkinson's disease.

  Biological signals and receptors 20010101

• [Mexidol potentiates antiparkinsonian effect of L-DOPA in MPTP-induced parkinsonism model].

  Eksperimental'naia i klinicheskaia farmakologiia 20010101

• Microtubule assembly is directly affected by MPP(+)in vitro.

  Cell biology international 20010101

• Mouse model of Parkinsonism: a comparison between subacute MPTP and chronic MPTP/probenecid treatment.

  Neuroscience 20010101

• Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.

  Journal of neural transmission (Vienna, Austria : 1996) 20010101

• Effects of single and repeated administration of 1,2,3,4-tetrahydroisoquinoline analogs on the binding of [11C]raclopride to dopamine D2 receptors in the mouse brain.

  Journal of neural transmission (Vienna, Austria : 1996) 20010101

• Neuronal ectopic expression of tyrosine hydroxylase in the mouse striatum by combined administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 3-nitropropionic acid.

  Neuroscience 20010101

• Are dopamine, norepinephrine, and serotonin precursors of biologically reactive intermediates involved in the pathogenesis of neurodegenerative brain disorders?

  Advances in experimental medicine and biology 20010101

• Neurochemical findings in the MPTP model of Parkinson's disease.

  Journal of neural transmission (Vienna, Austria : 1996) 20010101

• Current evidence for neuroprotective effects of nicotine and caffeine against Parkinson's disease.

  Drugs & aging 20010101

• Neurotoxicology of the brain barrier system: new implications.

  Journal of toxicology. Clinical toxicology 20010101

• Complex I and Parkinson's disease.

  IUBMB life 20010101

• [Treatment of neurodegenerative diseases: new perspectives].

  Neurologia i neurochirurgia polska 20010101

• Apomorphine as a neuroprotective drug: a study in MPTP-treated mice and potential relevance to ischemia.

  Functional neurology 20010101

• Experimental parkinsonism in primates.

  Stereotactic and functional neurosurgery 20010101

• The role of the pedunculopontine tegmental nucleus in experimental parkinsonism in primates.

  Stereotactic and functional neurosurgery 20010101

• Oxidative stress indices in Parkinson's disease : biochemical determination.

  Methods in molecular medicine 20010101

• Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model.

  Movement disorders : official journal of the Movement Disorder Society 20000501

• AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys.

  Neurology 20000425

• Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys.

  Experimental neurology 20000401

• Investigating levodopa-induced dyskinesias in the parkinsonian primate.

  Annals of neurology 20000401

• Effects of the partial glycine agonist D-cycloserine on cognitive functioning in chronic low dose MPTP-treated monkeys.

  Brain research 20000331

• Noradrenoceptor antagonism with idazoxan improves L-dopa-induced dyskinesias in MPTP monkeys.

  Naunyn-Schmiedeberg's archives of pharmacology 20000201

• Sustained cabergoline treatment reverses levodopa-induced dyskinesias in parkinsonian monkeys.

  Clinical neuropharmacology 20000101

• Neuroprotective effects of estrogen upon the nigrostriatal dopaminergic system.

  Journal of neurocytology 20000101

• Internal globus pallidus discharge is nearly suppressed during levodopa-induced dyskinesias.

  Annals of neurology 19991101

• Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP.

  Psychopharmacology 19991101

• The alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease.

  Movement disorders : official journal of the Movement Disorder Society 19990901

• D1 receptor blockade improves L-dopa-induced dyskinesia but worsens parkinsonism in MPTP monkeys.

  Neurology 19990310

• CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons In vivo.

  The Journal of pharmacology and experimental therapeutics 19990201

• Differential regulation of striatal preproenkephalin and preprotachykinin mRNA levels in MPTP-lesioned monkeys chronically treated with dopamine D1 or D2 receptor agonists.

  Journal of neurochemistry 19990201

• Nicotine prevents experimental parkinsonism in rodents and induces striatal increase of neurotrophic factors.

  Journal of neurochemistry 19981201

• Effects of pramipexole on contraversive rotation and functional motor impairments in 1-methyl-4-phenyl1,2,3, 6-tetrahydropyridine-induced chronic hemiparkinsonian monkeys.

  The Journal of pharmacology and experimental therapeutics 19981201

• Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys.

  Movement disorders : official journal of the Movement Disorder Society 19980901

• Glial cell line-derived neurotrophic factor-levodopa interactions and reduction of side effects in parkinsonian monkeys.

  Annals of neurology 19970801

• Potential therapeutic use of the selective dopamine D1 receptor agonist, A-86929: an acute study in parkinsonian levodopa-primed monkeys.

  Neurology 19970801

• (-)-OSU 6162 inhibits levodopa-induced dyskinesias in a monkey model of Parkinson's disease.

  Neuroreport 19970728

• The selective dopamine D1 receptor agonist A-86929 maintains efficacy with repeated treatment in rodent and primate models of Parkinson's disease.

  The Journal of pharmacology and experimental therapeutics 19970401

• Striatal increase of neurotrophic factors as a mechanism of nicotine protection in experimental parkinsonism.

  Journal of neural transmission (Vienna, Austria : 1996) 19970101

• Effects of L-DOPA-therapy on dopamine D2 receptor mRNA expression in the striatum of MPTP-intoxicated parkinsonian monkeys.

  Brain research. Molecular brain research 19961101

• Poly(ADP-ribose) polymerase inhibitors protect against MPTP-induced depletions of striatal dopamine and cortical noradrenaline in C57B1/6 mice.

  Brain research 19960812

• Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys.

  Annals of neurology 19960501

• Chronic alterations in dopaminergic neurotransmission produce a persistent elevation of deltaFosB-like protein(s) in both the rodent and primate striatum.

  The European journal of neuroscience 19960201

• ABT-431: the diacetyl prodrug of A-86929, a potent and selective dopamine D1 receptor agonist: in vitro characterization and effects in animal models of Parkinson's disease.

  The Journal of pharmacology and experimental therapeutics 19960101

• Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus).

  Movement disorders : official journal of the Movement Disorder Society 19951101

• Levodopa or D2 agonist induced dyskinesia in MPTP monkeys: correlation with changes in dopamine and GABAA receptors in the striatopallidal complex.

  Brain research 19950522

• Behavioral involvement of central dopamine D1 and D2 receptors in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned parkinsonian cynomolgus monkeys.

  Japanese journal of pharmacology 19950201

• Is striatal dopaminergic receptor imbalance responsible for levodopa-induced dyskinesia?

  Fundamental & clinical pharmacology 19950101

• Protection against methamphetamine-induced neurotoxicity to neostriatal dopaminergic neurons by adenosine receptor activation.

  The Journal of pharmacology and experimental therapeutics 19941201

• Excitotoxic lateral pallidotomy does not relieve L-dopa-induced dyskinesia in MPTP parkinsonian monkeys.

  Brain research 19940704

• Dopamine-depleting effects of MPTP and reserpine in weaver mutant mice.

  Molecular and chemical neuropathology 19931201

• Effect of nondopaminergic drugs on L-dopa-induced dyskinesias in MPTP-treated monkeys.

  Clinical neuropharmacology 19931001

• Thalamotomy for the alleviation of levodopa-induced dyskinesia: experimental studies in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated parkinsonian monkey.

  Neuroscience 19930701

• Effects of terguride, a partial D2 agonist, on MPTP-lesioned parkinsonian cynomolgus monkeys.

  Annals of neurology 19930501

• Dystonia induced by combined treatment with L-dopa and MK-801 in parkinsonian monkeys.

  Annals of neurology 19920701

• [Dopa-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated hemiparkinsonian monkeys].

  Zhonghua shen jing jing shen ke za zhi = Chinese journal of neurology and psychiatry 19920201

• Effect of ethosuximide on rest tremor in the MPTP monkey model.

  Movement disorders : official journal of the Movement Disorder Society 19920101

• Quantitative structure-metabolism relationship analyses of MAO-mediated toxication of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and analogues.

  Chemical research in toxicology 19920101

• Effect of D1 and D2 agonists and antagonists on dyskinesia produced by L-dopa in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys.

  The Journal of pharmacology and experimental therapeutics 19911001

• Unilateral MPTP-induced parkinsonism in monkeys. A quantitative autoradiographic study of dopamine D1 and D2 receptors and re-uptake sites.

  Neuro-Chirurgie 19910101

• Oral levodopa dose-response study in MPTP-induced hemiparkinsonian monkeys: assessment with a new rating scale for monkey parkinsonism.

  Movement disorders : official journal of the Movement Disorder Society 19910101

• Contrasting tissue factors predict heterogeneous striatal dopamine neurotoxicity after MPTP or methamphetamine treatment.

  Brain research 19901126

• Nigrostriatal damage is required for induction of dyskinesias by L-DOPA in squirrel monkeys.

  Clinical neuropharmacology 19901001

• (+)-PHNO: a new anti-parkinsonian agent which does not induce chorea in MPTP-treated squirrel monkeys.

  Journal of neurology, neurosurgery, and psychiatry 19900701

• Differential effects of D1 and D2 agonists in MPTP-treated primates: functional implications for Parkinson's disease.

  Neurology 19900601

• CCK-8S inhibits L-dopa-induced dyskinesias in parkinsonian squirrel monkeys.

  Neurology 19900401

• Ro 19-6327, a reversible and highly selective monoamine, oxidase B inhibitor: a novel tool to explore the MAO-B function in humans.

  Advances in neurology 19900101

• Induction of chorea and dystonia in parkinsonian primates.

  Movement disorders : official journal of the Movement Disorder Society 19900101

• Neural mechanisms of dystonia: evidence from a 2-deoxyglucose uptake study in a primate model of dopamine agonist-induced dystonia.

  Movement disorders : official journal of the Movement Disorder Society 19900101

• Characterisation of dyskinesias induced by L-dopa in MPTP-treated squirrel monkeys.

  Psychopharmacology 19900101

• NB-355: a novel prodrug for L-DOPA with reduced risk for peak-dose dyskinesias in MPTP-treated squirrel monkeys.

  Clinical neuropharmacology 19891001

• Levodopa-induced dyskinesias in parkinsonian monkeys: relationship to extent of nigrostriatal damage.

  Pharmacology, biochemistry, and behavior 19890901

• The effect of deprenyl (selegiline) on the natural history of Parkinson's disease.

  Science (New York, N.Y.) 19890804

• MPTP-induced parkinsonism in the monkey: neurochemical pathology, complications of treatment and pathophysiological mechanisms.

  The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 19870801

• Levodopa-induced dyskinesia and response fluctuations in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

  Journal of the neurological sciences 19870501

• Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): implications for treatment and the pathogenesis of Parkinson's disease.

  The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 19840201